

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

12

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> C12N 15/12, 15/62, 15/85, 15/86, 5/10, C07K 14/435, C12Q 1/02, 1/68, G01N 33/50, 33/52	<b>A1</b>	<b>(11) International Publication Number:</b> WO 97/42320 <b>(43) International Publication Date:</b> 13 November 1997 (13.11.97)
<b>(21) International Application Number:</b> PCT/US97/07625 <b>(22) International Filing Date:</b> 7 May 1997 (07.05.97) <b>(30) Priority Data:</b> 08/646,538 8 May 1996 (08.05.96) US <b>(71) Applicant:</b> THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; Bethesda, MD 20892 (US). <b>(72) Inventors:</b> PAVLAKIS, George, N.; 9 Purdue Court, Rockville, MD 20850 (US). GAITANARIS, George, A.; 9 Augustine Court, Gaithersburg, MD 20879 (US). STAUBER, Roland, H.; 1820 Hammond Court, Frederick, MD 21702 (US). VOURNAKIS, John, N.; 6 Carriage Lane, Hanover, NH 03755 (US). <b>(74) Agents:</b> WEBER, Ellen, L. et al.; Townsend and Townsend and Crew LLP, 8th floor, Two Embarcadero Center, San Francisco, CA 94111 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> MUTANT AEQUOREA VICTORIA FLUORESCENT PROTEINS HAVING INCREASED CELLULAR FLUORESCENCE		
<b>(57) Abstract</b> <p>The present invention is directed to mutants of the jellyfish <i>Aequorea victoria</i> green fluorescent protein (GFP) having at least 5 and preferably greater than 20 times the specific green fluorescence of the wild type protein. In other embodiments, the invention comprises mutant blue fluorescent proteins (BFPs) that emit an enhanced blue fluorescence. The invention also encompasses the expression of nucleic acids that encode a mutant GFP or BFP in a wide variety of engineered host cells, and the isolation of engineered proteins having increased fluorescent activity. The novel mutants of the present invention allow for a significantly more sensitive detection of fluorescence in engineered host cells than is possible with GFP or with its known mutants. Thus, the mutant fluorescent proteins provided herein can be used as sensitive reporter molecules to detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or BFP mutants, or of chimeric proteins comprising GFP or BFP mutants fused to a regulatory sequence or to a second protein sequence.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5                   **MUTANT *Aequorea victoria* FLUORESCENT PROTEINS  
                  HAVING INCREASED CELLULAR FLUORESCENCE**

**FIELD OF THE INVENTION**

10               This invention generally relates to novel proteins  
                  and their production which are useful for detecting gene  
                  expression and for visualizing the subcellular targeting and  
                  distribution of selected proteins and peptides, among other  
                  things. The invention specifically relates to mutations in  
15               the gene coding for the jellyfish *Aequorea victoria* green  
                  fluorescent protein ("GFP"), which mutations encode mutant GFP  
                  proteins having either an enhanced green or a blue  
                  fluorescence, and uses for them.

**BACKGROUND OF THE INVENTION**

20               Green fluorescent protein ("GFP") is a monomeric  
                  protein of about 27 kDa which can be isolated from the  
                  bioluminescent jellyfish *Aequorea victoria*. When wild type  
                  GFP is illuminated by blue or ultraviolet light, it emits a  
25               brilliant green fluorescence. Similar to fluorescein  
                  isothiocyanate, GFP absorbs ultraviolet and blue light with a  
                  maximum absorbance at 395 nm and a minor peak of absorbance at  
                  470 nm, and emits green light with a maximum emission at 509  
                  nm with a minor peak at 540 nm. GFP fluorescence persists  
30               even after fixation with formaldehyde, and it is more stable  
                  to photobleaching than fluorescein.

                  The gene for GFP has been isolated and sequenced.  
                  Prasher, D. C. et al. (1992), "Primary structure of the  
                  *Aequorea victoria* green fluorescent protein," *Gene* 111:229-  
35               233. Expression vectors that comprise the GFP gene or cDNA  
                  have been introduced into a variety of host cells. These host  
                  cells include: Chinese hamster ovary (CHO) cells, human  
                  embryonic kidney cells (HEK293), COS-1 monkey cells, myeloma

cells, NIH 3T3 mouse fibroblasts, PtK1 cells, BHK cells, PC12 cells, *Xenopus*, leech, transgenic zebra fish, transgenic mice, *Drosophila* and several plants. The GFP molecules expressed by these different cells have a similar fluorescence as the native molecules, demonstrating that the GFP fluorescence does not require any species-specific cofactors or substrates. See, e.g., Baulcombe, D. et al. (1995), "Jellyfish green fluorescent protein as a reporter for virus infections," *The Plant Journal* 7:1045-1053; Chalfie, M. et al. (1994), "Green fluorescent protein as a marker for gene expression," *Science* 263:802-805; Inouye, S. & Tsuji, F. (1994), "Aequorea green fluorescent protein: expression of the gene and fluorescent characteristics of the recombinant protein," *FEBS Letters* 341:277-280; Inouye, S. & Tsuji, F. (1994), "Evidence for redox forms of the Aequorea green fluorescent protein," *FEBS Letters* 351:211-214; Kain, S. et al. (1995), "The green fluorescent protein as a reporter of gene expression and protein localization," *BioTechniques* (in press); Kitts, P. et al. (1995), "Green Fluorescent Protein (GFP): A novel reporter for monitoring gene expression in living organisms," *CLONTECHniques* X(1):1-3; Lo, D. et al. (1994), "Neuronal transfection in brain slices using particle-mediated gene transfer," *Neuron* 13:1263-1268; Moss, J. B. & Rosenthal, N. (1994), "Analysis of gene expression patterns in the embryonic mouse myotome with the green fluorescent protein, a new vital marker," *J. Cell. Biochem., Supplement* 18D W161; Niedz, R. et al. (1995), "Green fluorescent protein: an in vivo reporter of plant gene expression," *Plant Cell Reports* 14:403-406; Wu, G.-I. et al. (1995), "Infection of frog neurons with vaccinia virus permits in vivo expression of foreign proteins," *Neuron* 14:681-684; Yu, J. & van den Engh, G. (1995), "Flow-sort and growth of single bacterial cells transformed with cosmid and plasmid vectors that include the gene for green-fluorescent protein as a visible marker," Abstracts of papers presented at the 1995 meeting on "Genome Mapping and Sequencing," Cold Spring Harbor, p. 293.

The active GFP chromophore is a hexapeptide which contains a cyclized Ser-dehydroTyr-gly trimer at positions 65-

67. This chromophore is only fluorescent when embedded within the intact GFP protein. Chromophore formation occurs post-translationally; nascent GFP is not fluorescent. The chromophore is thought to be formed by a cyclization reaction and an oxidation step that requires molecular oxygen.

Proteins can be fused to the amino (N-) or carboxy (C-) terminus of GFP. Such fused proteins have been shown to retain the fluorescent properties of GFP and the functional properties of the fusion partner. Bian, J. et al. (1995), "Nuclear localization of HIV-1 matrix protein P17: The use of A. victoria GFP in protein tagging and tracing," *FASEB J.* 9:AI279; Flach, J. et al. (1994), "A yeast RNA-binding protein shuttles between the nucleus and the cytoplasm," *Mol. Cell. Biol.* 14:8399-8407; Marshall, J. et al. (1995), "The jellyfish green fluorescent protein: a new tool for studying ion channel expression and function," *Neuron* 14:211-215; Olmsted, J. et al. (1994), "Green Fluorescent Protein (GFP) chimeras as reporters for MAP4 behavior in living cells," *Mol. Biol. of the Cell* 5:167a; Rizzuto, R. et al. (1995), "Chimeric green fluorescent protein as a tool for visualizing subcellular organelles in living cells," *Current Biol.* 5:635-642; Sengupta, P. et al. (1994), "The C. elegans gene odr-7 encodes an olfactory-specific member of the nuclear receptor superfamily," *Cell* 79:971-980; Stearns, T. (1995), "The green revolution," *Current Biol.* 5:262-264; Treinin, M. & Chalfie, M. (1995), "A mutated acetylcholine receptor subunit causes neuronal degeneration in C. elegans," *Neuron* 14:871-877; Wang, S. & Hazelrigg, T. (1994), "Implications for bcd mRNA localization from spatial distribution of exu protein in Drosophila oogenesis," *Nature* 369:400-403.

A number of GFP mutants have been reported. Delagrave, S. et al. (1995) "Red-shifted excitation mutants of the green fluorescent protein," *Bio/Technology* 13:151-154; Heim, R. et al. (1994) "Wavelength mutations and posttranslational autooxidation of green fluorescent protein," *Proc. Natl. Acad. Sci. USA* 91:12501-12504; Heim, R. et al. (1995), "Improved green fluorescence," *Nature* 373:663-664. Delgrave et al. (1995) *Bio/Technology* 13:151-154 isolated

mutants of cloned *Aequorea victoria* GFP that had red-shifted excitation spectra. Heim, R. et al. (1994) "Wavelength mutations and posttranslational autooxidation of green fluorescent protein," *Proc. Natl. Acad. Sci. USA* 91:12501-12504 reported a mutant (Tyr66 to His) having a blue fluorescence, which is herein designated BFP(Tyr<sub>67</sub>→His). These references have neither taught nor suggested that their mutations resulted in an increase in the cellular fluorescence of the mutant GFPs.

In general, the level of fluorescence of a protein expressed in a cell depends on several factors, such as number of copies made of the fluorescent protein, stability of the protein, efficiency of formation of the chromophore, and interactions with cellular solvents, solutes and structures. Although the fluorescent signal from wild type GFP or from the reported mutants is generally adequate for bulk detection of abundantly expressed GFP or of GFP-containing chimeras, it is inadequate for detecting transient low or constitutively low levels of expression, or for performing fine structural subcellular localizations. This limitation severely restricts the use of native GFP or of the reported mutants as a biochemical and structural marker for gene expression and morphological studies.

## SUMMARY OF THE INVENTION

It is an object of the invention to provide engineered GFP-encoding nucleic acid sequences that encode modified GFP molecules having a greater cellular fluorescence than wild type GFP or prior described recombinant GFP.

It is a further object of this invention to provide recombinant vectors containing these modified GFP-encoding nucleic acid sequences, which vectors are capable of being inserted into a variety of cells (including mammalian and eukaryotic cells) and expressing the modified GFP.

It is also an object of this invention to provide host cells capable of providing useful quantities of homogeneous modified GFP.

It is yet another object of this invention to provide peptides that possess a greater cellular fluorescence than native GFP or unaltered recombinant GFP and that can be produced in large quantities in a laboratory, by a  
5 microorganism or by a cell in culture.

These and other objects of the invention have been accomplished by providing mutant GFP-encoding nucleic acids whose gene product exhibits an increased cellular fluorescence relative to naturally occurring or recombinantly produced wild  
10 type GFP ("wtGFP"). In some embodiments, the modified GFPs possess fluorescent activity that is 50-100 fold greater than that of unmodified GFP.

The modified proteins of the present invention are produced by making mutations in a genetic sequence that  
15 result in alterations in the amino acid sequence of the resulting gene product. Our starting material was a GFP-encoding nucleic acid wherein a codon encoding an additional nucleic acid was inserted at position 2 of the previously published GFP amino acid sequence (Chalfie et al., 1994), to  
20 introduce a useful restriction site. Due to the amino acid insertion at position 2 of the GFP amino acid sequence, our numbering of the GFP amino acids and description of the amino acid mutations is off by one as compared to the originally reported wild type GFP sequence (Prasher et al., 1992). Thus,  
25 amino acid 65 by our numbering corresponds to amino acid 64 of the originally reported wild type GFP, amino acid 168 corresponds to amino acid 167 of the originally reported wild type GFP, etc.

Using the modified wild type GFP described herein, a  
30 number of the unique mutants described herein derive from the discovery of an unplanned and unexpected mutation called "SG12", obtained in the course of site-directed mutagenesis experiments, wherein a phenylalanine at position 65 of wtGFP was converted to leucine. A mutant referred to as "SG11,"  
35 which combined the phenylalanine 65 to leucine alteration with an isoleucine 168 to threonine substitution and a lysine 239 to asparagine substitution, gave a further enhanced fluorescence intensity. The lysine 239 to asparagine

substitution does not affect the fluorescence of GFP; indeed the C-terminal lysine or asparagine may be deleted without affecting fluorescence. A third and further improved GFP mutant was obtained by further mutating "SG11." This mutant  
5 is referred to as "SG25" and, in addition to the SG11 mutations, contains an additional mutation, a substitution of a cysteine at position 66 for the serine normally found at that position in the sequence.

In addition, the invention encompasses novel GFP  
10 mutants that emit a blue fluorescence. These blue mutants are derived from a mutation of the wild type GFP (Heim, R. et al. (1994) "Wavelength mutations and posttranslational autoxidation of green fluorescent protein," *Proc. Natl. Acad. Sci. USA* 91:12501-12504), in which histidine was substituted  
15 for tyrosine at amino acid position 66. This mutant emits a blue fluorescence, i.e., it becomes a Blue Fluorescent Protein (BFP).

Novel BFP mutants having an enhanced blue fluorescence were made by further modifying this  
20 BFP(Tyr<sub>67</sub>→His). The introduction of the same mutation used to generate SG12, (i.e., phenylalanine to leucine at position 65) into BFP(Tyr<sub>67</sub>→His) resulted in a new mutant having a brighter fluorescence, designated "SuperBlue-42" (SB42). A second independently generated mutation of BFP(Tyr<sub>67</sub>→His), in which a  
25 valine at position 164 was converted to alanine, also emitted an enhanced blue fluorescent signal and is referred to as "SB49." A combination of the above two mutations resulted in "SB50", which exhibited an even greater fluorescence enhancement than either of the previous mutations.

30 The novel GFP and BFP mutants of this invention allow for a significantly more sensitive detection of fluorescence in host cells than is possible with the wild type protein. Accordingly, the mutant GFPs provided herein can be used, among other things, as sensitive reporter molecules to  
35 detect the cell and tissue-specific expression and subcellular compartmentalization of GFP or of chimeric proteins comprising GFP fused to a regulatory sequence or to a second protein sequence. In addition, these mutations make possible a



variety of one and two color protein assays to quantitate expression in mammalian cells.

5

## DETAILED DESCRIPTION OF THE INVENTION

The present invention comprises mutant nucleic acids that encode engineered GFPs having a greater cellular fluorescence than either native GFP or unaltered ("wild type") recombinant GFP, and the mutant GFPs themselves. It further comprises a subset of mutant GFPs that are mutant blue fluorescent proteins ("BFPs") that are derived from a published BFP, designated BFP(Tyr<sub>67</sub>→His), wherein the mutant BFPs have a cellular fluorescence that is at least five times greater, preferably ten times greater, and most preferably 20 times greater than that of BFP(Tyr<sub>67</sub>→His). The invention also encompasses compositions such as vectors and cells that comprise either the mutant nucleic acids or the mutant protein gene products. The mutant GFP nucleic acids and proteins may be used to detect and quantify gene expression in living cells, and to detect and quantify tissue specific expression and subcellular distribution of GFP or of GFP fused to other proteins.

25

### I. General Definitions

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton et al. (1994) *Dictionary of Microbiology and Molecular Biology*, second edition, John Wiley and Sons (New York) provides one of skill with a general dictionary of many of the terms used in this invention. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described. For purposes of the present invention, the following terms are defined below.

35

The symbols, abbreviations and definitions used herein are set forth below:

DNA, deoxyribonucleic acid

RNA, ribonucleic acid

5 mRNA, messenger RNA

cDNA, complementary DNA (enzymatically synthesized from an mRNA sequence)

A-Adenine

T-Thymine

10 G-Guanine

C-Cytosine

U-Uracil

GFP, Green Fluorescent Protein

15 BFP, Blue Fluorescent Protein

Amino acids are sometimes referred to herein by the conventional one or three letter codes.

Wild type green fluorescent protein ("wtGFP") refers to the 239 amino acid sequence described by Chalfie et al.,  
20 *Science* 263, 802-805, 1994, the nucleotide sequence of which is set out as SEQ ID NO:1, and the amino acid sequence of which is set out as SEQ ID NO:2. This sequence differs from the original 238 amino acid GFP isolated from the bioluminescent jellyfish *Aequorea victoria* in that one amino  
25 acid has been inserted after position 2 of the 238 amino acid sequence. When reference in this application is made to an amino acid position of GFP, the position is made with reference to that described by Chalfie et al., *supra* and thus of SEQ ID NO:2.

30 The term "blue fluorescent protein" (BFP) refers to mutants of wtGFP wherein the tyrosine at position 67 is converted to a histidine, which mutants emit a blue fluorescence. The non-limiting prototype is herein designated BFP(Tyr<sub>67</sub>→His).

35 A shorthand designation for mutations that result in a change in amino acid sequence is the one or three letter code for the original amino acid, the number of the position of the amino acid in the wtGFP sequence, followed by the one or three letter code for the new amino acid. Thus, Phe<sub>65</sub>Leu  
40 or F<sub>65</sub>L both designate a mutation wherein the phenylalanine at position 65 of the wtGFP is converted to leucine.

Salts of any of the proteins described herein will naturally occur when such proteins are present in (or isolated

from) aqueous solutions of various pHs. All salts of peptides having the indicated biological activity are considered to be within the scope of the present invention. Examples include alkali, alkaline earth, and other metal salts of carboxylic acid residues, acid addition salts (e.g., HCl) of amino residues, and Zwitterions formed by reactions between carboxylic acid and amino acid residues within the same molecule.

The terms "bioluminescent" and "fluorescent" refer to the ability of GFP or of a derivative thereof to emit light ("emitted or fluorescent light") of a characteristic wavelength when excited by light which is generally of a characteristic and different wavelength than that used to generate the emission.

The term "cellular fluorescence" denotes the fluorescence of a GFP-derived protein of the present invention when expressed in a cell, especially a mammalian cell.

The term "nucleic acid" refers to a deoxyribonucleotide or ribonucleotide polymer in either single- or double-stranded form, and unless specifically limited, encompasses known analogues of natural nucleotides that hybridize to nucleic acids in a manner similar to naturally occurring nucleotides. Unless otherwise indicated, a particular nucleic acid sequence implicitly provides the complementary sequence thereof, as well as the sequence explicitly indicated. As used herein, the terms "nucleic acid" and "gene" are interchangeable, and they encompass the term "cDNA."

The phrase "a nucleic acid sequence encoding" refers to a nucleic acid which contains sequence information that, if translated, yields the primary amino acid sequence of a specific protein or peptide. This phrase specifically encompasses degenerate codons (i.e., different codons which encode a single amino acid) of the native sequence or sequences which may be introduced to conform with codon preference in a specific host cell.

The phrase "nucleic acid construct" denotes a nucleic acid that is composed of two or more nucleic acid

sequences that are derived from different sources and that are ligated together using methods known in the art.

5 The term "regulatory sequence" denotes all the non-coding elements of a nucleic acid sequence required for the correct and efficient expression of the "coding region" (i.e., the region that actually encodes the amino acid sequence of a peptide or protein), e.g., binding sites for polymerases and transcription factors, transcription and translation initiation and termination sequences, TATA box, a promoter to 10 direct transcription, a ribosome binding site for translational initiation, polyadenylation sequences, enhancer elements.

The term "isolated" refers to material which is substantially or essentially free from components which 15 normally accompany it as found in its native state (for example, a band on a gel). The isolated nucleic acids and the isolated proteins of this invention do not contain materials normally associated with their *in situ* environment, in particular, nuclear, cytosolic or membrane associated proteins 20 or nucleic acids other than those nucleic acids which are indicated. The term "homogeneous" refers to a peptide or DNA sequence where the primary molecular structure (i.e., the sequence of amino acids or nucleotides) of substantially all molecules present in the composition under consideration is 25 identical. The term "substantially" used in the preceding sentences preferably means at least 80% by weight, more preferably at least 95% by weight, and most preferably at least 99% by weight.

The nucleic acids of this invention, whether RNA, 30 cDNA, genomic DNA, or a hybrid of the various combinations, are synthesized *in vitro* or are isolated from natural sources or recombinant clones. The nucleic acids claimed herein are present in transformed or transfected whole cells, in transformed or transfected cell lysates, or in a partially 35 purified or substantially pure form. The nucleic acids of the present invention are obtained as homogeneous preparations. They may be prepared by standard techniques well known in the art, including selective precipitation with such substances as

ammonium sulfate, isopropyl alcohol, ethyl alcohol, and/or exclusion, ion exchange or affinity column chromatography, immunopurification methods, and others.

5       The phrase "conservatively modified variants thereof," when used with reference to a protein, denotes conservative amino acid substitutions in which both the original and the substituted amino acids have similar structure (e.g., the R group contains a carboxylic acid) and properties (e.g., the original and the substituted amino acids  
10       are acidic, such as glutamic and aspartic acid), such that the substitutions do not essentially alter specified properties of the protein, such as fluorescence. Amino acid substitutions that are conservative are well known in the art. The phrase  
15       "conservatively modified variants thereof," when used to describe a reference nucleic acid, denotes nucleic acids having nucleotide substitutions that yield degenerate codons for a given amino acid or that encode conservative amino acid substitutions, as compared to the reference nucleic acid.

20       The term "recombinant" or "engineered" when used with reference to a nucleic acid or a protein generally denotes that the composition or primary sequence of said nucleic acid or protein has been altered from the naturally occurring sequence using experimental manipulations well known to those skilled in the art. It may also denote that a  
25       nucleic acid or protein has been isolated and cloned into a vector, or that the nucleic acid that has been introduced into or expressed in a cell or cellular environment other than the cell or cellular environment in which said nucleic acid or protein may be found in nature. The phrase "engineered  
30       Aequorea victoria fluorescent protein" specifically encompasses a protein obtained by introducing one or more sequence alterations into the coding region of a nucleic acid that encodes wild type Aequorea victoria GFP, wherein the gene product of the engineered nucleic acid is a fluorescent  
35       protein recognized by antisera to wild type Aequorea victoria GFP.

      The term "recombinant" or "engineered" when used with reference to a cell indicates that, as a result of

experimental manipulation, the cell replicates or expresses a nucleic acid or expresses a peptide or protein encoded by a nucleic acid, whose origin is exogenous to the cell.

5 Recombinant cells can express nucleic acids that are not found within the native (non-recombinant) form of the cell.

Recombinant cells can also express nucleic acids found in the native form of the cell wherein the nucleic acids are re-introduced into the cell by artificial means.

10 The term "vector" denotes an engineered nucleic acid construct that contains sequence elements that mediate the replication of the vector sequence and/or the expression of coding sequences present on the vector. Examples of vectors include eukaryotic and prokaryotic plasmids, viruses (for example, the HIV virus), cosmids, phagemids, and the like.

15 The term "operably linked" refers to functional linkage between a first nucleic acid (for example, an expression control sequence such as a promoter or an array of transcription factor binding sites) and a second nucleic acid sequence, wherein the expression control sequence directs  
20 transcription of the nucleic acid corresponding to the second sequence. One or more selected isolated nucleic acids may be operably linked to a vector by methods known in the art.

"Transduction" or "transformation" denotes the process whereby exogenous extracellular DNA is introduced into  
25 a cell, such that the cell is capable of replicating and or expressing the exogenous DNA. Generally, a selected nucleic acid is first inserted into a vector and the vector is then introduced into the cell. For example, plasmid DNA that is introduced under appropriate environmental conditions may  
30 undergo replication in the transformed cell, and the replicated copies are distributed to progeny cells when cell division occurs. As a result, a new cell line is established, containing the plasmid and carrying the genetic determinants thereof. Transformation by a plasmid in this manner, where  
35 the plasmid genes are maintained in the cell line by plasmid replication, occurs at high frequency when the transforming plasmid DNA is in closed loop form, and does not or rarely occurs if linear plasmid DNA is used.

All the patents and publications cited in this disclosure are indicative of the level of skill of those skilled in the art to which this invention pertains and are all herein individually incorporated by reference for all purposes.

## II. The GFP Mutants and Their Expression

### A. The GFP mutants

The isolated nucleic acids reported here are those that encode an engineered protein derived from *Aequorea victoria* green fluorescent protein ("GFP") having a fluorescence at maximum emission that is at least five times greater, preferably ten times greater, and most preferably twenty times greater than the fluorescence at maximum emission of wild type GFP. In one embodiment, a nucleic acid encodes for leucine at amino acid position 65. This amino acid position is important for the enhanced fluorescence. In another embodiment the engineered isolated GFP nucleic acid also encodes for threonine at amino acid position 168. In an additional embodiment, the engineered isolated GFP nucleic acid further encodes for cysteine at amino acid position 66.

Also described here are GFP mutants that have enhanced blue fluorescent properties. These mutants have an isolated nucleic acid that encode an engineered *Aequorea victoria* blue fluorescent protein that encodes for histidine at amino acid position 67, leucine at amino acid position 65 and has a cellular fluorescence that is at least five times greater, preferably 10 times greater, most preferably 20 times greater than that of BFP(Tyr<sub>67</sub>→His). An alternative isolated BFP nucleic acid is one that encodes for an engineered *Aequorea victoria* blue fluorescent protein wherein the engineered BFP has histidine at amino acid position 67 and alanine at amino acid position 164. A third engineered isolated BFP nucleic acid sequence is one that has histidine at amino acid position 67, leucine at amino acid position 65 and alanine at amino acid position 164.

The nucleic acid and amino acid sequences for the wild type GFP are set out in SEQ ID NO:1 and SEQ ID NO:2. The sequence is well-known, well-described and readily available for manipulation and use. Vectors bearing the nucleic acid sequence are commercially readily available from, for example, Clontech Laboratories, Inc., Clontech Laboratories, Inc., Palo Alto, CA. Clontech provides a line of reporter vectors for GFP, including the cDNA construct described by Chalfie, et al., *supra*, a promoterless GFP vector for monitoring the expression of cloned promoters in mammalian cells, and a series of vectors for creating fusion proteins to either the amino or carboxy terminus of GFP.

One of skill in the art will recognize many ways of generating alterations in a given nucleic acid sequence. Such well-known methods include site-directed mutagenesis, PCR amplification using degenerate oligonucleotides, exposure of cells containing the nucleic acid to mutagenic agents or radiation, chemical synthesis of a desired oligonucleotide (e.g., in conjunction with ligation and/or cloning to generate large nucleic acids) and other well-known techniques. See, e.g., Berger and Kimmel, *Guide to Molecular Cloning Techniques, Methods in Enzymology* Volume 152 Academic Press, Inc., San Diego, CA (Berger); Sambrook et al. (1989) *Molecular Cloning - A Laboratory Manual* (2nd ed.) Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY, (Sambrook); and *Current Protocols in Molecular Biology*, F.M. Ausubel et al., eds., *Current Protocols*, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1994 Supplement) (Ausubel); Pirrung et al., U.S. Patent No. 5,143,854; and Fodor et al., *Science*, 251, 767-77 (1991). Product information from manufacturers of biological reagents and experimental equipment also provide information useful in known biological methods. Such manufacturers include the SIGMA Chemical Company (Saint Louis, MO), R&D systems (Minneapolis, MN), Pharmacia LKB Biotechnology (Piscataway, NJ), CLONTECH Laboratories, Inc. (Palo Alto, CA), Chem Genes Corp., Aldrich Chemical Company (Milwaukee, WI), Glen Research, Inc., GIBCO BRL Life Technologies, Inc.



(Gaithersburg, MD), Fluka Chemica-Biochemika Analytika (Fluka Chemie AG, Buchs, Switzerland), and Applied Biosystems (Foster City, CA), as well as many other commercial sources known to one of skill. Using these techniques, it is possible to substitute at will any nucleotide in a nucleic acid that encodes any GFP or BFP disclosed herein or any amino acid in a GFP or BFP described herein for a predetermined nucleotide or amino acid. For example, it is possible to generate at will modified GFPs and BFP(Tyr<sub>67</sub>→His)s that contain leucine at position 65 and one or two or three additional mutations at any other position of the wtGFP or BFP(Tyr<sub>67</sub>→His).

The sequence of the cloned genes and synthetic oligonucleotides can be verified using the chemical degradation method of A.M. Maxam et al. (1980), *Methods in Enzymology* 65:499-560. The sequence can be confirmed after the assembly of the oligonucleotide fragments into the double-stranded DNA sequence using the method of Maxam and Gilbert, *supra*, or the chain termination method for sequencing double-stranded templates of R.B. Wallace et al. (1981), *Gene*, 16:21-26. DNA sequencing may also be performed by the PCR-assisted fluorescent terminator method (ReadyReaction DyeDeoxy Terminator Cycle Sequencing Kit, ABI, Columbia, MD) according to the manufacturer's instructions, using the ABI Model 373A DNA Sequencing System. Sequencing data is analyzed using the commercially available Sequencher program (Gene Codes, Gene Codes, Ann Arbor, MI).

#### B. Expression of Mutant GFP

Clearly, the nucleic acid sequences of the present invention are excellent reporter sequences since the expressed proteins can be readily detected by fluorescence as described below. The sequences can be used in conjunction with any application appreciated to date for GFP and further in applications where a greater degree of fluorescence is required. Expression of the sequences described herein whether expression is desired alone or in combination with other sequences of interest is described below.

Vectors to which selected foreign nucleic acids are operably linked may be used to introduce these selected nucleic acids into host cells and mediate their replication and/or expression. Cloning vectors are useful for replicating  
5 the foreign nucleic acids and obtaining clones of specific foreign nucleic acid-containing vectors. Expression vectors mediate the expression of the foreign nucleic acid. Some vectors are both cloning and expression vectors.

Once a nucleic acid is synthesized or isolated and  
10 inserted into a vector and cloned, one may express the nucleic acid in a variety of recombinantly engineered cells known to those of skill in the art. As used herein, "expression" refers to transcription of nucleic acids, either without or preferably with subsequent translation.

15 Expression of a mutant BFP or of wild type or mutant GFP can be enhanced by including multiple copies of the GFP-encoding nucleic acid in a transformed host, by selecting a vector known to reproduce in the host, thereby producing large quantities of protein from exogenous inserted DNA (such as  
20 pUC8, ptacl2, or pIN-III-ompA1, 2, or 3), or by any other known means of enhancing peptide expression. In all cases, wtGFP or mutant GFPs will be expressed when the DNA sequence is functionally inserted into a vector. "Functionally inserted" means that it is inserted in proper reading frame  
25 and orientation. Typically, a GFP gene will be inserted downstream from a promoter and will be followed by a stop codon, although production as a hybrid protein followed by cleavage may be used, if desired.

Examples of cells which are suitable for the cloning  
30 and expression of the nucleic acids of the invention include bacteria, yeast, filamentous fungi, insect (especially employing baculoviral vectors), and mammalian cells, in particular cells capable of being maintained in tissue culture.

35 Host cells are competent or rendered competent for transformation by various means. There are several well-known methods of introducing DNA into animal cells. These include: calcium phosphate precipitation, fusion of the recipient cells

with bacterial protoplasts containing the DNA, treatment of the recipient cells with liposomes containing the DNA, DEAE dextran, receptor-mediated endocytosis, electroporation and micro-injection of the DNA directly into the cells.

5           It is expected that those of skill in the art are knowledgeable in the numerous systems available for cloning and expression of nucleic acids. In brief summary, the expression of natural or synthetic nucleic acids is typically achieved by operably linking a nucleic acid of interest to a  
10           promoter (which is either constitutive or inducible), and incorporating the construct into an expression vector. The vectors are suitable for replication and integration in prokaryotes, eukaryotes, or both. Typical cloning vectors contain transcription and translation terminators,  
15           transcription and translation initiation sequences, and promoters useful for regulation of the expression of the particular nucleic acid. The vectors optionally comprise generic expression cassettes containing at least one independent terminator sequence, sequences permitting  
20           replication of the cassette in eukaryotes, or prokaryotes, or both, (e.g., shuttle vectors) and selection markers for both prokaryotic and eukaryotic systems. See, e.g., Sambrook and Ausbel (both *supra*).

#### 25           1.    **Expression in Prokaryotes**

          Prokaryotic systems for cloning and/or expressing engineered GFP or BFP proteins are available using *E. coli*, *Bacillus* sp. and *Salmonella* (Palva, I. et al. (1983), *Gene* 22:229-235; Mosbach, K. et al. (1983), *Nature* 302:543-545. To  
30           obtain high level expression in a prokaryotic system of a cloned nucleic acid such as those encoding engineered GFPs or BFPs, it is essential to construct expression vectors which contain, at a minimum, a strong promoter to direct transcription, a ribosome binding site for translational  
35           initiation, a transcription/translation terminator, a bacterial replicon, a nucleic acid encoding antibiotic resistance to permit selection of bacteria that harbor recombinant plasmids, and unique restriction sites in

nonessential regions of the plasmid to allow insertion of foreign nucleic acids. The particular antibiotic resistance gene chosen is not critical, any of the many resistance genes known in the art are suitable. Examples of regulatory regions suitable for this purpose in *E. coli* are the promoter and operator region of the *E. coli* tryptophan biosynthetic pathway as described by Yanofsky, C. (1984), *J. Bacteriol.*, 158:1018-1024, and the leftward promoter of phage lambda ( $P_L$ ) as described by Herskowitz, I. and Hagen, D. (1980), *Ann. Rev. Genet.*, 14:399-445 (1980).

The particular vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for replication, cloning and/or expression in prokaryotic cells may be used.

The foreign nucleic acid can be incorporated into a nonessential region of the host cell's chromosome. This is achieved by first inserting the nucleic acid into a vector such that it is flanked by regions of DNA homologous to the insertion site in the host chromosome. After introduction of the vector into a host cell, the foreign nucleic acid is incorporated into the chromosome by homologous recombination between the flanking sequences and chromosomal DNA.

Detection of the expressed protein is achieved by methods known in the art as radioimmunoassays, or Western blotting techniques or immunoprecipitation. Purification from *E. coli* can be achieved following procedures described in U.S. Patent No. 4,511,503.

## 2. Expression in Eukaryotes

Standard eukaryotic transfection methods are used to produce mammalian, yeast or insect cell lines which express large quantities of engineered GFP or BFP protein which are then purified using standard techniques. See, e.g., Colley et al. (1989), *J. Biol. Chem.* 264:17619-17622, and Guide to Protein Purification, in Vol. 182 of *Methods in Enzymology* (Deutscher ed., 1990), D.A. Morrison (1977), *J. Bact.*, 132:349-351, or by J.E. Clark-Curtiss and R. Curtiss (1983),

*Methods in Enzymology* 101:347-362, Eds. R. Wu et al., Academic Press, New York.

The particular eukaryotic expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic cells may be used. Expression vectors containing regulatory elements from eukaryotic viruses such as retroviruses are typically used. SV40 vectors include pSVT7 and pMT2. Vectors derived from bovine papilloma virus include pBV-1MTHA, and vectors derived from Epstein Barr virus include pHEBO, and p205. Other exemplary vectors include pMSG, pAV009/A<sup>+</sup>, pMT010/A<sup>+</sup>, pMAMneo-5, baculovirus pDSVE, and any other vector allowing expression of proteins under the direction of the SV-40 early promoter, SV-40 later promoter, metallothionein promoter, murine mammary tumor virus promoter, Rous sarcoma virus promoter, polyhedrin promoter, or other promoters shown effective for expression in eukaryotic cells.

The expression vector typically comprises a eukaryotic transcription unit or expression cassette that contains all the elements required for the expression of the engineered GFP or BFP DNA in eukaryotic cells. A typical expression cassette contains a promoter operably linked to the DNA sequence encoding a engineered GFP or BFP protein and signals required for efficient polyadenylation of the transcript.

Eukaryotic promoters typically contain two types of recognition sequences, the TATA box and upstream promoter elements. The TATA box, located 25-30 base pairs upstream of the transcription initiation site, is thought to be involved in directing RNA polymerase to begin RNA synthesis. The other upstream promoter elements determine the rate at which transcription is initiated.

Enhancer elements can stimulate transcription up to 1,000 fold from linked homologous or heterologous promoters. Enhancers are active when placed downstream or upstream from the transcription initiation site. Many enhancer elements derived from viruses have a broad host range and are active in a variety of tissues. For example, the SV40 early gene

enhancer is suitable for many cell types. Other enhancer/promoter combinations that are suitable for the present invention include those derived from polyoma virus, human or murine cytomegalovirus, the long term repeat from various retroviruses such as murine leukemia virus, murine or Rous sarcoma virus and HIV. See, *Enhancers and Eukaryotic Expression*, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 1983, which is incorporated herein by reference.

In the construction of the expression cassette, the promoter is preferably positioned about the same distance from the heterologous transcription start site as it is from the transcription start site in its natural setting. As is known in the art, however, some variation in this distance can be accommodated without loss of promoter function.

In addition to a promoter sequence, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

If the mRNA encoded by the structural gene is to be efficiently translated, polyadenylation sequences are also commonly added to the vector construct. Two distinct sequence elements are required for accurate and efficient polyadenylation: GU or U rich sequences located downstream from the polyadenylation site and a highly conserved sequence of six nucleotides, AAUAAA, located 11-30 nucleotides upstream. Termination and polyadenylation signals that are suitable for the present invention include those derived from SV40, or a partial genomic copy of a gene already resident on the expression vector.

In addition to the elements already described, the expression vector of the present invention may typically contain other specialized elements intended to increase the level of expression of cloned nucleic acids or to facilitate the identification of cells that carry the transfected DNA. For instance, a number of animal viruses contain DNA sequences that promote the extra chromosomal replication of the viral

genome in permissive cell types. Plasmids bearing these viral replicons are replicated episomally as long as the appropriate factors are provided by genes either carried on the plasmid or with the genome of the host cell.

5           The DNA sequence encoding the engineered GFP or BFP protein may typically be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell. Such signal peptides would include, among others, the signal peptides from tissue plasminogen activator, 10 insulin, neuron growth factor, and juvenile hormone esterase of *Heliothis virescens*. Additional elements of the cassette may include enhancers and, if genomic DNA is used as the structural gene, introns with functional splice donor and acceptor sites.

15           The vector may or may not comprise a eukaryotic replicon. If a eukaryotic replicon is present, then the vector is amplifiable in eukaryotic cells using the appropriate selectable marker. If the vector does not comprise a eukaryotic replicon, no episomal amplification is 20 possible. Instead, the transfected DNA integrates into the genome of the transfected cell, where the promoter directs expression of the desired nucleic acid.

          The vectors usually comprise selectable markers which result in nucleic acid amplification such as the sodium, 25 potassium ATPase, thymidine kinase, aminoglycoside phosphotransferase, hygromycin B phosphotransferase, xanthine-guanine phosphoribosyl transferase, CAD (carbamyl phosphate synthetase, aspartate transcarbamylase, and dihydroorotase), adenosine deaminase, dihydrofolate reductase, 30 and asparagine synthetase and ouabain selection.

Alternatively, high yield expression systems not involving nucleic acid amplification are also suitable, such as using a baculovirus vector in insect cells, with the engineered GFP or BFP encoding sequence under the direction of the polyhedrin 35 promoter or other strong baculovirus promoters.

          The expression vectors of the present invention will typically contain both prokaryotic sequences that facilitate the cloning of the vector in bacteria as well as one or more

eukaryotic transcription units that are expressed only in eukaryotic cells, such as mammalian cells. The prokaryotic sequences are preferably chosen such that they do not interfere with the replication of the DNA in eukaryotic cells.

5           Any of the well known procedures for introducing foreign nucleotide sequences into host cells may be used. These include the use of calcium phosphate transfection, polybrene, protoplast fusion, electroporation, liposomes, microinjection, plasma vectors, viral vectors and any of the  
10           other well known methods for introducing cloned genomic DNA, cDNA, synthetic DNA or other foreign nucleic acid material into a host cell (see Sambrook et al., *supra*). It is only necessary that the particular genetic engineering procedure  
15           utilized be capable of successfully introducing at least one nucleic acid into the host cell which is capable of expressing the engineered GFP or BFP protein.

### 3. Expression in insect cells

          The baculovirus expression vector utilizes the  
20           highly expressed and regulated *Autographa californica* nuclear polyhedrosis virus (AcMNPV) polyhedrin promoter modified for the insertion of foreign nucleic acids. Synthesis of polyhedrin protein results in the formation of occlusion  
25           bodies in the infected insect cell. The baculovirus vector utilizes many of the protein modification, processing, and  
30           transport systems that occur in higher eukaryotic cells. The recombinant eukaryotic proteins expressed using this vector have been found in many cases to be, antigenically, immunogenically, and functionally similar to their natural counterparts.

          Briefly, a DNA sequence encoding an engineered GFP or BFP is inserted into a transfer plasmid vector in the proper orientation downstream from the polyhedrin promoter, and flanked on both ends with baculovirus sequences. Cultured  
35           insect cells, commonly *Spodoptera frugiperda* cells, are transfected with a mixture of viral and plasmid DNAs. The virus that develop, some of which are recombinant virus that result from homologous recombination between the two DNAs, are



plated at 100-1000 plaques per plate. The plaques containing recombinant virus can be identified visually because of their ability to form occlusion bodies or by DNA hybridization. The recombinant virus is isolated by plaque purification. The  
5 resulting recombinant virus, capable of expressing engineered GFP or BFP, is self-propagating in that no helper virus is required for maintenance or replication. After infecting an insect culture with recombinant virus, one can expect to find recombinant protein within 48-72 hours. The infection is  
10 essentially lytic within 4-5 days.

There are a variety of transfer vectors into which the engineered GFP or BFP nucleic acid can be inserted. For a summary of transfer vectors see Luckow, V.A. and Summers, M.D. (1988), *Bio/Technology* 6:47-55. Preferred is the transfer  
15 vector pAcUW21 described by Bishop, D.H.L. (1992) in *Seminars in Virology* 3:253-264.

#### 4. Retroviral Vectors

Retroviral vectors are particularly useful for  
20 modifying eukaryotic cells because of the high efficiency with which the retroviral vectors transduce target cells and integrate into the target cell genome. Additionally, the retroviruses harboring the retroviral vector are capable of infecting cells from a wide variety of tissues.

Retroviral vectors are produced by genetically  
25 manipulating retroviruses. Retroviruses are RNA viruses because the viral genome is RNA. Upon infection, this genomic RNA is reverse transcribed into a DNA copy which is integrated into the chromosomal DNA of transduced cells with a high  
30 degree of stability and efficiency. The integrated DNA copy is referred to as a provirus and is inherited by daughter cells as is any other gene. The wild type retroviral genome and the proviral DNA have three genes: the *gag*, the *pol* and the *env* genes, which are flanked by two long terminal repeat  
35 (LTR) sequences. The *gag* gene encodes the internal structural (nucleocapsid) proteins; the *pol* gene encodes the RNA directed DNA polymerase (reverse transcriptase); and the *env* gene encodes viral envelope glycoproteins. The 5' and 3' LTRs

serve to promote transcription and polyadenylation of virion RNAs. Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsulation of viral RNA into particles (the Psi site). See Mulligan, R.C. (1983), In: *Experimental Manipulation of Gene Expression*, M. Inouye (ed), 155-173; Mann, R. et al. (1983), *Cell*, 33:153-159; Cone, R.D. and R.C. Mulligan (1984), *Proceedings of the National Academy of Sciences, U.S.A.* 81:6349-6353.

10           The design of retroviral vectors is well known to one of skill in the art. See Singer, M. and Berg, P. *supra*. In brief, if the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virions) are missing from the viral genome, the result is a *cis* acting defect which prevents encapsidation of genomic RNA. However, the resulting mutant is still capable of directing the synthesis of all virion proteins. Retroviral genomes from which these sequences have been deleted, as well as cell lines containing the mutant genome stably integrated into the chromosome are well known in the art and are used to construct retroviral vectors. Preparation of retroviral vectors and their uses are described in many publications including European Patent Application EPA 0 178 220, U.S. Patent 4,405,712, Gilboa (1986), *Biotechniques* 4:504-512, Mann, et al. (1983), *Cell* 33:153-159, Cone and Mulligan (1984), *Proc. Natl. Acad. Sci. USA* 81:6349-6353, Eglitis, M.A, et al. (1988) *Biotechniques* 6:608-614, Miller, A.D. et al. (1989) *Biotechniques* 7:981-990, Miller, A.D. (1992) *Nature*, *supra*, Mulligan, R.C. (1993), *supra*. and Gould, B. et al., and International Patent Application No. WO 92/07943 entitled "Retroviral Vectors Useful in Gene Therapy." The teachings of these patents and publications are incorporated herein by reference.

35           The retroviral vector particles are prepared by recombinantly inserting the nucleic acid encoding engineered GFP or BFP into a retrovirus vector and packaging the vector with retroviral capsid proteins by use of a packaging cell line. The resultant retroviral vector particle is incapable

of replication in the host cell and is capable of integrating into the host cell genome as a proviral sequence containing the engineered GFP or BFP nucleic acid. As a result, the patient is capable of producing engineered GFP or BFP and  
5 metabolize glycogen to completion.

Packaging cell lines are used to prepare the retroviral vector particles. A packaging cell line is a genetically constructed mammalian tissue culture cell line that produces the necessary viral structural proteins required  
10 for packaging, but which is incapable of producing infectious virions. Retroviral vectors, on the other hand, lack the structural genes but have the nucleic acid sequences necessary for packaging. To prepare a packaging cell line, an infectious clone of a desired retrovirus, in which the  
15 packaging site has been deleted, is constructed. Cells comprising this construct will express all structural proteins but the introduced DNA will be incapable of being packaged. Alternatively, packaging cell lines can be produced by transforming a cell line with one or more expression plasmids  
20 encoding the appropriate core and envelope proteins. In these cells, the *gag*, *pol*, and *env* genes can be derived from the same or different retroviruses.

A number of packaging cell lines suitable for the present invention are available in the prior art. Examples of  
25 these cell lines include Crip, GPE86, PA317 and PG13. See Miller et al. (1991), *J. Virol.* 65:2220-2224, which is incorporated herein by reference. Examples of other packaging cell lines are described in Cone, R. and Mulligan, R.C. (1984), *Proceedings of the National Academy of Sciences*,  
30 U.S.A., 81:6349-6353 and in Danos, O. and R.C. Mulligan (1988), *Proceedings of the National Academy of Sciences*, U.S.A., 85:6460-6464, Eglitis, M.A., et al. (1988) *Biotechniques* 6:608-614, also all incorporated herein by reference.

35 Packaging cell lines capable of producing retroviral vector particles with chimeric envelope proteins may be used. Alternatively, amphotropic or xenotropic envelope proteins,

such as those produced by PA317 and GPX packaging cell lines may be used to package the retroviral vectors.

Transforming cells with nucleic acids can involve, for example, incubating the cells with viral vectors (e.g., retroviral or adeno-associated viral vectors) containing with cells within the host range of the vector. See, e.g., *Methods in Enzymology*, Vol. 185, Academic Press, Inc., San Diego, CA (D.V. Goeddel, ed.) (1990) or M. Krieger (1990), *Gene Transfer and Expression -- A Laboratory Manual*, Stockton Press, New York, NY, and the references cited therein.

#### 5. Transformation with adeno-associated virus

Adeno associated viruses (AAVs) require helper viruses such as adenovirus or herpes virus to achieve productive infection. In the absence of helper virus functions, AAV integrates (site-specifically) into a host cell's genome, but the integrated AAV genome has no pathogenic effect. The integration step allows the AAV genome to remain genetically intact until the host is exposed to the appropriate environmental conditions (e.g., a lytic helper virus), whereupon it re-enters the lytic life-cycle. Samulski (1993), *Current Opinion in Genetic and Development* 3:74-80 and the references cited therein provides an overview of the AAV life cycle.

AAV-based vectors are used to transduce cells with target nucleic acids, e.g., in the *in vitro* production of nucleic acids and peptides, and in *in vivo* and *ex vivo* gene therapy procedures. See, West et al. (1987), *Virology* 160:38-47; Carter et al. (1989) U.S. Patent No. 4,797,368; Carter et al. (1993), WO 93/24641; Kotin (1994), *Human Gene Therapy* 5:793-801; Muzyczka (1994), *J. Clin. Invest.* 94:1351 and Samulski (*supra*) for an overview of AAV vectors.

Recombinant AAV vectors (rAAV vectors) deliver foreign nucleic acids to a wide range of mammalian cells (Hermonat & Muzyczka (1984), *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985), *Mol. Cell Biol.* 5:3251-3260), integrate into the host chromosome (McLaughlin et al. (1988), *J. Virol.* 62:1963-1973), and show stable

expression of the transgene in cell and animal models (Flotte et al. (1993), *Proc. Natl. Acad. Sci. USA* 90:10613-10617). Moreover, unlike some retroviral vectors, rAAV vectors are able to infect non-dividing cells (Podsakoff et al. (1994), *J. Virol.* 68:5656-66; Flotte et al. (1994), *Am. J. Respir. Cell Mol. Biol.* 11:517-521). Further advantages of rAAV vectors include the lack of an intrinsic strong promoter, thus avoiding possible activation of downstream cellular sequences, and their naked icosahedral capsid structure, which renders them stable and easy to concentrate by common laboratory techniques. rAAV vectors are used to inhibit, e.g., viral infection, by including anti-viral transcription cassettes in the rAAV vector which comprise an inhibitor of the invention.

**6. Expression in recombinant vaccinia virus-infected cells**

The nucleic acid encoding engineered GFP or BFP is inserted into a plasmid designed for producing recombinant vaccinia, such as pGS62, Langford, C.L. et al. (1986), *Mol. Cell. Biol.* 6:3191-3199. This plasmid consists of a cloning site for insertion of foreign nucleic acids, the P7.5 promoter of vaccinia to direct synthesis of the inserted nucleic acid, and the vaccinia TK gene flanking both ends of the foreign nucleic acid.

When the plasmid containing the engineered GFP or BFP nucleic acid is constructed, the nucleic acid can be transferred to vaccinia virus by homologous recombination in the infected cell. To achieve this, suitable recipient cells are transfected with the recombinant plasmid by standard calcium phosphate precipitation techniques into cells already infected with the desirable strain of vaccinia virus, such as Wyeth, Lister, WR or Copenhagen. Homologous recombination occurs between the TK gene in the virus and the flanking TK gene sequences in the plasmid. This results in a recombinant virus with the foreign nucleic acid inserted into the viral TK gene, thus rendering the TK gene inactive. Cells containing recombinant viruses are selected by adding medium containing 5-bromodeoxyuridine, which is lethal for cells expressing a TK gene.

Confirmation of production of recombinant virus is achieved by DNA hybridization using cDNA encoding the engineered GFP or BFP and by immunodetection techniques using antibodies specific for the expressed protein. Virus stocks  
5 may be prepared by infection of cells such as HeLa S3 spinner cells and harvesting of virus progeny.

#### 7. Expression in cell cultures

GFP- or BFP-encoding nucleic acids can be ligated to  
10 various expression vectors for use in transforming host cell cultures. The culture of cells used in conjunction with the present invention is well known in the art. Freshney (1994) (*Culture of Animal Cells, a Manual of Basic Technique*, third edition Wiley-Liss, New York), Kuchler et al. (1977)  
15 *Biochemical Methods in Cell Culture and Virology*, Kuchler, R.J., Dowden, Hutchinson and Ross, Inc., and the references cited therein provides a general guide to the culture of cells. Illustrative cell cultures useful for the production of recombinant proteins include cells of insect or mammalian  
20 origin. Mammalian cell systems often will be in the form of monolayers of cells, although mammalian cell suspensions are also used. Illustrative examples of mammalian cell lines include monocytes, lymphocytes, macrophage, VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK,  
25 Cos-7 or MDCK cell lines (see, e.g., Freshney, *supra*).

Cells of mammalian origin are illustrative of cell cultures useful for the production of the engineered GFP or BFP. Mammalian cell systems often will be in the form of monolayers of cells although mammalian cell suspensions may  
30 also be used. Illustrative examples of mammalian cell lines include VERO and HeLa cells, Chinese hamster ovary (CHO) cell lines, WI38, BHK, COS-7 or MDCK cell lines.

As indicated above, the vector, e.g., a plasmid, which is used to transform the host cell, preferably contains  
35 DNA sequences to initiate transcription and sequences to control the translation of the engineered GFP or BFP nucleic acid sequence. These sequences are referred to as expression control sequences. Illustrative expression control sequences

are obtained from the SV-40 promoter (*Science* 222:524-527, (1983)), the CMV i.e. Promoter (*Proc. Natl. Acad. Sci.* 81:659-663, (1984)) or the metallothionein promoter (*Nature* 296:39-42, (1982)). The cloning vector containing the  
5 expression control sequences is cleaved using restriction enzymes and adjusted in size as necessary or desirable and ligated with sequences encoding the engineered GFP or BFP protein by means well known in the art.

The vectors for transforming cells in culture  
10 typically contain gene sequences to initiate transcription and translation of the engineered GFP or BFP gene. These sequences need to be compatible with the selected host cell. In addition, the vectors preferably contain a marker to provide a phenotypic trait for selection of transformed host  
15 cells such as dihydrofolate reductase or metallothionein. Additionally, a vector might contain a replicative origin.

As mentioned above, when higher animal host cells are employed, polyadenylation or transcription terminator sequences from known mammalian genes need to be incorporated  
20 into the vector. An example of a terminator sequence is the polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of the transcript may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague, J. et al. (1983), *J. Virol.* 45: 773-781).

25 Additionally gene sequences to control replication in the host cell may be incorporated into the vector such as those found in bovine papilloma virus type-vectors. Saveria-Campo, M. (1985), "Bovine Papilloma virus DNA a Eukaryotic Cloning Vector" in *DNA Cloning Vol.II a Practical Approach* Ed. D.M. Glover, IRL Press, Arlington, Virginia pp.  
30 213-238.

The transformed cells are cultured by means well known in the art. For example, as published in Kuchler, R.J. et al., (1977), *Biochemical Methods in Cell Culture and*  
35 *Virology*.

In addition to the above general procedures which can be used for preparing recombinant DNA molecules and transformed unicellular organisms in accordance with the

practices of this invention, other known techniques and modifications thereof can be used in carrying out the practice of the invention. Any known system for expression of isolated genes is suitable for use in the present invention. For  
5 example, viral expression systems such as the baculovirus expression system are specifically contemplated within the scope of the invention. Many recent U.S. patents disclose plasmids, genetically engineering microorganisms, and methods of conducting genetic engineering which can be used in the  
10 practice of the present invention. For example, U.S. Pat. No. 4,273,875 discloses a plasmid and a process of isolating the same. U.S. Pat. No. 4,304,863 discloses a process for producing bacteria by genetic engineering in which a hybrid plasmid is constructed and used to transform a bacterial host.  
15 U.S. Pat. No. 4,419,450 discloses a plasmid useful as a cloning vehicle in recombinant DNA work. U.S. Pat. No. 4,362,867 discloses recombinant cDNA construction methods and hybrid nucleotides produced thereby which are useful in cloning processes. U.S. Pat. No. 4,403,036 discloses genetic  
20 reagents for generating plasmids containing multiple copies of DNA segments. U.S. Pat. No. 4,363,877 discloses recombinant DNA transfer vectors. U.S. Pat. No. 4,356,270 discloses a recombinant DNA cloning vehicle and is a particularly useful disclosure for those with limited experience in the area of  
25 genetic engineering since it defines many of the terms used in genetic engineering and the basic processes used therein. U.S. Pat. No. 4,336,336 discloses a fused gene and a method of making the same. U.S. Pat. No. 4,319,629 discloses plasmid vectors and the production and use thereof. U.S. Pat. No.  
30 4,332,901 discloses a cloning vector useful in recombinant DNA. Although some of these patents are directed to the production of a particular gene product that is not within the scope of the present invention, the procedures described therein can easily be modified to the practice of the  
35 invention described in this specification by those skilled in the art of genetic engineering. Transferring the isolated GFP cDNA to other expression vectors will produce constructs which



improve the expression of the GFP polypeptide in *E. coli* or express GFP in other hosts.

### III. Detection of GFP and BFP Nucleic Acids and Proteins

5

#### A. General detection methods

The nucleic acids and proteins of the invention are detected, confirmed and quantified by any of a number of means well known to those of skill in the art. The unique quality of the inventive expressed proteins here is that they provide an enhanced fluorescence which can be readily and easily observed. Fluorescence assays for the expressed proteins are described in detail below. Other general methods for detecting both nucleic acids and corresponding proteins include analytic biochemical methods such as spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC), thin layer chromatography (TLC), hyperdiffusion chromatography, and the like, and various immunological methods such as fluid or gel precipitin reactions, immunodiffusion (single or double), immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immunofluorescent assays, and the like. The detection of nucleic acids proceeds by well known methods such as Southern analysis, northern analysis, gel electrophoresis, PCR, radiolabeling, scintillation counting, and affinity chromatography.

A variety of methods of specific DNA and RNA measurement using nucleic acid hybridization techniques are known to those of skill in the art. For example, one method for evaluating the presence or absence of engineered GFP or BFP DNA in a sample involves a Southern transfer. Southern et al. (1975), *J. Mol. Biol.* 98:503. Briefly, the digested genomic DNA is run on agarose slab gels in buffer and transferred to membranes. Hybridization is carried out using the probes discussed above. Visualization of the hybridized portions allows the qualitative determination of the presence or absence of engineered GFP or BFP genes.

Similarly, a Northern transfer may be used for the detection of engineered GFP or BFP mRNA in samples of RNA from cells expressing the engineered GFP or BFP gene. In brief, the mRNA is isolated from a given cell sample using an acid  
5 guanidinium-phenol-chloroform extraction method. The mRNA is then electrophoresed to separate the mRNA species and the mRNA is transferred from the gel to a nitrocellulose membrane. As with the Southern blots, labeled probes are used to identify the presence or absence of the engineered GFP or BFP  
10 transcript.

The selection of a nucleic acid hybridization format is not critical. A variety of nucleic acid hybridization formats are known to those skilled in the art. For example, common formats include sandwich assays and competition or  
15 displacement assays. Hybridization techniques are generally described in "Nucleic Acid Hybridization, A Practical Approach," Ed. Hames, B.D. and Higgins, S.J., IRL Press, 1985; Gall and Pardue (1969), *Proc. Natl. Acad. Sci. USA* 63:378-383; and John, Burnsteil and Jones (1969), *Nature* 223:582-587.

For example, sandwich assays are commercially useful hybridization assays for detecting or isolating nucleic acid sequences. Such assays utilize a "capture" nucleic acid covalently immobilized to a solid support and labelled  
20 "signal" nucleic acid in solution. The clinical sample will provide the target nucleic acid. The "capture" nucleic acid and "signal" nucleic acid probe hybridize with the target  
25 nucleic acid to form a "sandwich" hybridization complex. To be effective, the signal nucleic acid cannot hybridize with the capture nucleic acid.

The nucleic acid sequences used in this invention can be either positive or negative probes. Positive probes bind to their targets and the presence of duplex formation is evidence of the presence of the target. Negative probes fail to bind to the suspect target and the absence of duplex  
30 formation is evidence of the presence of the target. For example, the use of a wild type specific nucleic acid probe or PCR primers may act as a negative probe in an assay sample where only the mutant engineered GFP or BFP is present.  
35

Labelled signal nucleic acids, whether those described herein or others known in the art are used to detect hybridization. Complementary nucleic acids or signal nucleic acids may be labelled by any one of several methods typically used to detect the presence of hybridized polynucleotides. One common method of detection is the use of autoradiography with  $^3\text{H}$ ,  $^{125}\text{I}$ ,  $^{35}\text{S}$ ,  $^{14}\text{C}$ , or  $^{32}\text{P}$ -labelled probes or the like. Other labels include ligands which bind to labelled antibodies, fluorophores, chemiluminescent agents, enzymes, and antibodies which can serve as specific binding pair members for a labelled ligand.

Detection of a hybridization complex may require the binding of a signal generating complex to a duplex of target and probe polynucleotides or nucleic acids. Typically, such binding occurs through ligand and anti-ligand interactions as between a ligand-conjugated probe and an anti-ligand conjugated with a signal. The binding of the signal generation complex is also readily amenable to accelerations by exposure to ultrasonic energy.

The label may also allow indirect detection of the hybridization complex. For example, where the label is a hapten or antigen, the sample can be detected by using antibodies. In these systems, a signal is generated by attaching fluorescent or enzyme molecules to the antibodies or in some cases, by attachment to a radioactive label. (Tijssen, P. (1985), "Practice and Theory of Enzyme Immunoassays," *Laboratory Techniques in Biochemistry and Molecular Biology*, Burdon, R.H., van Knippenberg, P.H., Eds., Elsevier, pp. 9-20.)

The sensitivity of the hybridization assays may be enhanced through use of a nucleic acid amplification system which multiplies the target nucleic acid being detected. *In vitro* amplification techniques suitable for amplifying sequences for use as molecular probes or for generating nucleic acid fragments for subsequent subcloning are known. Examples of techniques sufficient to direct persons of skill through such *in vitro* amplification methods, including the polymerase chain reaction (PCR) the ligase chain reaction

(LCR), Q $\beta$ -replicase amplification and other RNA polymerase mediated techniques (e.g., NASBA) are found in Berger, Sambrook, and Ausubel, as well as Mullis et al. (1987), U.S. Patent No. 4,683,202; *PCR Protocols A Guide to Methods and Applications* (Innis et al., eds) Academic Press Inc. San Diego, CA (1990) (Innis); Arnheim & Levinson (October 1, 1990), *Chem. Eng. News* 36-47; *J. NIH Res.* (1991) 3:81-94; (Kwoh et al. (1989), *Proc. Natl. Acad. Sci. USA* 86:1173; Guatelli et al. (1990), *Proc. Natl. Acad. Sci. USA* 87:1874; Lomell et al. (1989), *J. Clin. Chem.* 35:1826; Landegren et al. (1988), *Science* 241:1077-1080; Van Brunt (1990), *Biotechnology* 8:291-294; Wu and Wallace (1989), *Gene* 4:560; Barringer et al. (1990), *Gene* 89:117, and Sooknanan and Malek (1995), *Biotechnology* 13:563-564. Improved methods of cloning in vitro amplified nucleic acids are described in Wallace et al., U.S. Pat. No. 5,426,039. Other methods recently described in the art are the nucleic acid sequence based amplification (NASBA<sup>™</sup>, Cangene, Mississauga, Ontario) and Q Beta Replicase systems. These systems can be used to directly identify mutants where the PCR or LCR primers are designed to be extended or ligated only when a select sequence is present. Alternatively, the select sequences can be generally amplified using, for example, nonspecific PCR primers and the amplified target region later probed for a specific sequence indicative of a mutation.

Oligonucleotides for use as probes, e.g., in in vitro amplification methods, for use as gene probes, or as inhibitor components are typically synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage and Caruthers (1981), *Tetrahedron Letts.* 22(20):1859-1862, e.g., using an automated synthesizer, as described in Needham-VanDevanter et al. (1984), *Nucleic Acids Res.* 12:6159-6168. Purification of oligonucleotides, where necessary, is typically performed by either native acrylamide gel electrophoresis or by anion-exchange HPLC as described in Pearson and Regnier (1983), *J. Chrom.* 255:137-149. The sequence of the synthetic oligonucleotides can be verified using the chemical degradation method of Maxam and Gilbert

(1980) in Grossman and Moldave (eds.) Academic Press, New York, *Methods in Enzymology* 65:499-560.

An alternative means for determining the level of expression of the engineered GFP or BFP gene is *in situ* hybridization. *In situ* hybridization assays are well known and are generally described in Angerer et al. (1987), *Methods Enzymol.* 152:649-660. In an *in situ* hybridization assay cells are fixed to a solid support, typically a glass slide. If DNA is to be probed, the cells are denatured with heat or alkali. The cells are then contacted with a hybridization solution at a moderate temperature to permit annealing of engineered GFP or BFP specific probes that are labelled. The probes are preferably labelled with radioisotopes or fluorescent reporters.

#### B. Fluorescence Assay

When a fluorophore such as protein that is capable of fluorescing is exposed to a light of appropriate wavelength, it will absorb and store light and then release the stored light energy. The range of wavelengths that a fluorophore is capable of absorbing is the excitation spectrum and the range of wavelengths of light that a fluorophore is capable of emitting is the emission or fluorescence spectrum. The excitation and fluorescence spectra for a given fluorophore usually differ and may be readily measured using known instruments and methods. For example, scintillation counters and photometers (e.g. luminometers), photographic film, and solid state devices such as charge coupled devices, may be used to detect and measure the emission of light.

The nucleic acids, vectors, mutant proteins provided herein, in combination with well known techniques for over-expressing recombinant proteins, make it possible to obtain unlimited supplies of homogeneous mutant GFPs and BFPs. These modified GFPs or BFPs having increased fluorescent activity replace wtGFP or other currently employed tracers in existing diagnostic and assay systems. Such currently employed tracers include radioactive atoms or molecules and color-producing enzymes such as horseradish peroxidase.

The benefits of using the mutants of the present invention are at least four-fold: the modified GFPs and BFPs are safer than radioactive-based assays, modified GFPs and BFPs can be assayed quickly and easily, and large numbers of samples can be handled simultaneously, reducing overall handling and increasing efficiency. Of great significance, the expression and subcellular distribution of the fluorescent proteins within cells can be detected in living tissues without any other experimental manipulation than to placing the cells on a slide and viewing them through a fluorescence microscope. This represents a vast improvement over methods of immunodetection that require fixation and subsequent labelling.

The modified GFPs and BFPs of the present invention can be used in standard assays involving a fluorescent marker. For example, ligand-ligand binding pairs that can be modified with the mutants of the present invention without disrupting the ability of each to bind to the other can form the basis of an assay encompassed by the present invention. These and other assays are known in the art and their use with the GFPs and BFPs of the present invention will become obvious to one skilled in the art in light of the teachings disclosed herein. Examples of such assays include competitive assays wherein labeled and unlabeled ligands competitively bind to a ligand, noncompetitive assay where a ligand is captured by a ligand and either measured directly or "sandwiched" with a secondary ligand that is labeled. Still other types of assays include immunoassays, single-step homogeneous assays, multiple-step heterogeneous assays, and enzyme assays.

In a number of embodiments, the mutant GFPs and BFPs are combined with fluorescent microscopy using known techniques (see, e.g., Stauber et al., *Virology* 213:439-454 (1995)) or preferably with fluorescence activated cell sorting (FACS) to detect and optionally purify or clone cells that express specific recombinant constructs. For a brief overview of the FACS and its uses, see: Herzenberg et al., 1976, "Fluorescence activated cell sorting", *Sci. Amer.* 234, 108; see also FLOW CYTOMETRY AND SORTING, eds. Melamad, Mullaney and

Mendelsohn, John Wiley and Sons, Inc., New York, 1979). Briefly, fluorescence activated cell sorters take a suspension of cells and pass them single file into the light path of a laser placed near a detector. The laser usually has a set wavelength. The detector measures the fluorescent emission intensity of each cell as it passes through the instrument and generates a histogram plot of cell number versus fluorescent intensity. Gates or limits can be placed on the histogram thus identifying a particular population of cells. In one embodiment, the cell sorter is set up to select cells having the highest probe intensity, usually a small fraction of the cells in the culture, and to separate these selected cells away from all the other cells. The level of intensity at which the sorter is set and the fraction of cells which is selected, depend on the condition of the parent culture and the criteria of the isolation. In general, the operator should first sort an aliquot of the culture, and record the histogram of intensity versus number of cells. The operator can then set the selection level and isolate an appropriate number of the most active cells. Currently, fluorescence activated cell sorters are equipped with automated cell cloning devices. Such a device enables one to instruct the instrument to singly deposit a selected cell into an individual growth well, where it is allowed to grow into a monoclonal culture. Thus, genetic homogeneity is established within the newly cloned culture.

#### IV. General Applications for the GFP Mutants

It should be self-evident that the mutant GFP and BFP sequences described here have unlimited uses, particularly as signal or reporter sequences for the co-expression of other nucleic acid sequences of interest and/or to track the location and/or movement of other sequences within the cell, within tissue and the like. For example, these reporter type sequences could be used to track the spread (or lack thereof) of a disease causal agent in drug screening assays or could

readily be used in diagnostics. Some of the more interesting applications are described below.

#### A. Protein Trafficking

5 Normally, expressed mutant GFPs and BFPs are distributed throughout the cell (particularly mammalian cells), except for the nucleolus. However, as described below, when a GFP mutant is fused to the HIV-1 Rev protein, a hybrid molecule results which retains the Rev function and is  
10 localized mainly in the nucleolus where Rev is found. Fusion to the N-terminal domain of the HIV-1 Nef protein produces a hybrid protein detectable in the plasma membrane. Thus, the GFP mutants can be used to monitor the subcellular targeting and transport of proteins to which they are fused.

15

#### B. Gene Therapy

The mutant GFPs described here have interesting and useful applications in gene therapy. Gene therapy in general is the correction of genetic defects by insertion of exogenous  
20 cellular genes that encode a desired function into cells that lack that function, such that the expression of the exogenous gene a) corrects a genetic defect or b) causes the destruction of cells that are genetically defective. Methods of gene therapy are well known in the art, see, for example, Lu, M.,  
25 et al. (1994), *Human Gene Therapy* 5:203; Smith, C. (1992), *J. Hematotherapy* 1:155; Cassel, A., et al. (1993), *Exp. Hematol.* 21-:585 (1993); Larrick, J.W. and Burck, K.L., *GENE THERAPY: APPLICATION OF MOLECULAR BIOLOGY*, Elsevier Science Publishing Co., Inc., New York, New York (1991) and Kreigler, M. *GENE TRANSFER*  
30 *AND EXPRESSION: A LABORATORY MANUAL*, W.H. Freeman and Company, New York (1990), each incorporated herein by reference. One modality of gene therapy involves (a) obtaining from a patient a viable sample of primary cells of a particular cell type; (b) inserting into these primary cells a nucleic acid segment  
35 encoding a desired gene product; (c) identifying and isolating cells and cell lines that express the gene product; (d) re-introducing cells that express the gene product; (e) removing from the patient an aliquot of tissue including cells



resulting from step c and their progeny; and (f) determining the quantity of the cells resulting from step c and their progeny, in said aliquot. The introduction into cells in step c of a polycistronic vector that encodes GFP or BFP in addition to the desired gene allows for the quick identification of viable cells that contain and express the desired gene.

Another gene therapy modality involves inserting the desired nucleic acid into selected tissue cells *in situ*, for example into cancerous or diseased cells, by contacting the target cells *in situ* with retroviral vectors that encode the gene product in question. Here, it is important to quickly and reliably assess which and what proportion of cells have been transfected. Co-expression of GFP and BFP permits a quick assessment of proportion of cells that are transfected, and levels of expression.

### C. Diagnostics

One potential application of the GFP/BFP variants is in diagnostic testing. The GFP/BFP gene, when placed under the control of promoters induced by various agents, can serve as an indicator for these agents. Established cell lines or cells and tissues from transgenic animals carrying GFP/BFP expressed under the desired promoter will become fluorescent in the presence of the inducing agent.

Viral promoters which are transactivated by the corresponding virus, promoters of heat shock genes which are induced by various cellular stresses as well as promoters which are sensitive to organismal responses, e.g. inflammation, can be used in combination with the described GFP/BFP mutants in diagnostics.

In addition, the effect of selected culture conditions and components (salt concentrations, pH, temperature, trans-acting regulatory substances, hormones, cell-cell contacts, ligands of cell surface and internal receptors) can be assessed by incubating cells in which sequences encoding the fluorescent proteins provided herein are operably linked to nucleic acids (especially regulatory

elements such as promoters) derived from a selected gene, and detecting the expression and location of fluorescence.

#### D. Toxicology

Another application of the GFP/BFP-based methodologies is in the area of toxicology. Assessment of the mutagenic potential of any compound is a prerequisite for its use. Until recently, the Ames assay in *Salmonella* and tests based on chromosomal aberrations or sister chromatid exchanges in cultured mammalian cells were the main tools in toxicology. However, both assays are of limited sensitivity and specificity and do not allow studies on mutation induction in various organs or tissues of the intact organism.

The introduction of transgenic mice with a mutational target in a shuttle vector has made possible the detection of induced mutations in different tissues in vivo. The assay involves DNA isolation from tissues of exposed mice, packaging of the target DNA into bacteriophage lambda particles and subsequent infection of *E. coli*. The mutational target in this assay is either the lacZ or lacI genes and quantitation of blue vs white plaques on the bacterial lawn allows for mutagenic assessment.

GFP/BFP could significantly simplify both the tissue culture and transgenic mouse procedures. Expression of GFP/BFP under the control of a repressor, which in turn is driven by the promoter of a constitutively expressed gene, will establish a rapid method for evaluating the mutagenic potential of an agent. The presence of fluorescent cells, following exposure of a cell line, tissue or whole animal carrying the GFP/BFP-based detection construct, will reflect the mutagenicity of the compound in question. GFP/BFP expressed under the control of the target DNA, the repressor gene, will only be synthesized when the repressor is inactivated or turned off or the repressor recognition sequences are mutated. Direct visualization of the detector cell line or tissue biopsy can qualitatively assess the mutagenicity of the agent, while FACS of the dissociated cells can provide for quantitative analysis.

### E. Drug Screening

The GFP/BFP detection system could also significantly expedite and reduce the cost of some current drug screening procedures. A dual color screening system (DCSS), in which GFP is placed under the promoter of a target gene and BFP is expressed from a constitutive promoter, could provide for rapid analysis of agents that specifically affect the target gene. Established cell lines with the DCSS could be screened with hundreds of compounds in few hours. The desired drug will only influence the expression of GFP. Non-specific or cytotoxic effects will be detected by the second marker, BFP. The advantages of this system are that no exogenous substances are required for GFP and BFP detection, the assay can be used with single cells, cell populations, or cell extracts, and that the same detection technology and instrumentation is used for very rapid and non-destructive detection.

The search for antiviral agents which specifically block viral transcription without affecting cellular transcription, could be significantly improved by the DCSS. In the case of HIV, appropriate cell lines expressing GFP under the HIV LTR and BFP under a cellular constitutive promoter, could identify compounds which selectively inhibit HIV transcription. Reduction of only the green but not the blue fluorescent signal will indicate drug specificity for the HIV promoter. Similar approaches could also be designed for other viruses.

Furthermore, the search for antiparasitic agents could also be helped by the DCSS. Established cell lines or transgenic nematodes or even parasitic extracts where expression of GFP depends on parasite-specific trans splicing sequences while BFP is under the control of host-specific cis splicing elements, could provide for rapid screen of selective antiparasitic drugs.

The invention will be more readily understood by reference to the following specific examples which are

included for purposes of illustration only and are not intended to limit the invention unless so stated.

### EXAMPLES

The following general protocol was used to generate mutant GFP- or BFP-encoding nucleic acids, transform host cells, and express the mutant GFP and BFP proteins:

- Clone a nucleic acid that encodes either wtGFP or BFP(Tyr<sub>67</sub>→His), under the control of eukaryotic or prokaryotic promoters, into a standard ds-DNA plasmid
- Convert the plasmid vector to a ss-DNA by standard methods
- Anneal the ss-DNA to 40-50 nucleotide DNA oligomers having base mismatches at the site(s) intended to be engineered
- Convert the ss-DNA to a closed ds-DNA plasmid vector by use of DNA polymerase and standard protocols
- Identify plasmids containing the desired mutations by restriction analysis following plasmid DNA isolation from *E. coli* strains transformed with the mutagenized DNA
- verify the presence of mutations by DNA sequencing
- transfect human transformed embryonic kidney 293 cells with equal amounts of DNA from the appropriate plasmids
- compare the fluorescence intensity of the signals

#### Nucleic acids and vectors

The wtGFP cDNA (SEQ ID NO:1) was obtained from Dr. Chalfie of Columbia University. All mutants described were obtained by modifying this wtGFP sequence as detailed below.

The vectors used to clone and to express the GFPs and BFPs are derivatives of the commercially available plasmids pcDNA3 (Invitrogen, San Diego, CA), pBSSK+ (Stratagene, La Jolla, CA) and pET11a (Novagen, Madison, WI).

**wtGFP protein expression in mammalian cells**

Several vectors for the expression of GFP in mammalian cells were constructed:

pFRED4 carries the wtGFP sequences under the control of the cytomegalovirus (CMV) early promoter and the polyadenylation signal of the Human Immunodeficiency Virus-1 (HIV) 3' Long Terminal Repeat (LTR). To derive pFRED4 we amplified the GFP coding sequence from plasmid #TU58 (Chalfie et al., 1994) by the polymerase chain reaction (PCR). For PCR amplification of the GFP coding region, oligonucleotides #16417 and #16418 were used as primers. Oligonucleotide #16417:

5'-GGAGGCGCGCAAGAAATGGCTAGCAAAGGAGAAGA-3' (SEQ ID NO:3), containing the BssHII recognition sequence and the translation initiation sequence of the HIV-1 Tat protein, was the sense primer. The antisense primer, #16418:

5'-GCGGGATCCTTATTTGTATAGTTCATCCATGCCATG-3' (SEQ ID NO:4) contained the BamHI recognition sequence. The amplified fragment was digested with BssHII and BamHI and cloned into BssHII and BamHI digested pCMV37M1-10D, a plasmid containing the CMV early promoter and the HIV-1 p37gag region, followed by several cloning sites and the HIV-1 3' LTR. Thus the p37gag gene was replaced by GFP, resulting in pFRED4.

In a second step, the 1485bp fragment from pFRED4, generated from StuI and BamHI double digestion, was subcloned into the 4747bp vector derived from the NruI and BamHI double digestion of pcDNA3. The resulting plasmid, pFRED7 (SEQ ID NO:5), expresses GFP under the control of the early CMV promoter and the bovine growth hormone polyadenylation signal.

**Bacterial expression**

For bacterial expression, we constructed plasmid pBSGFP (SEQ ID NO:6), a pBSSK+ derivative carrying wtGFP. pBSGFP was generated by inserting the GFP containing region of pFRED4, digested with BamHII and BamHI and subsequently treated with Klenow, into the EcoRV digested pBSSK+ vector. In pBSGFP the wtGFP is fused downstream to the 43 amino acids of the alpha peptide of beta galactosidase, present in the pBSSK+ polylinker region. The added amino acids at the

N-terminus of wtGFP have no apparent effect on the GFP signal, as judged from subsequent plasmids containing precise deletions of the extra amino acids.

For GFP overexpression and purification we generated plasmid pFRED13 (SEQ ID NO:7) by ligating the 717bp fragment from pFRED7 digested with NheI and BamHI, to the 5644bp fragment resulting from the NheI and BamHI double digestion of pET11a. In pFRED13, GFP is synthesized under the control of the bacteriophage T7 phl10 promoter.

The oligonucleotides used for GFP mutagenesis were synthesized by the DNA Support Services of the ABL Basic Research Program of the National Cancer Institute. DNA sequencing was performed by the PCR-assisted fluorescent terminator method (ReadyReaction DyeDeoxy Terminator Cycle Sequencing Kit, ABI, Columbia, MD) according to the manufacturer's instructions. Sequencing reactions were resolved on the ABI Model 373A DNA Sequencing System. Sequencing data were analyzed using the Sequencher program (Gene Codes, Ann Arbor, MI).

Enzymes were purchased from New England Biolabs (Beverly, MA) and used according to conditions described by the supplier. Chemicals used for the purification of wild type and mutant proteins were purchased from SIGMA (St. Louis, MO). Tissue culture media were obtained from Biofluids (Rockville, MD) and GIBCO/BRL (Gaithersburg, MD). Competent bacterial cells were purchased from GIBCO/BRL.

#### Preparation of mutants

Initially, plasmid pBSGFP was used to mutagenize the GFP coding sequence by single-stranded DNA site directed mutagenesis, as described by Schwartz et al. (1992) *J. Virol.* 66:7176. In addition to changing specific codons, our strategy was also to improve GFP expression by replacing potential inhibitory nucleotide sequences without altering the GFP amino acid sequence. This approach has been successfully employed in the past for other proteins (Schwartz et al. (1992) *J. Virol.* 66:7176).

For the pBSGFP mutagenesis the following oligonucleotides were used:

#17422 (SEQ ID NO:8):

5'-CAATTTGTGTCCCAGAATGTTGCCATCTTCCTTGAAGTCAATACCTTT-3'

#17423 (SEQ ID NO:9):

5'-GTCTTGTAGTTGCCGTCATCTTTGAAGAAGATGCTCCTTTCTGTAC-3'

#17424 (SEQ ID NO:10):

5'-CATGGAACAGGCAGTTTGCCAGTAGTGCAGATGAACTTCAGGGTAAGTTTTTC-3'

#17425 (SEQ ID NO:11):

5'-CTCCACTGACAGAGAACTTGTGGCCGTTAACATCACCATC-3'

#17426 (SEQ ID NO:12):

5'-CCATCTTCAATGTTGTGGCGGGTCTTGAAGTTCACCTTGATTCCATT-3'

#17465 (SEQ ID NO:13):

5'-CGATAAGCTTGAGGATCCTCAGTTGTACAGTTCATCCATGC-3'

Oligonucleotide #17426 introduces a mutation in GFP, converting the Isoleucine (Ile) at position 168 into Threonine (Thr). The Ile168Thr change has been shown to alter the GFP spectrum and to also increase the intensity of GFP fluorescence by almost two-fold at the emission maxima (Heim et al. (1994), *supra*).

The mutagenesis mixture was used to transform DH5a competent *E. coli* cells. Ampicilin resistant colonies were obtained and examined for their fluorescent properties by excitation with UV light. One colony, significantly brighter than the rest, was apparent on the agar plate. This colony was further purified, the plasmid DNA was isolated and used to transform DH5a competent bacteria. This time all the colonies were bright green when excited with the UV light, indicating that the bright green fluorescence was associated with the presence of the plasmid. The sequence of the GFP segment (SEQ ID NO:14, representing only the segment and not the whole plasmid) of this plasmid, called pBSGFPsg11, was then determined. The sequence analysis revealed that in addition to the designed nucleotide changes, which do not alter the amino acid sequence of GFP, and the Ile168Thr mutation, a second spontaneous mutation had occurred. A thymidine at position 322 of SEQ ID NO:14, which is the GFP-coding region of the pBSGFPsg11 DNA, was replaced by a cytosine. This

nucleotide change converts the phenylalanine (Phe) at position 65 of the GFP amino acid sequence into a leucine (Leu). A series of experiments, which will be described below, demonstrated that indeed the Phe65Leu mutation was responsible for the increase in the intensity of the fluorescent GFP signal.

In subsequent experiments, involving generation of rationally designed GFP mutant combinations to be detailed below, we also used the single-stranded DNA site directed mutagenesis approach. This time, however, the template DNAs were pFRED7 derivatives instead of pBSGFP.

#### Transfection and expression

The 293 cell line, an adenovirus-transformed human embryonal kidney cell line (Graham et al. (1977), *J. Gen. Virol.* 5:59) was used for protein expression analysis. The cells were cultured in Dulbecco's modified culture medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS, Biofluids).

Transfection was performed by the calcium phosphate coprecipitation technique as previously described (Graham et al. (1973), *Virol.* 52:456; Felber et al. (1990), *J. Virol.* 64:3734. Plasmid DNA was purified by Qiagen columns according to the manufacturer's instructions (Qiagen). A mix of 5 to 10 µg of total DNA per ml of final precipitate was overlaid on the cells in 60 mm or 6- and 12-well tissue culture plates (Falcon), using 0.5, 0.25 and 0.125 ml of precipitate, respectively. After overnight incubation, the cells were washed, placed in medium without phenol red and measured in a plate spectrofluorometer, e.g., Cytofluor II (Perceptive Biosystems, Framingham, MA.)

#### Purification of wild-type and mutant proteins:

*E. coli* strains carrying pFRED13 or other pET11a derivatives with mutant GFP genes were used for the overproduction and purification of the wt and mutant GFPs or BFPS. The cells were grown in 1 liter LB broth containing 100



$\mu$ g/ml ampicillin at 32° C to a density of 0.6-0.8 optical density units at 600 nm. At this point, the cells were induced with 0.6 mM IPTG and incubated for four more hours. Following harvesting of the cell pellets, cellular extracts were prepared as described by Johnson, B.H and Hecht, M.H., 1994, *Biotechnol.* 12: 1357.

GFPs and BFPs were purified from the cellular extracts as follows: Ammonium sulfate (AS) was added first to the extracts (50g AS per 100g supernatant) to precipitate the proteins. The precipitants were collected by centrifugation at 7500 x g for 15 min and the pellets were dissolved in 5ml of 1 M AS. The samples were then loaded on phenylsepharose column (HR10/10, Pharmacia, Piscataway, NJ) and washed with 20 mM 2-(N-morpholino) ethanesulfonic Acid (MES) pH 5.6 and 1 M AS. Proteins were eluted with a 45 ml gradient to 20 mM MES, pH 5.6. Fractions containing the GFP or BFP protein were colored even under visible light.

Green or blue-colored fractions were further purified on Q-sepharose (Mono Q, HR5/5, Pharmacia) with a 20 ml gradient from 20 mM Tris pH 7.0 to 20 mM Tris pH 7.0, 0.25 M NaCl.

The AS precipitation step was performed at 4° C while the chromatographic procedures were performed at room temperature.

#### Determination of protein concentration

Protein concentrations were determined using the commercially available Bradford protein assay (BioRad, Hercules, CA) with bovine IgG protein as a standard.

#### Analytical polyacrylamide gels

Analytical polyacrylamide gel electrophoresis was used to visualize the degree of purity of the purified GFP or BFP proteins. In all cases, 1 mm thick, 12% acrylamide gels (containing 0.1% SDS, in Tris buffer, pH 7.4) were used, and electrophoresis was performed for 2 hours at 120 V. Gels were stained with Coomassie Blue to visualize the proteins.

**Fluorescence measurements**

Excitation and emission spectra of solutions of the fluorescent proteins were obtained using a Perkin Elmer L550B spectrofluorimeter (Perkin Elmer, Advanced Biosystems, Foster City,, CA).

The relative fluorescence data for the GFP mutants in Table I below were obtained by comparing the cellular fluorescence of the GFP mutants expressed in the transformed human embryonic kidney cell line 293 with wtGFP expressed in the same cell line. Likewise, the relative fluorescence data for the BFP mutants in Table I below were obtained by comparing the cellular fluorescence of the BFP mutants expressed in 293 cells with BFP(Tyr<sub>67</sub>→His) expressed in the same cell line. Equal amounts of DNA encoding wild type or mutant proteins were introduced into 293 cells. Cellular fluorescence was quantified 24 h or 48 hr. post-transfection using Cytofluor II.

A list of GFP mutant proteins indicating the introduced amino acid mutations is shown in Table I.

**TABLE I: GFP and BFP mutants**

PROTEIN	Amino Acid Position					
	65	66	67	164	168	239
wt GFP	F	S	Y	V	I	K
SG12	L					
SG11	L				T	N
SG25	L	C			T	N
BFP			H			
SB42	L		H			
SB49			H	A		
SB50	L		H	A		

**Example 1: SG12**

A number of the unique mutants described herein derive from the discovery of an unplanned and unexpected mutation called "SG12", obtained in the course of site-

directed mutagenesis experiments, wherein a phenylalanine at position 65 of wtGFP was converted to leucine. SG12 was prepared as follows: Two plasmids carrying SG12 (SEQ ID NO:15) were generated, pFRED12 for expression in mammalian cells, and pFRED16 for expression in *E. coli* and protein purification. pFRED12 was constructed by ligating the 1557 bp fragment from the double digestion of pFRED7 with Avr II and Pml I into the 4681 bp fragment generated from the Avr II and Pml I digestion of pFRED11 (see below). pFRED16 was derived by subcloning the 717bp segment resulting from the digestion of pFRED12 with NheI and BamHI to the 5644bp fragment of the pET11a vector digested with the same restriction enzymes.

The specific activity of SG12 was about 9-12 times that of wtGFP. See Table II.

#### Example 2: SG11

A mutant referred to as "SG11," which combined the phenylalanine 65 to leucine alteration with an isoleucine 168 to threonine substitution and a lysine 239 to asparagine substitution, gave a further enhanced fluorescence intensity. SG11 was prepared as follows: Two plasmids carrying SG11 (SEQ ID NO:16) were generated: pFRED11 for expression in mammalian cells and pFRED15 for expression in *E. coli* and protein purification. pFRED11 was constructed by ligating the 717bp region from pBSGFPsg11 DNA digested with NheI and BamHI to the 5221bp fragment derived from the digestion of pFRED7 with the same enzymes. pFRED15 was generated by subcloning the 717bp segment resulting from the digestion of pFRED11 with NheI and BamHI to the 5644 bp fragment of the pET11a vector, digested with the same restriction enzymes.

The mutant SG11 encodes an engineered GFP wherein the alteration comprises the conversion of phenylalanine 65 to leucine and the conversion of isoleucine 168 to threonine. The additional alteration of the C-terminal lys 239 to asn is without effect; the C-terminal lys or asn may be deleted without affecting fluorescence. The specific activity of SG11 is about 19-38 times that of wtGFP. See Table II.

**Example 3: SG25**

A third and further improved GFP mutant was obtained by further mutating "SG11." This mutant is referred to as "SG25" and comprises, in addition to the SG11 substitutions, and additional substitution of a cysteine for the serine normally found at position 66 in the sequence. SG11 was prepared as follows: Two plasmids carrying SG25 (SEQ ID NO:17) were generated: pFRED25 for expression in mammalian cells and pFRED63 for expression in *E. coli* and protein purification. pFRED25 was constructed by site directed mutagenesis of pFRED11, using oligonucleotide #18217 (SEQ ID NO:18): 5'-CATTGAACACCATAGCACAGAGTAGTGACTAGTGTGGCC-3'. This oligonucleotide incorporates the Ser66Cys mutation into SG11. Ser66Cys had been shown to both alter the GFP excitation maxima without significant change in the emission spectrum and to also increase the intensity of the fluorescent signal of GFP (Heim et al., 1995).

pFRED63 was generated by subcloning the 717 bp segment resulting from the digestion of pFRED25 with *NheI* and *BamHI* to the 5644 bp fragment of the pET11a vector, digested with the same restriction enzymes.

The mutant SG25 encodes an engineered GFP wherein the alteration comprises the conversion of phenylalanine 65 to leu, the conversion of isoleucine 168 to threonine and the conversion of serine 66 to cysteine. As with SG11, the additional alteration of the C-terminal lysine 239 to asparagine is without effect; the C-terminal lysine or asparagine may be deleted without affecting fluorescence. The specific activity of SG25 is about 56 times that of wtGFP. See Table II.

**Example 4: Additional green fluorescent mutants**

Additional alterations at different amino acids of the wtGFP, when combined with SG11 and SG25, yielded proteins having at least 5X greater cellular fluorescence compared to the wtGFP. A non-limiting list of these mutations is provided below:

**GFP variants with enhanced cellular fluorescence**

<u>Protein</u>	<u>Altered Amino Acids</u>
SG20	F65L, S66T, I168T, K239N
SG21	F65L, S66A, I168T, K239N
SG27	Y40L, F65L, I168T, K239N
SG30	F47L, F65L, I168T, K239N
SG32	F72L, F65L, I168T, K239N
SG43	F65L, I168T, Y201L, K239N
SG46	F65L, V164A, I168T, K239N
SG72	F65L, S66C, V164A, I168T, K239N
SG91	F65L, S66C, F100L, I168T, K239N
SG94	F65L, S66C, Y107L, I168T, K239N
SG95	F65L, S66C, F115L, I168T, K239N
SG96	F65L, S66C, F131L, I168T, K239N
SG98	F65L, S66C, Y146L, I168T, K239N
SG100	F65L, S66C, Y152L, I168T, K239N
SG101	F65L, S66C, I168T, Y183L, K239N
SG102	F65L, S66C, I168T, F224L, K239N
SG103	F65L, S66C, I168T, Y238L, K239N
SG106	F65L, S66T, V164A, I168T, K239N

**Example 5: SB42**

The blue fluorescent proteins described here and below were derived from the known GFP mutant (Heim et al., PNAS, 1994) wherein histidine is substituted for tyrosine at position 67. We have designated this known mutant BFP(Tyr<sub>67</sub>→His). BFP(Tyr<sub>67</sub>→His) has a shifted emission spectrum. It emits blue light, i.e., it is a blue fluorescent protein (BFP).

By introducing the same mutation in BFP(Tyr<sub>67</sub>→His) that was used to generate SG12, i.e., leucine for phenylalanine at position 65, we created a new mutant that has unexpectedly high fluorescence that we refer to as "SuperBlue-42" (SB42). SB42 was prepared as follows: Two plasmids carrying SB42 (SEQ ID NO:19) were generated: pFRED42 for expression in mammalian cells and pFRED65 for expression in *E. coli* and protein purification. pFRED42 was constructed by site directed mutagenesis of pFRED12, using oligonucleotide

#bio25 (5'-CATTGAACACCATGAGAGAGAGTAGTGACTAGTGTGGCC-3') (SEQ ID NO:20). This oligonucleotide incorporates the Tyr<sub>67</sub>→His mutation into SG12, thus generating the Phe65Leu, Tyr<sub>67</sub>→His double mutant.

pFRED65 was created by subcloning the 717 bp segment resulting from the digestion of pFRED42 with NheI and BamHI to the 5644 bp fragment of the pET11a vector, digested with the same restriction enzymes.

The mutant SB42 encodes an engineered BFP wherein the alterations comprise the conversion of tyrosine 67 to histidine and the conversion of phenylalanine 65 to leucine. The specific activity of SB42 is about 27 times that of BFP(Tyr<sub>67</sub>→His). See Table II.

#### Example 6: SB49

An independent mutation of BFP(Tyr<sub>67</sub>→His) which substitutes the valine at position 164 with an alanine is referred to as "SB49." SB49 was prepared as follows: Plasmid pFRED49 expresses SB49 (SEQ ID NO:21) in mammalian cells. pFRED49 was generated by site directed mutagenesis of pFRED12, using oligonucleotides #19059 and #bio24. Oligonucleotide #19059 (5'-CTTCAATGTTGTGGCGGATCTTGAAGTTCGCTTTGATTCCATTC-3') (SEQ ID NO:22) introduces the Val164Ala mutation in SG12 while oligonucleotide #bio24 (5'-CATTGAACACCATGAGAGAAAGTAGTGACTAGTGTGGCC-3') (SEQ ID NO:23) reverts the Phe65Leu alteration to the wt sequence and, at the same time, incorporates the Tyr<sub>67</sub>→His mutation.

The mutant SB49 encodes an engineered BFP wherein the alterations comprise the conversion of tyrosine 67 to histidine, and the conversion of valine 164 to alanine. The specific activity of SB49 was about 37 times that of BFP(Tyr<sub>67</sub>→His). See Table II.

#### Example 7: SB50

A combination of the above two BFP mutations resulted in "SB50," which gave an even greater fluorescence enhancement than either of the previous mutations. SB50 was prepared as follows: Two plasmids carrying SB50 (SEQ ID NO:

24) were generated: pFRED50 for expression in mammalian cells and pFRED67 for expression in *E. coli* and protein purification. pFRED50 was constructed by site directed mutagenesis of pFRED12, using oligonucleotides #19059 and #bio25.

pFRED67 was created by subcloning the 717bp segment resulting from the digestion of pFRED50 with NheI and BamHI to the 5644 bp fragment of the pET11a vector digested with the same restriction enzymes.

The mutant SB50 encodes an engineered BFP wherein the alterations comprise the conversion of tyrosine 67 to histidine, the conversion of phenylalanine 65 to leucine and the conversion of alanine 164 to valine. The specific activity of SB50 was about 63 times that of BFP(Tyr<sub>67</sub>→His). See Table II.

TABLE II

Mutant	Excitation Maximum (nm)	Emission Maximum (nm)	Factor of increased green fluorescence (at maximum emission) as compared to wtGFP	Factor of increased blue fluorescence (at maximum emission) as compared to BFP(Tyr <sub>67</sub> →His)
SG12	398	509	9-12X	
SG11	471	508	19-38X	
SG25	473	509	50-100X	
SB42	387	450		27X
SB49	387	450		37X
SB50	387	450		63X

The dramatic increase in fluorescent activity resulting from the amino acid substitutions of the present invention was wholly unexpected. The cellular fluorescence of the mutants was at least five times greater, and usually over  
 5 twenty times greater, than that of the parent wtGFP or BFP(Tyr<sub>67</sub>→His). Note that the maximum emission wavelengths vary among the mutants, and that the above-reported fold

increases refer only to minimal increases in relative cellular fluorescence at the maximum emission wavelength of the mutant. Given a particular wavelength, the values may be substantially larger, i.e., the mutants may have a 200-fold greater cellular fluorescence than the reference wtGFP or BFP(Tyr<sub>67</sub>→His). This is important because devices for measuring fluorescence often have set wavelengths, or the limitations of a given experiment often require the use of a set wavelength. Thus, for example, the emission and detection parameters of a fluorescence microscope or a fluorescence-activated cell sorter may be set for a wavelength wherein the cellular fluorescence of a given mutant is 200-fold greater than that of the known GFPs and BFPs.

The GFP and BFP mutants of this invention, in contrast to the wild type protein or other reported mutants, allow detection of green fluorescence in living mammalian cells when present in few copies stably integrated into the genome. This high cellular fluorescence of the mutant GFPs and BFPs is useful for rapid and simple detection of gene expression in living cells and tissues and for repeated analysis of gene expression over time under a variety of conditions. They are also useful for the construction of stable marked cell lines that can be quickly identified by fluorescence microscopy or fluorescence activated cell sorting.

#### Example 8

We have established fluoroplate-based assays for the quantitation of gene expression after transfections. In a number of embodiments, a nucleic acid encoding a mutant GFP or BFP of this invention is inserted into a vector and introduced into and expressed in a cell. Typically, expression of GFP mutants can be detected as quickly as 5 hours post-infection or less. Expression is followed over time in living cells by a simple measurement in multi-well plates. In this way, many transfections can be processed in parallel.



**Example 9**

- The vectors and nucleic acids provided herein are used to generate chimeric proteins wherein a nucleic acid sequence that encodes a selected gene product is fused to the C- or N-terminus of the mutant GFPs and/or BFPs of this invention. A number of unique viral, plasmid and hybrid gene constructs have been generated that incorporate the new mutant GFP and/or mutant BFP sequences indicated above. These include:
- 10     •     HIV viral sequences (in the nef gene) containing SG11 or SG25
  - Neomycin & hygromycin plasmids containing SG11 or SG25
  - Moloney Leukemia Virus vector (retrovirus) also expressing SG25
  - 15     •     Hybrid gene constructs expressing HIV viral proteins (rev, td-rev, tat, nef, gag, env, and vpr) and either SG11 or SG25 or SB50.
  - Hybrid gene construct containing vectors that incorporate the cytoplasmic proteins ran, B23, nucleolin, poly-A
  - 20     binding protein and either SG11 or SG25 or SB50.

These hybrids of the mutant nucleic acids provided herein are used to study protein trafficking in living mammalian cells. Like the wild type GFP, the mutant GFP proteins are normally distributed throughout the cell except for the nucleolus. Fusions to other proteins redistribute the fluorescence, depending on the partner in the hybrid. For example, fusion with the entire HIV-1 Rev protein results in a hybrid molecule which retains the Rev function and is localized in the nucleolus where Rev is preferentially found. Fusion to the N-terminal domain of the HIV-1 Nef protein created a chimeric protein detected in the plasma membrane, the site of Nef localization.

**Example 10: pCMVqfoll**

pCMVqfoll is a pFRED11 derivative containing the bacterial neomycin phosphotransferase gene (neo) (Southern and Berg (1982) *J. Mol. Appl. Genetics* 1:327) fused at the

C-terminus of SG11. A four amino acid (Gly-Ala-Gly-Ala) (SEQ ID NO:26) linker region connects the last amino acid of SG11 to the second amino acid of neo, thus generating the hybrid SG11-neo protein (gfoll, SEQ ID NO:25). Gfoll is expressed  
5 from the CMV promoter and contains the intact SG11 polypeptide and all of neo except for the first Met.

pCMVgfoll was constructed in several steps. First, pFRED11DNae was constructed by NaeI digestion of pFRED11 and self-ligation of the 4613bp fragment. The NaeI deletion  
10 removes the SV40 promoter and neo gene from pFRED11, thus creating pFRED11DNae. Next, in order to fuse the neo coding region downstream to SG11, the neo gene was PCR amplified from pcDNA3 using primers Bio51  
(5'-CGCGGATCCTTCGAACAAGATGGATTGCACGC-3') (SEQ ID NO:27) and  
15 Bio52 (5'-CCGGAATTCTCAGAAGAACTCGTCAAGAAGGCCGA-3') (SEQ ID NO:28). Primer Bio51 introduces a BamHI site followed by a BstBI recognition sequence at the 5' end of neo, while primer Bio52 introduces an EcoRI site 3' to the neo gene. The PCR product was digested with BamHI and EcoRI and cloned into the  
20 4582 bp vector resulting from the BamHI-EcoRI digestion of pFRED11DNae, thus generating pFRED11DNaeBstNeo. Subsequently, SG11 was PCR amplified from pFRED11DNae using primers Bio49  
(5'-GGCGCGCAAGAAATGGCTAGCAAAGGAGAAGAACTCTTCACTGGAG-3') (SEQ ID NO:29) and Bio50  
25 (5'-CCCATCGATAGCACCAGCACCGTTGTACAGTTCATCCATGCCATGT-3') (SEQ ID NO:30) to remove the sgII stop codon in pFRED11DNaeBstNeo and to introduce the four amino acid (Gly-Ala-Gly-Ala) linker followed by a ClaI site. The PCR product was digested with NheI and ClaI and cloned into the 4763 bp NheI/BstBI fragment  
30 from pFRED11DNaeBstNeo, thus generating pCMVgfoll.

Following transfection of 293 cells (Graham et al. (1977), *J. Gen. Virol.* 5:59) as well as other human and mouse cell lines with pCMVgfoll, bright fluorescent transfectants were apparent under the fluorescent microscope and colonies  
35 resistant to G418 could be obtained two weeks later.

It should be noted that pCMVgfoll was the best protein fusion in terms of fluorescent emission intensity and

number of G418 resistant colonies compared to several SG11-neo or neo-SG11 fusions generated and examined.

**Example 11: pPGKgfo25**

5 pPGKgfo25 is a pCMVgfoII derivative containing SG25 instead of SG11 within gfo (SEQ ID NO: 31). Expression of gfo25 in pPGKgfo25 is under the control of the mouse phosphoglycerate kinase-1 (PGK) promoter.

10 pPGKgfo25 was constructed in several steps. First, a SacII site was introduced downstream of the PGK promoter in pPGKneobpA (Soriano et al. (1991) Cell: 64-393) by:

i) annealing oligonucleotides #18990 (SEQ ID NO:32) (5'-GACCGGGACACGTATCCAGCCTCCGC-3') and 18991 (SEQ ID NO:33) (5'-GGAGGCTGGATACGTGTCCCGGTCTGCA-3') to create a  
15 double stranded adapter for PstI at the 5' end and SacII at the 3' end.

ii) ligating this adapter to the 3423bp fragment from the PstI-SacII double digestion of pPGKneobpA, thus generating pPGKPtAfSc.

20 Next, the CMV promoter of pFRED25 was replaced with the PGK promoter by cloning the 565bp SaII (filled with Klenow)-SacII region from pPGKPtAfSc to the 5288bp BgIII (filled with Klenow)-SacII fragment from pFRED25, resulting in pFRED25PGK. In the final step, pPGKgfo25 was constructed by ligating the  
25 813bp BgIII-NdeI fragment from pFRED25PGK containing the PGK promoter and SG25, to the 4185bp BgIII-NdeI fragment of pCMVgfo11.

**Example 12: pGen-PGKgfo25RO (SEQ ID NO: 34)**

30 pGen-PGKgfo25RO is a pGen- (Soriano et al. (1991), J. Virol. 65:2314) derivative containing the gfo25 hybrid under the control of PGK promoter. It was constructed by subcloning the 2810bp SaII fragment of pPGKgfo25 into the XhoI site of pGen. In viruses generated from pGen-PGKgfo25RO (see below)  
35 transcription originated from the PGK promoter is in reverse orientation (RO) to that initiated from the viral long terminal repeats (LTR).

To generate ecotropic or pseudotyped viruses, pGen-PGK<sub>gfo25RO</sub> was co-transfected into 293 cells together with pHIT60 and pHIT123 DNAs (production of ecotropic virus) or with pHIT60 and pHCMV-G DNAs (production of pseudotyped virus). pHIT60 and pHIT123 contain the gag-pol and env coding regions from the Moloney murine leukemia virus (Mo-MLV) respectively, under the control of the CMV promoter (Soneoka et al. (1995), *Nuc. Acid Res.* 23:628. pHCMV-G contains the coding region of the G protein from the vesicular stomatitis virus (VSV) expressed from the CMV promoter (Yee et al. (1994), *Proc. Nat'l Acad. Sci. USA* 91:9564. Virus-containing supernatants were harvested 48 hours post transfection, filtered and stored at -80°C.

**Example 13: pNLnSG11 (SEQ ID NO:35)**

The SG11 sequence from plasmid pFRED11 was PCR-amplified with primers #17982 (SEQ ID NO:36) (5'-GGGGCGTACGGAGCGCTCCGAATTCGGTACCGTTTAAACGGGCCCTCTCGAGTCC GTTGTACAGTTCATCCATG-3') and #17983 (SEQ ID NO:37) (5'-GGGGGAATTCGCGCGCTACGTAAGCGCTAGCTGAGCAAGAAATGGCTAGCAAA GGAGAAGAACTC-3'). The PCR product was digested with B<sub>l</sub>pI and XhoI and cloned into the large B<sub>l</sub>pI-XhoI fragment from pNL4-3 (Adachi et al. (1986), *J. Virol.* 59: 284. In pNLnSG11 the full SG11 polypeptide containing an additional four linker-encoded amino acids at the C-terminus, is expressed as a hybrid protein with the 24 N-terminal amino acids of the HIV-1 protein Nef.

We constructed transmissible HIV-1 stocks with our mutants, which generate green fluorescence upon transfection of human cells. These transmissible HIV-1 stocks are used to detect the kinetics of infection under a variety of conditions. In particular, they are used to study the effects of drugs on the kinetics of infection. The level of fluorescence, and the subcellular compartmentalization of that fluorescence, is easily visualized and quantified using well known methods. This system is easy to visualize, and dramatically cuts the costs of many experiments that are presently tedious and expensive.

To produce infectious virus, pNLnSG11 was transfected in 293 cells. 24 hours later, Jurkat cells were added to the transfectants. At various times post-infection, the medium was removed, filtered, and used to infect fresh Jurkat or other HIV-1-permissive cells. Two days later the infected cells were green under fluorescent microscope. Visible syncytia were also green. Viral stocks were generated and kept at -80° C.

When the nucleic acids, vectors, mutant proteins provided herein are combined with the knowledge of those skilled in the art of genetic engineering and the guidance provided herein, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the spirit or scope of the invention as set forth herein. These changes and modifications are encompassed by the present invention.

## SEQUENCE LISTING

- 5 (1) GENERAL INFORMATION:
- (i) APPLICANT: Pavlakis, George N.  
Gaitanaris, George A.  
Stauber, Roland H.  
Vournakis, John N.
- 10 (ii) TITLE OF INVENTION: Mutant Aequorea victoria Fluorescent  
Proteins Having Increased Cellular Fluorescence
- 15 (iii) NUMBER OF SEQUENCES: 37
- (iv) CORRESPONDENCE ADDRESS:  
(A) ADDRESSEE: Townsend and Townsend and Crew LLP  
(B) STREET: Two Embarcadero Center, 8th Floor  
(C) CITY: San Francisco  
20 (D) STATE: California  
(E) COUNTRY: USA  
(F) ZIP: 94111-3834
- 25 (v) COMPUTER READABLE FORM:  
(A) MEDIUM TYPE: Floppy disk  
(B) COMPUTER: IBM PC compatible  
(C) OPERATING SYSTEM: PC-DOS/MS-DOS  
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30
- 30 (vi) CURRENT APPLICATION DATA:  
(A) APPLICATION NUMBER: US Not yet assigned  
(B) FILING DATE: Not yet assigned  
(C) CLASSIFICATION:
- 35 (viii) ATTORNEY/AGENT INFORMATION:  
(A) NAME: Weber, Kenneth A.  
(B) REGISTRATION NUMBER: 31,677  
(C) REFERENCE/DOCKET NUMBER: 015280-249000
- 40 (ix) TELECOMMUNICATION INFORMATION:  
(A) TELEPHONE: (415) 576-0200  
(B) TELEFAX: (415) 576-0300
- 45 (2) INFORMATION FOR SEQ ID NO:1:
- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
50 (C) STRANDEDNESS: single  
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- 55 (ix) FEATURE:  
(A) NAME/KEY: CDS  
(B) LOCATION: 1..720  
(D) OTHER INFORMATION: /product= "wild type Aequorea victoria  
60 Green Fluorescent Protein (wtGF)"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5	ATG GCT AGC AAA GGA GAA GAA CTC TTC ACT GGA GTT GTC CCA ATT CTT Met Ala Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu	48
10	GTT GAA TTA GAT GGT GAT GTT AAT GGG CAC AAA TTT TCT GTC AGT GGA Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly	96
15	GAG GGT GAA GGT GAT GCA ACA TAC GGA AAA CTT ACC CTT AAA TTT ATT Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile	144
20	TGC ACT ACT GGA AAA CTA CCT GTT CCA TGG CCA ACA CTT GTC ACT ACT Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr	192
25	TTC TCT TAT GGT GTT CAA TGC TTT TCA AGA TAC CCG GAT CAT ATG AAA Phe Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys	240
30	CGG CAT GAC TTT TTC AAG AGT GCC ATG CCC GAA GGT TAT GTA CAG GAA Arg His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu	288
35	AGA ACT ATA TTT TTC AAA GAT GAC GGG AAC TAC AAG ACA CGT GCT GAA Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu	336
40	GTC AAG TTT GAA GGT GAT ACC CTT GTT AAT AGA ATC GAG TTA AAA GGT Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly	384
45	ATT GAT TTT AAA GAA GAT GGA AAC ATT CTT GGA CAC AAA TTG GAA TAC Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr	432
50	AAC TAT AAC TCA CAC AAT GTA TAC ATC ATG GCA GAC AAA CAA AAG AAT Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn	480
55	GGA ATC AAA GTT AAC TTC AAA ATT AGA CAC AAC ATT GAA GAT GGA AGC Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser	528
60	GTT CAA CTA GCA GAC CAT TAT CAA CAA AAT ACT CCA ATT GGC GAT GGC Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly	576
	CCT GTC CTT TTA CCA GAC AAC CAT TAC CTG TCC ACA CAA TCT GCC CTT Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu	624
	TCG AAA GAT CCC AAC GAA AAG AGA GAC CAC ATG GTC CTT CTT GAG TTT Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe	672
	GTA ACA GCT GCT GGG ATT ACA CAT GGC ATG GAT GAA CTA TAC AAA TAA Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys	720

62

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 239 amino acids  
(B) TYPE: amino acid  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  
1 5 10 15  
Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly  
20 25 30  
Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile  
35 40 45  
20 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr  
50 55 60  
Phe Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys  
25 65 70 75 80  
Arg His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu  
85 90 95  
30 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu  
100 105 110  
Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly  
115 120 125  
35 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  
130 135 140  
Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn  
40 145 150 155 160  
Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser  
165 170 175  
45 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly  
180 185 190  
Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu  
195 200 205  
50 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe  
210 215 220  
Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr Lys  
55 225 230 235

## (2) INFORMATION FOR SEQ ID NO:3:

## 60 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
65 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:



63

(A) NAME/KEY: -  
(B) LOCATION: 1..35  
(D) OTHER INFORMATION: /note= "oligonucleotide sense primer  
#16417"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

10 GGAGGCGCGC AAGAAATGGC TAGCAAAGGA GAAGA

35

(2) INFORMATION FOR SEQ ID NO:4:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 36 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
25 (A) NAME/KEY: -  
(B) LOCATION: 1..36  
(D) OTHER INFORMATION: /note= "oligonucleotide antisense primer  
#16418"

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

GCGGGATCCT TATTTGTATA GTTCATCCAT GCCATG

36

35 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 6238 base pairs  
40 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

45 (ix) FEATURE:  
(A) NAME/KEY: -  
(B) LOCATION: 1..6238  
50 (D) OTHER INFORMATION: /note= "pFRED7"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

55 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG 60  
CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 120  
CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 180  
60 TTAGGGTTAG GCGTTTTCG CTTGCTCGCC TCGAGGCCCTG GCCATTGCAT ACGTTGTATC 240  
CATATCATAA TATGTACATT TATATTGGCT CATGTCCAAC ATTACCGCCA TGTGACATT 300  
GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 360  
65 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 420  
CCCGCCCAT TACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 480

	ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA CTTGGCAGTA CATCAAGTGT	540
	ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT	600
5	ATGCCCAGTA CATGACCTTA TGGGACTTTC CTAATTGGCA GTACATCTAC GTATTAGTCA	660
	TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG	720
10	ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC	780
	AAAATCAACG GGAAGTTTCCA AAATGTGCGT ACAACTCCGC CCCATTGACG CAAATGGGCG	840
	GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCG TTTAGTGAAC CGTCAGATCG	900
15	CCTGGAGACG CCATCCACGC TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC	960
	TCCGCGGGCG CGCAAGAAAT GGCTAGCAAA GGAGAAGAAC TCTTCACTGG AGTTGTCCCA	1020
20	ATTCTTGTTG AATTAGATGG TGATGTTAAT GGGCACAAT TTTCTGTCAG TGGAGAGGGT	1080
	GAAGGTGATG CAACATACGG AAAACTTACC CTAAATTTA TTTGCACTAC TGGAAAACTA	1140
	CCTGTTCCAT GGCCAACACT TGTCACTACT TTCTCTTATG GTGTTCAATG CTTTTCAAGA	1200
25	TACCCGGATC ATATGAAACG GCATGACTTT TTCAAGAGTG CCATGCCCCG AGGTTATGTA	1260
	CAGGAAAGAA CTATATTTTT CAAAGATGAC GGGAACTACA AGACACGTGC TGAAGTCAAG	1320
30	TTTGAAGGTG ATACCCCTTG TAATAGAATC GAGTTAAAG GTATTGATT TAAAGAAGAT	1380
	GGAAACATTC TTGGACACAA ATTGGAATAC AACTATAACT CACACAATGT ATACATCATG	1440
	GCAGACAAAC AAAAGAATGG AATCAAAGTT AACTTCAAAA TTAGACACAA CATTGAAGAT	1500
35	GGGAGCGTTC AACTAGCAGA CCATTATCAA CAAAATACTC CAATTGGCGA TGGCCCTGTC	1560
	CTTTTACCAG ACAACCATTA CCTGTCCACA CAATCTGCCC TTTCGAAAGA TCCCAACGAA	1620
40	AAGAGAGACC ACATGGTCCT TCTTGAGTTT GTAACAGCTG CTGGGATTAC ACATGGCATG	1680
	GATGAACTAT ACAAATAAGG ATCCACTAGT AACGGCCGCC AGTGTGCTGG AATTCTGCAG	1740
	ATATCCATCA CACTGGCGGC CGCTCGAGCA TGCATCTAGA GGGCCCTATT CTATAGTGTC	1800
45	ACCTAAATGC TAGAGCTCGC TGATCAGCCT CGACTGTGCC TTCTAGTTGC CAGCCATCTG	1860
	TTGTTTGCCC CTCCCCGTG CCTTCCTTGA CCCTGGAAGG TGCCACTCCC ACTGTCCTTT	1920
50	CCTAATAAAA TGAGGAAAT GCATCGCATT GTCTGAGTAG GTGTCATTCT ATTCTGGGGG	1980
	GTGGGGTGGG GCAGGACAGC AAGGGGGAGG ATTGGGAAGA CAATAGCAGG CATGCTGGGG	2040
	ATGCGGTGGG CTCTATGGCT TCTGAGGCGG AAAGAACCAG CTGGGGCTCT AGGGGGTATC	2100
55	CCCACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG CGCAGCGTGA	2160
	CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC TTTCTTCCCT TCCTTTCTCG	2220
60	CCACGTTTCG CGGCTTTCCC CGTCAAGCTC TAAATCGGGG CATCCCTTTA GGGTTCCGAT	2280
	TTAGTGCTTT ACGGCACCTC GACCCCAAAA AACTTGATTA GGGTGATGGT TCACGTAGTG	2340
	GGCCATCGCC CTGATAGACG GTTTTTCGCC CTTTGACGTT GGAGTCCACG TTCTTTAATA	2400
65	GTGGACTCTT GTTCCAACT GGAACAACAC TCAACCCAT CTCGGTCTAT TCTTTTGATT	2460
	TATAAGGGAT TTTGGGGATT TCGGCCTATT GGTAAAAAAA TGAGCTGATT TAACAAAAAT	2520
	TTAACGCGAA TTAATTCTGT GGAATGTGTG TCAGTTAGGG TGTGGAAAGT CCCCAGGCTC	2580

	CCCAGGCAGG CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA	2640
	AGTCCCCAGG CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA	2700
5	CCATAGTCCC GCCCCTAACT CCGCCCATCC CGCCCTAAC TCCGCCAGT TCCGCCATT	2760
	CTCCGCCCCA TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT	2820
10	CTGAGCTATT CCAGAAGTAG TGAGGAGGCT TTTTGGAGG CCTAGGCTTT TGCAAAAAGC	2880
	TCCCGGGAGC TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC	2940
	GCATGATTGA ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT	3000
15	TCGGCTATGA CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT	3060
	CAGCGCAGGG GCGCCCGGTT CTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC	3120
20	TGCAGGACGA GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCAGAGCTG	3180
	TGCTCGACGT TGCTACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC	3240
	AGGATCTCCT GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA	3300
25	TGCGGCGGCT GCATACGCTT GATCCGGCTA CTGCCCCATT CGACCACCAA GCGAAACATC	3360
	GCATCGAGCG AGCACGTACT CGGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG	3420
30	AAGAGCATCA GGGGCTCGCG CCAGCCGAAC TGTTGCCAG GCTCAAGGCG CGCATGCCCCG	3480
	ACGGCGAGGA TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA	3540
	ATGGCCGCTT TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG	3600
35	ACATAGCGTT GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT	3660
	TCCTCGTGCT TTACGGTATC GCCGCTCCCG ATTCGCAGCG CATCGCCTTC TATCGCCTTC	3720
40	TTGACGAGTT CTTCTGAGCG GGACTCTGGG GTTCGAAATG ACCGACCAAG CGACGCCCAA	3780
	CCTGCCATCA CGAGATTTCTG ATTCCACCGC CGCCTTCTAT GAAAGGTTGG GCTTCGGAAT	3840
	CGTTTTCCGG GACGCCGGCT GGATGATCCT CCAGCGCGGG GATCTCATGC TGGAGTTCTT	3900
45	CGCCCACCCC AACTTGTTTA TTGCAGCTTA TAATGGTTAC AAATAAAGCA ATAGCATCAC	3960
	AAATTTTACA AATAAAGCAT TTTTTTCACT GCATTCTAGT TGTGGTTTGT CCAAACCTCAT	4020
50	CAATGTATCT TATCATGTCT GTATACCGTC GACCTCTAGC TAGAGCTTGG CGTAATCATG	4080
	GTCATAGCTG TTTCCTGTGT GAAATTGTTA TCCGCTCACA ATTCCACACA ACATACGAGC	4140
	CGGAAGCATA AAGTGTAAG CCTGGGGTGC CTAATGAGTG AGCTAACTCA CATTAATTGC	4200
55	GTTGCGCTCA CTGCCCCTT TCCAGTCGGG AAACCTGTCTG TGCCAGCTGC ATTAATGAAT	4260
	CGGCCAACGC GCGGGGAGAG GCGGTTTTCG TATTGGGCGC TCTCCGCTT CCTCGCTCAC	4320
60	TGACTCGCTG CGCTCGGTCTG TTCGGCTGCG GCGAGCGGTA TCAGCTCACT CAAAGGCGGT	4380
	AATACGGTTA TCCACAGAAT CAGGGGATAA CGCAGGAAAG AACATGTGAG CAAAAGGCCA	4440
	GCAAAAGGCC AGGAACCGTA AAAAGGCCGC GTTGCTGGCG TTTTTCATA GGCTCCGCCC	4500
65	CCCTGACGAG CATCACAAA ATCGACGCTC AAGTCAGAGG TGGCGAAACC CGACAGGACT	4560
	ATAAAGATAC CAGGCGTTTC CCCCTGGAAG CTCCTCGTG CGCTCTCCTG TTCCGACCCT	4620
	GCCGCTTACC GGATACCTGT CCGCCTTCT CCCTTCGGGA AGCGTGGCGC TTTCTCAATG	4680

66

CTCACGCTGT AGGTATCTCA GTTCGGTGTA GGTTCGTTTCGC TCCAAGCTGG GCTGTGTGCA 4740  
 CGAACCCCCC GTTCAGCCCG ACCGCTGCGC CTTATCCGGT AACTATCGTC TTGAGTCCAA 4800  
 5 CCCGGTAAGA CACGACTTAT CGCCACTGGC AGCAGCCACT GGTAACAGGA TTAGCAGAGC 4860  
 GAGGTATGTA GCGGTGCTA CAGAGTTCTT GAAGTGGTGG CCTAACTACG GCTACACTAG 4920  
 10 AAGGACAGTA TTTGGTATCT GCGCTCTGCT GAAGCCAGTT ACCTTCGGAA AAAGAGTTGG 4980  
 TAGCTCTTGA TCCGGCAAAC AAACCACCGC TGGTAGCGGT GGTTTTTTTT TTTGCAAGCA 5040  
 GCAGATTACG CGCAGAAAAA AAGGATCTCA AGAAGATCCT TTGATCTTTT CTACGGGGTC 5100  
 15 TGACGCTCAG TGGAACGAAA ACTCACGTTA AGGGATTTTG GTCATGAGAT TATCAAAAAG 5160  
 GATCTTCACC TAGATCCTTT TAAATTAAAA ATGAAGTTT AAATCAATCT AAAGTATATA 5220  
 TGAGTAAACT TGGTCTGACA GTTACCAATG CTTAATCAGT GAGGCACCTA TCTCAGCGAT 5280  
 20 CTGTCTATTT CGTTCATCCA TAGTTGCGCTG ACTCCCCGTC GTGTAGATAA CTACGATACG 5340  
 GGAGGGCTTA CCATCTGGCC CCAGTGCTGC AATGATACCG CGAGACCCAC GCTCACCGGC 5400  
 25 TCCAGATTTA TCAGCAATAA ACCAGCCAGC CGGAAGGGCC GAGCGCAGAA GTGGTCTGTC 5460  
 AACTTTATCC GCCTCCATCC AGTCTATTAA TTGTTGCCGG GAAGCTAGAG TAAGTAGTTC 5520  
 GCCAGTTAAT AGTTTGCACA ACGTTGTTGC CATTGCTACA GGCATCGTGG TGTCACGCTC 5580  
 30 GTCGTTTGGT ATGGCTTCAT TCAGCTCCGG TTCCCAACGA TCAAGGCGAG TTACATGATC 5640  
 CCCCATGTTG TGCAAAAAAG CGGTTAGCTC CTTCCGTCCT CCGATCGTTG TCAGAAGTAA 5700  
 35 GTTGGCCGCA GTGTTATCAC TCATGGTTAT GGCAGCACTG CATAATTCTC TTAGTGTGTCAT 5760  
 GCCATCCGTA AGATGCTTTT CTGTGACTGG TGAGTACTCA ACCAAGTCAT TCTGAGAATA 5820  
 GTGTATGCGG CGACCGAGTT GCTCTTGCCC GCGTCAATA CGGGATAATA CCGCGCCACA 5880  
 40 TAGCAGAACT TAAAAGTGC TCATCATTGG AAAACGTTCT TCGGGGCGAA AACTCTCAAG 5940  
 GATCTTACCG CTGTTGAGAT CCAGTTCGAT GTAACCCACT CGTGCACCCA ACTGATCTTC 6000  
 45 AGCATCTTTT ACTTTCACCA GCGTTTCTGG GTGAGCAAAA ACAGGAAGGC AAAATGCCGC 6060  
 AAAAAAGGGA ATAAGGGCGA CACGGAATG TTGAATACTC ATACTCTTCC TTTTCAATA 6120  
 TTATTGAAGC ATTTATCAGG GTTATTGTCT CATGAGCGGA TACATATTTG AATGTATTTA 6180  
 50 GAAAAATAAA CAAATAGGGG TTCCGCGCAC ATTTCCCCGA AAAGTGCCAC CTGACGTC 6238

## (2) INFORMATION FOR SEQ ID NO:6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3699 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

- (A) NAME/KEY: -  
 (B) LOCATION: 1..3699  
 (D) OTHER INFORMATION: /note= "pBSGFP"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

	GGAAATTGTA AACGTTAATA TTTTGTTAAA ATTCGCGTTA AATTTTGTGTT AAATCAGCTC	60
5	ATTTTTTAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT AAATCAAAAG AATAGACCGA	120
	GATAGGGTTG AGTGTGTTC CAGTTTGGAA CAAGAGTCCA CTATTAAAGA ACGTGGACTC	180
10	CAACGTCAAA GGGCGAAAAA CCGTCTATCA GGGCGATGGC CCACTACGTG AACCATCACC	240
	CTAATCAAGT TTTTGGGGT CGAGGTGCCG TAAAGCACTA AATCGGAACC CTAAAGGGAG	300
	CCCCGATTT AGAGCTTGAC GGGGAAAGCC GCGAACGTG GCGAGAAAGG AAGGGAAGAA	360
15	AGCGAAAGGA GCGGGCGCTA GGGCGCTGGC AAGTGTAGCG GTCACGCTGC GCGTAACCAC	420
	CACACCCGCC GCGCTTAATG CGCCGCTACA GGGCGCGTCG CGCCATTTCG CATTGAGGCT	480
20	GCGCAACTGT TGGGAAGGGC GATCGGTGCG GGCCTCTTCG CTATTACGCC AGCTGGCGAA	540
	AGGGGGATGT GCTGCAAGGC GATTAAGTTG GGTAACGCCA GGGTTTTCCC AGTCACGACG	600
	TTGTAAAACG ACGGCCAGTG AATTGTAATA CGACTCACTA TAGGGCGAAT TGGGTACCGG	660
25	GCCCCCCTC GAGGTCGACG GTATCGATAA GCTTGATGAT CCTTATTTGT ATAGTTCATC	720
	CATGCCATGT GTAATCCAG CAGCTGTTAC AAATCAAGA AGGACCATGT GGTCTCTCTT	780
30	TTCGTTGGGA TCTTTCGAAA GGGCAGATTG TGTGGACAGG TAATGGTTGT CTGGTAAAG	840
	GACAGGGCCA TCGCAATTG GAGTATTTTG TTGATAATGG TCTGCTAGTT GAACGCTTCC	900
	ATCTTCAATG TTGTGTCTAA TTTGAAGTT AACTTTGATT CCATTCTTTT GTTTGTCTGC	960
35	CATGATGTAT ACATTGTGTG AGTTATAGTT GTATTCCAAT TTGTGTCCAA GAATGTTTCC	1020
	ATCTTCTTTA AAATCAATAC CTTTAACTC GATTCTATTA ACAAGGGTAT CACCTTCAAA	1080
40	CTTGACTTCA GCACGTGTCT TGTAGTTCCC GTCATCTTTG AAAAATATAG TTCTTTCCTG	1140
	TACATAACCT TCGGGCATGG CACTCTTGAA AAAGTCATGC CGTTTCATAT GATCCGGGTA	1200
	TCTTGAAAAG CATTGAACAC CATAAGAGAA AGTAGTGACA AGTGTGGCC ATGGAACAGG	1260
45	TAGTTTTCCA GTAGTGCAA TAAATTTAAG GGTAAGTTT CCGTATGTTG CATCACCTTC	1320
	ACCCTCTCCA CTGACAGAAA ATTTGTGCCC ATTAACATCA CCATCTAATT CAACAAGAAT	1380
50	TGGGACAACT CCAAGTAAGA GTTCTTCTCC TTTGCTAGCC ATTCTTGCG CGATCGAATT	1440
	CCTGCAGCCC GGGGGATCCA CTAGTTCTAG AGCGGCCGCC ACCGCGGTGG AGCTCCAGCT	1500
	TTTGTTCCTT TTAGTGAGGG TTAATCCGA GCTTGGCGTA ATCATGGTCA TAGCTGTTTC	1560
55	CTGTGTGAAA TTGTTATCCG CTCACAATC CACACAACAT ACGAGCCGGA AGCATAAAGT	1620
	GTAAAGCCTG GGGTGCCTAA TGAGTGAGCT AACTCACATT AATTGCGTTG CGCTCACTGC	1680
60	CCGCTTTCCA GTCGGGAAAC CTGTCGTGCC AGCTGCATTA ATGAATCGGC CAACGCGCGG	1740
	GGAGAGGCGG TTTGCGTATT GGGCGCTCTT CCGCTTCCTC GCTCACTGAC TCGCTGCGCT	1800
	CGGTCGTTTC GCTGCGGCGA GCGGTATCAG CTCACTCAAA GGCGGTAATA CGGTTATCCA	1860
65	CAGAATCAGG GGATAACGCA GGAAAGAACA TGTGAGCAA AGGCCAGCAA AAGGCCAGGA	1920
	ACCGTAAAAA GGCCGCGTTG CTGGCGTTTT TCCATAGGCT CCGCCCCCT GACGAGCATC	1980
	ACAAAAATCG ACGCTCAAGT CAGAGGTGGC GAAACCCGAC AGGACTATAA AGATACCAGG	2040

68

	CGTTTCCCCC TGGAAGCTCC CTCGTGCGCT CTCCTGTTCC GACCCTGCCG CTTACCGGAT	2100
	ACCTGTCCGC CTTTCTCCCT TCGGGAAGCG TGGCGCTTTC TCATAGCTCA CGCTGTAGGT	2160
5	ATCTCAGTTC GGTGTAGGTC GTTCGCTCCA AGCTGGGCTG TGTGCACGAA CCCCCCGTTC	2220
	AGCCCCACCG CTGCGCCTTA TCCGGTAACT ATCGTCTTGA GTCCAACCCG GTAAGACACG	2280
10	ACTTATCGCC ACTGGCAGCA GCCACTGGTA ACAGGATTAG CAGAGCGAGG TATGTAGGCG	2340
	GTGCTACAGA GTTCTTGAAG TGGTGGCCTA ACTACGGCTA CACTAGAAGG ACAGTATTTG	2400
	GTATCTGCGC TCTGCTGAAG CCAGTTACCT TCGGAAAAAG AGTTGGTAGC TCTTGATCCG	2460
15	GCAAAACAAAC CACCGCTGGT AGCGGTGGTT TTTTGTGTTG CAAGCAGCAG ATTACGCGCA	2520
	GAAAAAAGG ATCTCAAGAA GATCCTTTGA TCTTTTCTAC GGGGTCTGAC GCTCAGTGGA	2580
20	ACGAAAACCTC ACGTTAAGGG ATTTTGGTCA TGAGATTATC AAAAAGGATC TTCACCTAGA	2640
	TCCTTTTAAA TTAATAATGA AGTTTATAAT CAATCTAAAG TATATATGAG TAAACTTGGT	2700
	CTGACAGTTA CCAATGCTTA ATCAGTGAGG CACCTATCTC AGCGATCTGT CTATTTTCGTT	2760
25	CATCCATAGT TGCCTGACTC CCCGTCGTGT AGATAACTAC GATACGGGAG GGCTTACCAT	2820
	CTGGCCCCAG TGCTGCAATG ATACCGCGAG ACCCAGCCTC ACCGGCTCCA GATTTATCAG	2880
30	CAATAAACCA GCCAGCCGGA AGGGCCGAGC GCAGAAGTGG TCCTGCAACT TTATCCGCTT	2940
	CCATCCAGTC TATTAATTGT TGCCGGGAAG CTAGAGTAAG TAGTTCGCCA GTTAATAGTT	3000
	TGCGCAACGT TGTTGCCATT GCTACAGGCA TCGTGGTGTC ACGCTCGTCG TTTGGTATGG	3060
35	CTTCATTAGT CTCCGGTTCC CAACGATCAA GCGAGTTAC ATGATCCCCC ATGTTGTGCA	3120
	AAAAAGCGGT TAGCTCCTTC GGTCTCCGA TCGTTGTCAG AAGTAAGTTG GCCGCAGTGT	3180
40	TATCACTCAT GGTATATGCA GCACTGCATA ATTCTCTTAC TGTCATGCCA TCCGTAAGAT	3240
	GCTTTTCTGT GACTGGTGAG TACTCAACCA AGTCATTCTG AGAATAGTGT ATGCGCGGAC	3300
	CGAGTTGCTC TTGCCCGGCG TCAATACGGG ATAATACCGC GCCACATAGC AGAACTTTAA	3360
45	AAGTGCTCAT CATTGGAAAA CGTTCTTCGG GCGGAAAACT CTCAAGGATC TTACCGCTGT	3420
	TGAGATCCAG TTCGATGTAA CCCACTCGTG CACCCAACTG ATCTTCAGCA TCTTTTACTT	3480
50	TCACCAGCGT TTCTGGGTGA GCAAAAACAG GAAGGCAAAA TGCCGCAAAA AAGGGAATAA	3540
	GGGCGACACG GAAATGTTGA ATACTCATAC TCTTCCTTTT TCAATATTAT TGAAGCATTT	3600
	ATCAGGGTTA TTGTCTCATG AGCGGATACA TATTTGAATG TATTTAGAAA AATAAACAAA	3660
55	TAGGGGTTCC GCGCACATTT CCCCAGAAAAG TGCCACCTG	3699

(2) INFORMATION FOR SEQ ID NO:7:

60 (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 6361 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
 (A) NAME/KEY: -

(B) LOCATION: 1..6361

(D) OTHER INFORMATION: /note= "pFRED13"

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

	TTCTCATGTT TGACAGCTTA TCATCGATAA GCTTTAATGC GGTAGTTTAT CACAGTTAAA	60
10	TTGCTAACGC AGTCAGGCAC CGTGTATGAA ATCTAACAAAT GCGCTCATCG TCATCCTCGG	120
	CACCGTCACC CTGGATGCTG TAGGCATAGG CTTGGTTATG CCGGTACTGC CGGGCCTCTT	180
	GCGGGATATC CGGATATAGT TCCTCCTTTC AGCAAAAAAC CCCTCAAGAC CCGTTTAGAG	240
15	GCCCCAAGGG GTTATGCTAG TTATTGCTCA GCGGTGGCAG CAGCCAACTC AGCTTCCTTT	300
	CGGGCTTTGT TAGCAGCCGG ATCCTTATTT GTATAGTTCA TCCATGCCAT GTGTAATCCC	360
20	AGCAGCTGTT ACAAACCTCAA GAAGGACCAT GTGGTCTCTC TTTTCGTTGG GATCTTTCCA	420
	AAGGGCAGAT TGTGTGGACA GGTAATGGTT GTCTGGTAAA AGGACAGGGC CATCGCCAAT	480
	TGGAGTATTT TGTTGATAAT GGTCTGCTAG TTGAACGCTT CCATCTTCAA TGTTGTGTCT	540
25	AATTTTGAAG TTAACCTTGA TTCCATTCTT TTGTTTGTCT GCCATGATGT ATACATTGTG	600
	TGAGTTATAG TTGTATTCCA ATTTGTGTCC AAGAATGTTT CCATCTTCTT TAAAATCAAT	660
30	ACCTTTTAAC TCGATTCTAT TAACAAGGGT ATCACCTTCA AACTTGACTT CAGCAGCTGT	720
	CTGTAGTTC CCGTCATCTT TGAAAAATAT AGTTCTTTCC TGTACATAAC CTTCGGGCAT	780
	GGCACTCTTG AAAAAGTCAT GCCGTTTCAT ATGATCCGGG TATCTTGAAA AGCATTGAAC	840
35	ACCATAAGAG AAAGTAGTGA CAAGTGTGG CCATGGAACA GGTAGTTTTC CAGTAGTGCA	900
	AATAAATTIA AGGGTAAGTT TTCCGTATGT TGCATCACCT TCACCCTCTC CACTGACAGA	960
40	AAATTTGTGC CCATTAAACAT CACCATCTAA TTCAACAAGA ATTGGGACAA CTCCAGTGAA	1020
	GAGTTCTTCT CCTTTGCTAG CCATATGTAT ATCTCCTTCT TAAAGTTAAA CAAAATTATT	1080
	TCTAGAGGGG AATTGTATC CGCTCACAAT TCCCCTATAG TGAGTCGTAT TAATTTCCGG	1140
45	GGATCGAGAT CTCGATCCTC TACGCCGGAC GCATCGTGGC CGGCATCACC GGCGCCACAG	1200
	GTGCGGTTGC TGGCGCCTAT ATCGCCGACA TCACCGATGG GGAAGATCGG GCTCGCCACT	1260
50	TCGGGCTCAT GAGCGCTTGT TTCGGCGTGG GTATGGTGGC AGGCCCCGTG GCCGGGGGAC	1320
	TGTTGGGCGC CATCTCCTTG CATGCACCAT TCCTTGCGGC GGCGGTGCTC AACGGCCTCA	1380
	ACCTACTACT GGGCTGCTTC CTAATGCAGG AGTCGCATAA GGGAGAGCGT CGAGATCCCCG	1440
55	GACACCATCG AATGGCGCAA AACCTTTCGC GGTATGGCAT GATAGCGCCC GGAAGAGAGT	1500
	CAATTCAGGG TGGTGAATGT GAAACCACTA ACGTTATACG ATGTCGCAGA GTATGCCGGT	1560
60	GTCTCTTATC AGACCGTTTC CCGCGTGGTG AACCAGGCCA GCCACGTTTC TGCGAAAACG	1620
	CGGGAAAAAG TGGAAGCGGC GATGGCGGAG CTGAATTACA TTCCCAACCG CGTGGCACAA	1680
	CAACTGGCGG GCAAACAGTC GTTGCTGATT GGCCTTGCCA CCTCCAGTCT GGCCCTGCAC	1740
65	GCGCCGTCGC AAATTGTGCG GCGGATTAAA TCTCGCGCCG ATCAACTGGG TGCCAGCGTG	1800
	GTGGTGTCTA TGGTAGAACG AAGCGGCGTC GAAGCCTGTA AAGCGGCGGT GCACAATCTT	1860
	CTCGCGCAAC GCGTCAGTGG GCTGATCATT AACTATCCGC TGGATGACCA GGATGCCATT	1920

	GCTGTGGAAG	CTGCCTGCAC	TAATGTTCCG	GCGTTATTTT	TTGATGTCTC	TGACCAGACA	1980
	CCCATCAACA	GTATTATTTT	CTCCCATGAA	GACGGTACGC	GACTGGGCGT	GGAGCATCTG	2040
5	GTCGCATTGG	GTCACCAGCA	AATCGCGCTG	TTAGCGGGCC	CATTAAGTTC	TGTCTCGGCG	2100
	CGTCTGCGTC	TGGCTGGCTG	GCATAAATAT	CTCACTCGCA	ATCAAATTCA	GCCGATAGCG	2160
10	GAACGGGAAG	GCGACTGGAG	TGCCATGTCC	GGTTTTC AAC	AAACCATGCA	AATGCTGAAT	2220
	GAGGGCATCG	TCCCCACTGC	GATGCTGGTT	GCCAACGATC	AGATGGCGCT	GGGCGCAATG	2280
	CGCGCCATTA	CCGAGTCCGG	GCTGCGCGTT	GGTGCGGATA	TCTCGGTAGT	GGGATACGAC	2340
15	GATACCGAAG	ACAGCTCATG	TTATATCCCG	CCGTAAACCA	CCATCAAACA	GGATTTTCGC	2400
	CTGCTGGGGC	AAACCAGCGT	GGACCGCTTG	CTGCAACTCT	CTCAGGGCCA	GGCGGTGAAG	2460
20	GGCAATCAGC	TGTTGCCCCG	CTCACTGGTG	AAAAGAAAAA	CCACCCTGGC	GCCCAATACG	2520
	CAAACCGCCT	CTCCCCGCGC	GTTGGCCGAT	TCATTAATGC	AGCTGGCACG	ACAGGTTTCC	2580
	C GACTGGAAA	GCGGGCAGTG	AGCGCAACGC	AATTAATGTA	AGTTAGCTCA	CTCATTAGGC	2640
25	ACCGGGATCT	CGACCGATGC	CCTTGAGAGC	CTTCAACCCA	GTCAGCTCCT	TCCGGTGGGC	2700
	GCGGGGCATG	ACTATCGTCG	CCGCACTTAT	GACTGTCTTC	TTTATCATGC	AACTCGTAGG	2760
30	ACAGGTGCCG	GCAGCGCTCT	GGGTCAATTT	CGGCGAGGAC	CGCTTTCGCT	GGAGCGCGAC	2820
	GATGATCGGC	CTGTCGCTTG	CGGTATTTCG	AATCTTGAC	GCCCTCGCTC	AAGCCTTCGT	2880
	CACTGGTCCC	GCCACCAAAC	GTTTCGGCGA	GAAGCAGGCC	ATTATCGCCG	GCATGGCGGC	2940
35	CGACGCGCTG	GGCTACGTCT	TGCTGGCGTT	CGCGACGCGA	GGCTGGATGG	CCTTCCCCAT	3000
	TATGATTCTT	CTCGCTTCCG	GCGGCATCGG	GATGCCCCGG	TTGCAGGCCA	TGCTGTCCAG	3060
40	GCAGGTAGAT	GACGACCATC	AGGGACAGCT	TCAAGGATCG	CTCGCGGCTC	TTACCAGCCT	3120
	AACTTCGATC	ACTGGACCGC	TGATCGTCAC	GGCGATTTAT	GCCGCCTCGG	CGAGCACATG	3180
	GAACGGGTTG	GCATGGATTG	TAGGCGCCGC	CCTATACCTT	GTCTGCCTCC	CCGCGTTGCG	3240
45	TCGCGGTGCA	TGGAGCCGGG	CCACCTCGAC	CTGAATGGAA	GCCGGCGGCA	CCTCGCTAAC	3300
	GGATTACCA	CTCCAAGAAT	TGGAGCCAAT	CAATTCTTGC	GGAGAACTGT	GAATGCGCAA	3360
50	ACCAACCCTT	GGCAGAACAT	ATCCATCGCG	TCCGCCATCT	CCAGCAGCCG	CACGCGGCGC	3420
	ATCTCGGGCA	GCGTTGGGTC	CTGGCCACGG	GTGCGCATGA	TCGTGCTCCT	GTCGTTGAGG	3480
	ACCCGGCTAG	GCTGGCGGGG	TTGCCTTACT	GGTTAGCAGA	ATGAATCACC	GATACGCGAG	3540
55	CGAACGTGAA	GCGACTGCTG	CTGCAAAACG	TCTGCGACCT	GAGCAACAAC	ATGAATGGTC	3600
	TTCCGTTTCC	GTGTTTCGTA	AAGTCTGGAA	ACGCGGAAGT	CAGCGCCCTG	CACCATTATG	3660
60	TTCCGGATCT	GCATCGCAGG	ATGCTGCTGG	CTACCCTGTG	GAACACCTAC	ATCTGTATTA	3720
	ACGAAGCGCT	GGCATTGACC	CTGAGTGATT	TTTCTCTGGT	CCCGCCGCAT	CCATACCGCC	3780
	AGTTGTTTAC	CCTCACAACG	TTCCAGTAAC	CGGGCATGTT	CATCATCAGT	AACCCGTATC	3840
65	GTGAGCATCC	TCTCTCGTTT	CATCGGTATC	ATTACCCCCA	TGAACAGAAA	TCCCCCTTAC	3900
	ACGGAGGCAT	CAGTGACCAA	ACAGGAAAAA	ACCGCCCTTA	ACATGGCCCG	CTTTATCAGA	3960
	AGCCAGACAT	TAACGCTTCT	GGAGAAACTC	AACGAGCTGG	ACGCGGATGA	ACAGGCAGAC	4020



	ATCTGTGAAT CGCTTCACGA CCACGCTGAT GAGCTTTACC GCAGCTGCCT CGCGCGTTTC	4080
	GGTGATGACG GTGAAAACCT CTGACACATG CAGCTCCCGG AGACGGTCAC AGCTTGTCTG	4140
5	TAAGCGGATG CCGGGAGCAG ACAAGCCCGT CAGGGCGCGT CAGCGGGTGT TGGCGGGTGT	4200
	CGGGGCGCAG CCATGACCCA GTCACGTAGC GATAGCGGAG TGTATACTGG CTTAACTATG	4260
10	CGGCATCAGA GCAGATTGTA CTGAGAGTGC ACCATATATG CGGTGTGAAA TACCGCACAG	4320
	ATGCGTAAGG AGAAAATACC GCATCAGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT	4380
	GCGCTCGGTC GTTCGGCTGC GGCAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT	4440
15	ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC AGCAAAAGGC	4500
	CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCAT AGGCTCCGCC CCCCTGACGA	4560
20	GCATCACAAA AATCGACGCT CAAGTCAGAG GTGGCGAAAC CCGACAGGAC TATAAGATA	4620
	CCAGGCGTTT CCCCTGGAA GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC	4680
	CGGATACCTG TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG	4740
25	TAGGTATCTC AGTTCGGTGT AGGTCGTTCT CTCCAAGCTG GGCTGTGTGC ACGAACCCCC	4800
	CGTTCAGCCC GACCGCTGCG CTTATCCGG TAACTATCGT CTTGAGTCCA ACCCGGTAAG	4860
30	ACACGACTTA TCGCCACTGG CAGCAGCCAC TGGTAACAGG ATTAGCAGAG CGAGGTATGT	4920
	AGGCGGTGCT ACAGAGTTCT TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT	4980
	ATTTGGTATC TCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG	5040
35	ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC AGCAGATTAC	5100
	GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT TCTACGGGGT CTGACGCTCA	5160
40	GTGGAACGAA AACTCACGTT AAGGGATTTT GGTCAAGAGA TTATCAAAAA GGATCTTCAC	5220
	CTAGATCCTT TTAAATTAAA AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC	5280
	TTGGTCTGAC AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT	5340
45	TCGTTTCATC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC GGGAGGGCTT	5400
	ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA CGCTCACCAG CTCCAGATTT	5460
50	ATCAGCAATA AACCAGCCAG CCGGAAGGGC CGAGCGCAGA AGTGGTCCTG CAACTTTATC	5520
	CGCCTCCATC CAGTCTATTA ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA	5580
	TAGTTTGCGC AACGTTGTTG CCATTGCTGC AGGCATCGTG GTGTCACGCT CGTCGTTTGG	5640
55	TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT CCCCCATGTT	5700
	GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT GTCAGAAGTA AGTTGGCCGC	5760
60	AGTGTTATCA CTCATGGTTA TGGCAGCACT GCATAATTCT CTTACTGTCA TGCCATCCGT	5820
	AAGATGCTTT TCTGTGACTG GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG	5880
	GCGACCGAGT TGCTCTTGCC CGGCGTCAAC ACGGGATAAT ACCGCGCCAC ATAGCAGAAC	5940
65	TTTAAAAGTG CTCATCATTG GAAAACGTTT TCCGGGGCGA AACTCTCAA GGATCTTACC	6000
	GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGACCC AACTGATCTT CAGCATCTTT	6060
	TACTTTCACC AGCGTTTCTG GGTGAGCAAA AACAGGAAGG CAAAATGCCG CAAAAAGGG	6120

72

AATAAGGGCG ACACGGAAAT GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG 6180  
CATTATCAG GGTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA 6240  
5 ACAAATAGGG GTTCCGCGCA CATTTCCTCCG AAAAGTGCCA CCTGACGTCT AAGAAACCAT 6300  
TATTATCATG ACATTAACT ATAAAAATAG GCGTATCACG AGGCCCTTTC GTCTTCAAGA 6360  
10 A 6361

## (2) INFORMATION FOR SEQ ID NO:8:

15 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 48 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
20 (ii) MOLECULE TYPE: DNA  
(ix) FEATURE:  
25 (A) NAME/KEY: -  
(B) LOCATION: 1..48  
(D) OTHER INFORMATION: /note= "oligonucleotide #17422"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

30 CAATTTGTGT CCCAGAAATGT TGCCATCTTC CTTGAAGTCA ATACCTTT 48

## (2) INFORMATION FOR SEQ ID NO:9:

35 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 47 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
40 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA

45

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..47  
    (D) OTHER INFORMATION: /note= "oligonucleotide #17423"  
5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:  
10 GTCTTGTAGT TGCCGTCATC TTTGAAGAAG ATGCTCCTTT CCTGTAC 47

(2) INFORMATION FOR SEQ ID NO:10:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 52 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
15  
    (ii) MOLECULE TYPE: DNA  
20

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..52  
    (D) OTHER INFORMATION: /note= "oligonucleotide #17424"  
25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:  
30 CATGGAACAG GCAGTTTGCC AGTAGTGCAG ATGAACTTCA GGGTAAGTTT TC 52

(2) INFORMATION FOR SEQ ID NO:11:  
35  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 40 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
40  
    (ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..40  
    (D) OTHER INFORMATION: /note= "oligonucleotide #17425"  
45  
50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:  
CTCCACTGAC AGAGAACTTG TGGCCGTAA CATCACCATC 40  
55

(2) INFORMATION FOR SEQ ID NO:12:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 47 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
60  
    (ii) MOLECULE TYPE: DNA  
65

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..47  
    (D) OTHER INFORMATION: /note= "oligonucleotide #17426"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:  
CCATCTTCAA TGTTGTGGCG GGTCTTGAAG TTCAC TTTGA TTCCATT

(2) INFORMATION FOR SEQ ID NO:13:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 41 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
    (ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..41  
    (D) OTHER INFORMATION: /note= "oligonucleotide #17465"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:  
CGATAAGCTT GAGGATCCTC AGTTGTACAG TTCATCCATG C

(2) INFORMATION FOR SEQ ID NO:14:  
    (i) SEQUENCE CHARACTERISTICS:  
        (A) LENGTH: 849 base pairs  
        (B) TYPE: nucleic acid  
        (C) STRANDEDNESS: single  
        (D) TOPOLOGY: linear  
    (ii) MOLECULE TYPE: DNA

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..849  
    (D) OTHER INFORMATION: /note= "pBSGFPsg11"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:  
ATGACCATGA TTACGCCAAG CTCGGAATTA ACCCTCACTA AAGGGAACAA AAGCTGGAGC  
TCCACCGCGG TGGCGGCCGC TCTAGAACTA GTGGATCCCC CGGGCTGCAG GAATTCGATC  
GCGCAAGAAA TGGCTAGCAA AGGAGAAGAA CTCTTCACTG GAGTTGTCCC AATTCTTGTT  
GAATTAGATG GTGATGTAA CGGCCACAAG TTCTCTGTCA GTGGAGAGGG TGAAGGTGAT  
GCAACATACG GAAACTTAC CCTGAAGTTC ATCTGCACTA CTGGCAAAC TGCCTGTTCCA  
TGGCCAACAC TTGTCACTAC TCTCTCTTAT GGTGTTCAAT GCTTTTCAAG ATACCCGGAT  
CATATGAAAC GGCATGACTT TTCAAGAGT GCCATGCCCG AAGGTTATGT ACAGGAAAGG  
ACCATCTTCT TCAAAGATGA CGGCAACTAC AAGACACGTG CTGAAGTCAA GTTTGAAGGT  
GATACCCTTG TTAATAGAAT CGAGTTAAAA GGTATTGACT TCAAGGAAGA TGGCAACATT

75

CTGGGACACA AATTGGAATA CAACTATAAC TCACACAATG TATACATCAT GGCAGACAAA 600  
CAAAAGAATG GAATCAAAGT GAACTTCAAG ACCCGCCACA ACATTGAAGA TGGGAAGCGTT 660  
5 CAACTAGCAG ACCATTATCA ACAAATACT CCAATTGGCG ATGGCCCTGT CCTTTTACCA 720  
GACAACCATT ACCTGTCCAC ACAATCTGCC CTTTCGAAAG ATCCCAACGA AAAGAGAGAC 780  
10 CACATGGTCC TTCTTGAGTT TGTAACAGCT GCTGGGATTA CACATGGCAT GGATGAACTG 840  
TACAACTGA 849

## (2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

(A) NAME/KEY: -  
(B) LOCATION: 1..720  
(D) OTHER INFORMATION: /note= "SG12"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT 60  
35 GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC 120  
GGAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA 180  
40 CTTGTCCTA CTCTCTCTTA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA 240  
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC 300  
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCCTT 360  
45 GTTAATAGAA TCGAGTTAAA AGGTATTGAT TTAAAGAAG ATGGAACAT TCTTGACAC 420  
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT 480  
GGAATCAAAG TTAACCTCAA AATTAGACAC AACATTGAAG ATGGAAGCGT TCAACTAGCA 540  
50 GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
TACCTGTCCA CACAATCTGC CTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660  
55 CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT ATACAAATAA 720

## (2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
65 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: -  
(B) LOCATION: 1..720  
(D) OTHER INFORMATION: /note= "SG11"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT	60
GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC	120
GGAAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA	180
CTTGTCCTA CTCTCTCTTA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA	240
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC	300
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT	360
GTTAATAGAA TCGAGTTAAA AGGTATTGAC TTCAAGGAAG ATGGCAACAT TCTGGGACAC	420
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT	480
GGAATCAAAG TGAAGTTCAA GACCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA	540
GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT	600
TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC	660
CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT GTACAACTGA	720

(2) INFORMATION FOR SEQ ID NO:17:

35

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

45

(A) NAME/KEY: -  
(B) LOCATION: 1..720  
(D) OTHER INFORMATION: /note= "SG25"

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT	60
GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC	120
GGAAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA	180
CTAGTCACTA CTCTGTGCTA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA	240
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC	300
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT	360
GTTAATAGAA TCGAGTTAAA AGGTATTGAC TTCAAGGAAG ATGGCAACAT TCTGGGACAC	420
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT	480
GGAATCAAAG TGAAGTTCAA GACCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA	540

77

GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660  
5 CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT GTACAACTGA 720

## (2) INFORMATION FOR SEQ ID NO:18:

10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
15 (D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA  
(ix) FEATURE:  
20 (A) NAME/KEY: -  
(B) LOCATION: 1..40  
(D) OTHER INFORMATION: /note= "oligonucleotide #18217"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CATTGAACAC CATAGCACAG AGTAGTGACT AGTGTGGCC 40

## (2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
35 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear  
(ii) MOLECULE TYPE: DNA  
40 (ix) FEATURE:  
(A) NAME/KEY: -  
(B) LOCATION: 1..720  
45 (D) OTHER INFORMATION: /note= "SB42"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

50 ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT 60  
GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC 120  
GGAAAACCTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA 180  
55 CTAGTCACTA CTCTCTCTCA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA 240  
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC 300  
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT 360  
60 GTTAATAGAA TCGAGTTAAA AGGTATTGAT TTAAAGAAG ATGGAAACAT TCTTGGACAC 420  
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT 480  
65 GGAATCAAAG TTAACCTCAA AATTAGACAC AACATTGAAG ATGGAAGCGT TCAACTAGCA 540  
GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660

CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT ATACAAATAA 720

5 (2) INFORMATION FOR SEQ ID NO:20:

- 10 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

15 (ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..40  
(D) OTHER INFORMATION: /note= "oligonucleotide #bio25"

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CATTGAACAC CATGAGAGAG AGTAGTGACT AGTGTGGCC 40

25 (2) INFORMATION FOR SEQ ID NO:21:

- 30 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..720  
40 (D) OTHER INFORMATION: /note= "SB49"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

45 ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT 60  
GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGAGAGG GTGAAGGTGA TGCAACATAC 120  
GGAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA 180  
50 CTAGTCACTA CTTTCTCTCA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA 240  
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC 300  
55 TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT 360  
GTTAATAGAA TCGAGTTAAA AGGTATTGAT TTTAAAGAAG ATGGAAACAT TCTTGGACAC 420  
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT 480  
60 GGAATCAAAG CGAACTTCAA GATCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA 540  
GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
65 TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660  
CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT ATACAAATAA 720



79

## (2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 44 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..44  
(D) OTHER INFORMATION: /note= "oligonucleotide #19059"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CTTCAATGTT GTGGCGGATC TTGAAGTTCG CTTTGATTCC ATTC

44

## (2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 40 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..40  
(D) OTHER INFORMATION: /note= "oligonucleotide #bio24"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

CATTGAACAC CATGAGAGAA AGTAGTGACT AGTGTGGCC

40

## (2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 720 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

(A) NAME/KEY: -

(B) LOCATION: 1..720

(D) OTHER INFORMATION: /note= "SB50"

5

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

10 ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT 60  
GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC 120  
GGAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA 180  
15 CTAGTCACTA CTCTCTCTCA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA 240  
CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC 300  
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT 360  
20 GTTAATAGAA TCGAGTTAAA AGGTATTGAT TTAAAGAAG ATGGAAACAT TCTTGGACAC 420  
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT 480  
25 GGAATCAAAG CGAACTTCAA GATCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA 540  
GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660  
30 CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT ATACAAATAA 720

## (2) INFORMATION FOR SEQ ID NO:25:

35

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1521 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

40

## (ii) MOLECULE TYPE: DNA

45

## (ix) FEATURE:

(A) NAME/KEY: -

(B) LOCATION: 1..1521

(D) OTHER INFORMATION: /note= "pCMVgfol1"

50

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT 60  
55 GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC 120  
GGAAACTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA 180  
CTTGTCATA CTCTCTCTTA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA 240  
60 CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC 300  
TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT 360  
65 GTTAATAGAA TCGAGTTAAA AGGTATTGAC TTCAAGGAAG ATGGCAACAT TCTGGGACAC 420  
AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT 480  
GGAATCAAAG TGAACCTCAA GACCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA 540

81

5 GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT 600  
TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC 660  
CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT GTACAACGGT 720  
GCTGGTGCTA TCGAACAAGA TGGATTGCAC GCAGGTTCTC CGGCCGCTTG GGTGGAGAGG 780  
10 CTATTTCGGCT ATGACTGGGC ACAACAGACA ATCGGCTGCT CTGATGCCGC CGTGTTCGGG 840  
CTGTCAGCGC AGGGGCGCCC GGTTCCTTTT GTCAAGACCG ACCTGTCCGG TGCCCTGAAT 900  
GAACTGCAGG ACGAGGCAGC GCGGCTATCG TGGCTGGCCA CGACGGGCGT TCCTTGCGCA 960  
15 GCTGTGCTCG ACGTTGTCAC TGAAGCGGGA AGGGACTGGC TGCTATTGGG CGAAGTGCCG 1020  
GGGCAGGATC TCCTGTCATC TCACCTTGCT CCTGCCGAGA AAGTATCCAT CATGGCTGAT 1080  
GCAATGCGGC GGCTGCATAC GCTTGATCCG GCTACCTGCC CATTGACCA CCAAGCGAAA 1140  
20 CATCGCATCG AGCGAGCAGC TACTCGGATG GAAGCCGGTC TTGTCGATCA GGATGATCTG 1200  
GACGAAGAGC ATCAGGGGCT CGCGCCAGCC GAACTGTTTCG CCAGGCTCAA GGC GCGCATG 1260  
25 CCCGACGGCG AGGATCTCGT CGTGACCCAT GCGCATGCCT GCTTGCCGAA TATCATGGTG 1320  
GAAAATGGCC GCTTTTCTGG ATTCATCGAC TGTGGCCGGC TGGGTGTGGC GGACCGCTAT 1380  
30 CAGGACATAG CGTTGGCTAC CCGTGATATT GCTGAAGAGC TTGGCGGCGA ATGGGCTGAC 1440  
CGCTTCTCG TGCTTTACGG TATCGCCGCT CCCGATTGCG AGCGCATCGC CTTCTATCGC 1500  
CTTCTTGACG AGTTCTTCTG A 1521

35

(2) INFORMATION FOR SEQ ID NO:26:

40 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 4 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

50 Gly Ala Gly Ala  
1

(2) INFORMATION FOR SEQ ID NO:27:

55 (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
60 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

82

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..32  
    (D) OTHER INFORMATION: /note= "primer Bio51"

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CGCGGATCCT TCGAACAAGA TGGATTGCAC GC

32

10

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 34 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: DNA

20

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..34  
    (D) OTHER INFORMATION: /note= "primer Bio52"

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CCGGAATTCT CAGAAGAACT CGTCAAGAAG GCGA

34

30

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 46 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

35

(ii) MOLECULE TYPE: DNA

40

(ix) FEATURE:  
    (A) NAME/KEY: -  
    (B) LOCATION: 1..46  
    (D) OTHER INFORMATION: /note= "primer Bio49"

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GGCGCGCAAG AAATGGCTAG CAAAGGAGAA GAACTCTTCA CTGGAG

46

50

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:  
    (A) LENGTH: 46 base pairs  
    (B) TYPE: nucleic acid  
    (C) STRANDEDNESS: single  
    (D) TOPOLOGY: linear

55

(ii) MOLECULE TYPE: DNA

60

65

## (ix) FEATURE:

(A) NAME/KEY: -

(B) LOCATION: 1..46

(D) OTHER INFORMATION: /note= "primer Bio50"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

CCCATCGATA GCACCAGCAC CGTTGTACAG TTCATCCATG CCATGT

46

## (2) INFORMATION FOR SEQ ID NO:31:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1521 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

## (ix) FEATURE:

(A) NAME/KEY: -

(B) LOCATION: 1..1521

(D) OTHER INFORMATION: /note= "pPGKfo25"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

30	ATGGCTAGCA AAGGAGAAGA ACTCTTCACT GGAGTTGTCC CAATTCTTGT TGAATTAGAT	60
	GGTGATGTTA ACGGCCACAA GTTCTCTGTC AGTGGAGAGG GTGAAGGTGA TGCAACATAC	120
35	GGAAACTTTA CCCTGAAGTT CATCTGCACT ACTGGCAAAC TGCCTGTTCC ATGGCCAACA	180
	CTAGTCACTA CTCTGTGCTA TGGTGTTCAT TGCTTTTCAA GATACCCGGA TCATATGAAA	240
40	CGGCATGACT TTTTCAAGAG TGCCATGCCC GAAGGTTATG TACAGGAAAG GACCATCTTC	300
	TTCAAAGATG ACGGCAACTA CAAGACACGT GCTGAAGTCA AGTTTGAAGG TGATACCCTT	360
	GTTAATAGAA TCGAGTTAAA AGGTATTGAC TTCAAGGAAG ATGGCAACAT TCTGGGACAC	420
45	AAATTGGAAT ACAACTATAA CTCACACAAT GTATACATCA TGGCAGACAA AAAAAAGAAT	480
	GGAATCAAAG TGAAGTTCAA GACCCGCCAC AACATTGAAG ATGGAAGCGT TCAACTAGCA	540
50	GACCATTATC AACAAAATAC TCCAATTGGC GATGGCCCTG TCCTTTTACC AGACAACCAT	600
	TACCTGTCCA CACAATCTGC CCTTTCGAAA GATCCCAACG AAAAGAGAGA CCACATGGTC	660
	CTTCTTGAGT TTGTAACAGC TGCTGGGATT ACACATGGCA TGGATGAACT GTACAACGGT	720
55	GCTGGTGCTA TCGAACAAGA TGGATTGCAC GCAGGTTCTC CGGCCGCTTG GGTGGAGAGG	780
	CTATTCGGCT ATGACTGGGC ACAACAGACA ATCGGCTGCT CTGATGCCGC CGTGTTCGCG	840
60	CTGTCAGCGC AGGGGCGCCC GGTTCCTTTT GTCAAGACCG ACCTGTCCGG TGCCCTGAAT	900
	GAACTGCAGG ACGAGGCAGC GCGGCTATCG TGGCTGGCCA CGACGGGCGT TCCTTGCGCA	960
	GCTGTGCTCG ACGTTGTCAC TGAAGCGGGA AGGGACTGGC TGCTATTGGG CGAAGTGCCG	1020
65	GGGCAGGATC TCCTGTCATC TCACCTTGCT CCTGCCGAGA AAGTATCCAT CATGGCTGAT	1080
	GCAATGCGGC GGCTGCATAC GCTTGATCCG GCTACCTGCC CATTGACCA CCAAGCGAAA	1140
	CATCGCATCG AGCGAGCACG TACTCGGATG GAAGCCGGTC TTGTCGATCA GGATGATCTG	1200

84

GACGAAGAGC ATCAGGGGCT CGCGCCAGCC GAACTGTTCG CCAGGCTCAA GGCGCGCATG 1260  
CCCGACGGCG AGGATCTCGT CGTGACCCAT GGCGATGCCT GCTTGCCGAA TATCATGGTG 1320  
5 GAAAATGGCC GCTTTTCTGG ATTCATCGAC TGTGGCCGGC TGGGTGTGGC GGACCGCTAT 1380  
CAGGACATAG CGTTGGCTAC CCGTGATATT GCTGAAGAGC TTGGCGGCGA ATGGGCTGAC 1440  
CGCTTCCTCG TGCTTTACGG TATCGCCGCT CCCGATTTCG AGCGCATCGC CTTCTATCGC 1500  
10 CTTCTTGACG AGTTCTTCTG A 1521

## (2) INFORMATION FOR SEQ ID NO:32:

15

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

25

- (ix) FEATURE:  
(A) NAME/KEY: -  
(B) LOCATION: 1..26  
(D) OTHER INFORMATION: /note= "oligonucleotide #18990"

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

GACCGGGACA CGTATCCAGC CTCCGC

26

35

## (2) INFORMATION FOR SEQ ID NO:33:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 28 base pairs  
40 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..28  
50 (D) OTHER INFORMATION: /note= "oligonucleotide #18991"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

55 GGAGGCTGGA TACGTGTCCC GGTCTGCA

28

## (2) INFORMATION FOR SEQ ID NO:34:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 7617 base pairs  
60 (B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

65

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

(A) NAME/KEY: -  
(B) LOCATION: 1..7617  
(D) OTHER INFORMATION: /note= "pGen-PGKgfo25R0"

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

	TCGAGGTCGA CGGTATCGAT TAGTCCAATT TGTTAAAGAC AGGATATCAG TGGTCCAGGC	60
10	TCTAGTTTTG ACTCAACAAT ATCACCAGCT GAAGCCTATA GAGTACGAGC CATAGATAAA	120
	ATAAAAGATT TTATTTAGTC TCCAGAAAAA GGGGGGAATG AAAGACCCCA CCTGTAGGTT	180
15	TGGCAAGCTA GCTTAAGTAA CGCCATTTTG CAAGGCATGG AAAAATACAT AACTGAGAAT	240
	AGAGAAGTTC AGATCAAGGT CAGGAACAGA TGGAACAGCT GAATATGGGC CAAACAGGAT	300
	ATCTGTGGTA AGCAGTTCCT GCCCCGGCTC AGGGCCAAGA ACAGATGGAA CAGCTGAATA	360
20	TGGGCCAAAC AGGATATCTG TGTAAGCAG TTCCTGCCCC GGCTCAGGGC CAAGAACAGA	420
	TGGTCCCCAG ATCGGTCCA GCCCTCAGCA GTTCTAGAG AACCATCAGA TGTTCCAGG	480
	GTGCCCCAAG GACCTGAAAT GACCCTGTGC CTTATTGAA CTAACCAATC AGTTCGCTTC	540
25	TCGCTTCTGT TCGCGCGCTT CTGCTCCCCG AGCTCAATAA AAGAGCCCAC AACCCTCAC	600
	TCGGGGCGCC AGTCCTCCGA TTGACTGAGT CGCCCGGGTA CCCGTGTATC CAATAAACCC	660
30	TCTTGCAATT GCATCCGACT TGTGGTCTCG CTGTTCCCTG GGAGGGTCTC CTCTGAGTGA	720
	TTGACTACCC GTCAGCGGGG GTCTTTCATT TGGGGGCTCG TCCGGGATCG GGAGACCCCT	780
35	GCCCGAGGAC CACCGACCCA CCACCGGGAG GTAAGCTGGC CAGCAACTTA TCTGTGTCTG	840
	TCCGATTGTC TAGTGTCTAT GACTGATTTT ATGCGCCTGC GTCGGTACTA GTTAGCTAAC	900
	TAGCTCTGTA TCTGGCGGAC CCGTGGTGGA ACTGACGAGT TCGGAACACC CGGCCCAAC	960
40	CCTGGGAGAC GTCCAGGGA CTTCGGGGGC CGTTTTGTG GCCCGACCTG AGTCCAAAAA	1020
	TCCCGATCGT TTTGGACTCT TTGGTGCACC CCCCTTAGAG GAGGGATATG TGGTCTGGT	1080
45	AGGAGACGAG AACCTAAAC AGTCCCGCC TCCGTCTGAA TTTTGTCTT CGGTTTGGGA	1140
	CCGAAGCCGC GCCGCGCGTC TTGTCTGCTG CAGCATCGTT CTGTGTTGTC TCTGTCTGAC	1200
	TGTGTTTCTG TATTTGTCTG AGAATATGGG CCAGACTGTT ACCACTCCCT TAAGTTTGAC	1260
50	CTTAGGTCAC TGGAAAGATG TCGAGCGGAT CGCTCACAAC CAGTCGGTAG ATGTCAAGAA	1320
	GAGACGTTGG GTTACCTTCT GCTCTGCAGA ATGGCCAACC TTAAACGTCG GATGGCCGCG	1380
55	AGACGGCACC TTAAACCGAG ACCTCATCAC CCAGGTTAAG ATCAAGGTCT TTTCACCTGG	1440
	CCCGCATGGA CACCCAGACC AGGTCCCCTA CATCGTGACC TGGGAAGCCT TGGCTTTTGA	1500
	CCCCCTCCC TGGGTCAAGC CCTTTGTACA CCCTAAGCCT CCGCCTCCTC TTCCTCCATC	1560
60	CGCCCCGTCT CTCCCCCTTG AACCTCCTCG TTCGACCCG CCTCGATCCT CCCTTTATCC	1620
	AGCCCTCACT CTTCTCTGAC GGTATACAGA CATGATAAGA TACATTGATG AGTTTGGACA	1680
65	AACCACAACCT AGAATGCAGT GAAAAAATG CTTTATTTGT GAAATTTGTG ATGCTATTGC	1740
	TTTATTTGTA ACCATTATAA GCTGCAATAA ACAAGTTGGG GTGGGCGAAG AACTCCAGCA	1800
	TGAGATCCCC GCGCTGGAGG ATCATCCAGC CGGCGAACGT GGCGAGAAAG GAAGGAAGA	1860

	AAGCGAAAGG AGCGGGCGCT AGGGCGCTGG CAAGTGTAGC GGTCACGCTG CGCGTAACCA	1920
	CCACACCCGC CGCGCTTAAT GCGCCGCTAC AGGGCGCGTG GGGATACCCC CTAGAGCCCC	1980
5	AGCTGGTTCT TTCCGCCTCA GAAGCCATAG AGCCCACCGC ATCCCCAGCA TGCCTGCTAT	2040
	TGTCTTCCCA ATCCTCCCCC TTGCTGTCTT GCCCACCCC ACCCCCCAGA ATAGAATGAC	2100
10	ACCTACTCAG ACAATGCGAT GCAATTTCTT CATTTTATTA GGAAAGGACA GTGGGAGTGG	2160
	CACCTTCCAG GGTCAGGAA GGCACGGGG AGGGGCAAA AACAGATGGC TGGCAACTAG	2220
	AAGGCACAGT CGAGGCTGAT CAGCGAGCTC TAGCATTTAG GTGACACTAT AGAATAGGGC	2280
15	CCTCTAGATG CATGCTCGAG CGGCCGCCAG TGTGATGGAT ATCTGCAGAA TTCTCAGAAG	2340
	AACTCGTCAA GAAGGCGATA GAAGGCGATG CGTGCGAAT CGGGAGCGGC GATACCGTAA	2400
20	AGCACGAGGA AGCGGTCAGC CCATTTCGCC CCAAGCTCTT CAGCAATATC ACGGGTAGCC	2460
	AACGCTATGT CCTGATAGCG GTCCGCCACA CCCAGCCGGC CACAGTCGAT GAATCCAGAA	2520
	AAGCGGCCAT TTTCCACCAT GATATTCGGC AAGCAGGCAT CGCCATGGGT CACGACGAGA	2580
25	TCCTCGCCGT CGGGCATGCG CGCCTTGAGC CTGGCGAACA GTTCGGCTGG CGCGAGCCCC	2640
	TGATGCTCTT CGTCCAGATC ATCCTGATCG ACAAGACCGG CTTCATCCG AGTACGTGCT	2700
30	CGCTCGATGC GATGTTTCGC TTGGTGGTCG AATGGGCAGG TAGCCGGATC AAGCGTATGC	2760
	AGCCGCCGCA TTGCATCAGC CATGATGGAT ACTTTCTCGG CAGGAGCAAG GTGAGATGAC	2820
	AGGAGATCCT GCCCCGGCAC TTCGCCCAAT AGCAGCCAGT CCCTTCCCGC TTCAGTGACA	2880
35	ACGTCGAGCA CAGCTGCGCA AGGAACGCCC GTCGTGGCCA GCCACGATAG CCGCGCTGCC	2940
	TCGTCTTGCA GTTCATTAG GGCACCGGAC AGGTCGGTCT TGACAAAAG AACCGGGCGC	3000
40	CCCTGCGCTG ACAGCCGAA CACGGCGGCA TCAGAGCAGC CGATTGTCTG TTGTGCCCAG	3060
	TCATAGCCGA ATAGCCTCTC CACCCAAGCG GCCGAGAAC CTGCGTGCAA TCCATCTTGT	3120
	TCGATAGCAC CAGCACCATT GTACAGTTCA TCCATGCCAT GTGTAATCCC AGCAGCTGTT	3180
45	ACAAACTCAA GAAGGACCAT GTGGTCTCTC TTTTCGTTGG GATCTTTCGA AAGGGCAGAT	3240
	TGTGTGGACA GGTAATGGTT GTCTGGTAAA AGGACAGGGC CATCGCCAAT TGGAGTATTT	3300
50	TGTTGATAAT GGTCTGCTAG TTGAACGCTT CCATCTTCAA TGTTGTGGCG GGTCTTGAAG	3360
	TTCACTTTGA TTCCATTCTT TTGTTGTCTT GCCATGATGT ATACATTGTG TGAGTTATAG	3420
	TTGTATTCCA ATTTGTGTCC CAGAAATGTTG CCATCTTCCT TGAAGTCAAT ACCTTTTAAC	3480
55	TCGATTCTAT TAACAAGGGT ATCACCTTCA AACTTGACTT CAGCACGTGT CTTGTAGTTG	3540
	CCGTCACTTT TGAAGAAGAT GGTCTTTTCC TGTACATAAC CTTGCGGCAT GGCACCTTG	3600
60	AAAAAGTCAT GCCGTTTCAT ATGATCCGGG TATCTTGAAA AGCATTGAAC ACCATAGCAC	3660
	AGAGTAGTGA CTAGTGTGCG CCATGGAACA GGCAGTTTGC CAGTAGTGCA GATGAACCTC	3720
	AGGGTAAGTT TTCCGTATGT TGCATCACCT TCACCCTCTC CACTGACAGA GAACTTGTGG	3780
65	CCGTTAACAT CACCATCTAA TTCAACAAGA ATTGGGACAA CTCCAGTGAA GAGTTCTTCT	3840
	CCTTTGCTAG CCATTTCTTG CGCGCCCGCG GAGGCTGGAT ACGTGTCCTG GTCTGCAGGT	3900
	CGAAAGGCCC GGAGATGAGG AAGAGGAGAA CAGCGCGGCA GACGTGCGCT TTTGAAGCGT	3960



	GCAGAATGCC GGGCTCCGGA GGACCTTCGC GCGCGCCCCG CCCCTGAGCC CGCCCCTGAG	4020
	CGCGCCCCCG GACCCACCCC TTCCCAGCCT CTGAGCCCAG AAAGCGAAGG AGCCAAGCTG	4080
5	CTATTGGCCG CTGCCCCAAA GGCCTACCCG CTTCCATTGC TCAGCGGTGC TGTCCATCTG	4140
	CACGAGACTA GTGAGACGTG CTACTTCCAT TTGTCACGTC CTGCACGACG CGAGCTGCGG	4200
10	GGCGGGGGGG AACTTCCTGA CTAGGGGAGG AGTAGAAGGT GGCGCGAAGG GGCCACCAAA	4260
	GAAGGGAGCC GGTGGCGCT ACCGGTGGAT GTGGAATGTG TGCAGGCCA GAGGCCACTT	4320
	GTGTAGCGCC AAGTGCCAGC GGGGCTGCTA AAGCGCATGC TCCAGACTGC CTTGGGAAAA	4380
15	GCGCTCCCC TACCCGGTAG AATTCGATAT CAAGCTTATC GATACCGTCG AGATCTCCCG	4440
	ATCCGTCGAG GTCGACGTA TCGATTAGTC CAATTGTGA AAGACAGGAT ATCAGTGGTC	4500
20	CAGGCTCTAG TTTGACTCA ACAATATCAC CAGCTGAAGC CTATAGAGTA CGAGCCATAG	4560
	ATAAAATAAA AGATTTTATT TAGTCTCCAG AAAAAGGGGG GAATGAAAGA CCCCACCTGT	4620
	AGGTTTGGCA AGCTAGCTTA AGTAACGCCA TTTTGCAAGG CATGGAAAAA TACATAACTG	4680
25	AGAATAGAGA AGTTCAGATC GGGATCCCAA TTCTTTCCGA CTTTGAAG TGATGGTGGT	4740
	GGGGGAAGGA TTCGAACCTT CGAAGTCGAT GACGGCAGAT TTAGAGTCTG CTCCCTTTGG	4800
30	CCGCTCGGGA ACCCCACCAC GGGTAATGCT TTTACTGGCC TGCTCCCTTA TCGGGAAGCG	4860
	GGGCGCATCA TATCAAATGA CGCGCCGCTG TAAAGTGTTA CGTTGAGAAA GAATTGGGAT	4920
	CCCGATCAAG GTCAGGAACA GATGGAACAG CTAGAGAACC ATCAGATGTT TCCAGGGTGC	4980
35	CCCAAGGACC TGAAATGACC CTGTGCCTTA TTTGAACTAA CCAATCAGTT CGCTTCTCGC	5040
	TTCTGTTCCG GCGCTTCTGC TCCCCGAGCT CAATAAAAGA GCCCACAACC CCTCACTCGG	5100
40	GGCGCCAGTC CTCCGATTGA CTGAGTCGCC CGGGTACCCG TGTATCCAAT AAACCCCTTT	5160
	GCAGTTGCAT CCGACTTGTG GTCTCGCTGT TCCTTGGGAG GGTCTCCTCT GAGTGATTGA	5220
	CTACCCGTCA GCGGGGGTCT TTCACCCAGA GTTTGGAAC TACTGTCTTC TTGGGACCTG	5280
45	CAGCCCGGGG GATCCACTAG TTCTAGAGCG GCCGCCACCG CGGTGGATTG TGCCTCGCGC	5340
	GTTTCGGTGA TGACGGTGAA AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT	5400
50	GTCTGTAAGC GGATGCCGGG AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG	5460
	GGTGTGCGGG CGCAGCCATG ACCCAGTCAC GTAGCGATAG CGGAGTGTAT ACTGGCTTAA	5520
	CTATGCGGCA TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA	5580
55	CAGATGCGTA AGGAGAAAAT ACCGCATCAG GCGCTCTTCC GCTTCCTCGC TCACTGACTC	5640
	GCTGCGCTCG GTCGTTCCGC TCGGGCGAGC GGTATCAGCT CACTCAAAGG CGGTAATACG	5700
60	GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG TGAGCAAAAG GCCAGCAAAA	5760
	GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT GCGGTTTTTC CATAGGCTCC GCCCCCTGA	5820
	CGAGCATCAC AAAAATCGAC GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG	5880
65	ATACCAGGCG TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CTTGTTCCGA CCCTGCCCT	5940
	TACCGGATAC CTGTCCGCTT TTCTCCCTTC GGGGAAGCGT GCGCTTTCTC AATGCTCAGC	6000
	CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG CTGGGCTGTG TGCACGAACC	6060

	CCCCGTTTCAG	CCCGACCGCT	GCGCCTTATC	CGGTAACAT	CGTCTTGAGT	CCAACCCGGT	6120
	AAGACACGAC	TTATCGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	GAGCGAGGTA	6180
5	TGTAGGCGGT	GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	CTAGAAGGAC	6240
	AGTATTTGGT	ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	6300
	TTGATCCGGC	AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTTTGCA	AGCAGCAGAT	6360
10	TACGCGCAGA	AAAAAAGGAT	CTCAAGAAGA	TCCTTTGATC	TTTTCTACGG	GGTCTGACGC	6420
	TCAGTGGAAC	GAAAACTCAC	GTTAAGGGAT	TTTGGTCATG	AGATTATCAA	AAAGGATCTT	6480
15	CACCTAGATC	CTTTTAAATT	AAAAATGAAG	TTTTAAATCA	ATCTAAAGTA	TATATGAGTA	6540
	AACCTGGTCT	GACAGTTACC	AATGCTTAAT	CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	6600
	ATTTCTGTTCA	TCCATAGTTG	CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	6660
20	CTTACCATCT	GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	6720
	TTTATCAGCA	ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	CTGCAACTTT	6780
25	ATCCGCCTCC	ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	AGAGTAAGTA	GTTCCGCCAGT	6840
	TAATAGTTTG	CGCAACGTTG	TGCCCATTGC	TGCAGGCATC	GTGGTGTAC	GCTCGTCGTT	6900
	TGGTATGGCT	TCATTCAGCT	CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCCAT	6960
30	GTTGTGCAAA	AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTGTCAGAA	GTAAGTTGGC	7020
	CGCAGTGTTA	TCATCTATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	TCATGCCATC	7080
35	CGTAAGATGC	TTTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	TCATTCTGAG	AATAGTGTAT	7140
	GCGGCGACCG	AGTTGCTCTT	GCCCGGCGTC	AACACGGGAT	AATACCGCGC	CACATAGCAG	7200
	AACTTTAAAA	GTGCTCATCA	TTGGAAAACG	TTCTTCGGGG	CGAAAACTCT	CAAGGATCTT	7260
40	ACCGCTGTTG	AGATCCAGTT	CGATGTAACC	CACTCGTGCA	CCCAACTGAT	CTTCAGCATC	7320
	TTTTACTTTC	ACCAGCGTTT	CTGGGTGAGC	AAAAACAGGA	AGGCAAAATG	CCGCAAAAAA	7380
45	GGGAATAAGG	GCGACACGGA	AATGTTGAAT	ACTCATACTC	TTCCTTTTTC	AATATTATTG	7440
	AAGCATTTAT	CAGGGTTATT	GTCTCATGAG	CGGATACATA	TTTGAATGTA	TTTAGAAAAA	7500
	TAAACAAATA	GGGGTTCCGC	GCACATTTCC	CCGAAAAGTG	CCACCTGACG	TCTAAGAAAC	7560
50	CATTATTATC	ATGACATTAA	CCTATAAAAA	TAGGCGTATC	ACGAGGCCCT	TTCGTCT	7617

## (2) INFORMATION FOR SEQ ID NO:35:

## (i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 15581 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA

10

## (ix) FEATURE:

- 15 (A) NAME/KEY: -  
(B) LOCATION: 1..15581  
(D) OTHER INFORMATION: /note= "pNLnSG11"

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

20 TGGAAGGGCT AATTTGGTCC CAAAAAGAC AAGAGATCCT TGATCTGTGG ATCTACCACA 60  
CACAAGGCTA CTTCCCTGAT TGGCAGAACT ACACACCAGG GCCAGGGATC AGATATCCAC 120  
TGACCTTTGG ATGGTGCTTC AAGTTAGTAC CAGTTGAACC AGAGCAAGTA GAAGAGGCCA 180  
25 AATAAGGAGA GAAGAACAGC TTGTTACACC CTATGAGCCA GCATGGGATG GAGGACCCGG 240  
AGGGAGAAGT ATTAGTGTGG AAGTTTGACA GCCTCCTAGC ATTCGTCAC ATGGCCCGAG 300  
30 AGCTGCATCC GGAGTACTAC AAAGACTGCT GACATCGAGC TTTCTACAAG GGACTTTCCG 360  
CTGGGGACTT TCCAGGGAGG TGTGGCCTGG GCGGGACTGG GGAGTGGCGA GCCCTCAGAT 420  
GCTACATATA AGCAGCTGCT TTTTGCTGT ACTGGGTCTC TCTGGTTAGA CCAGATCTGA 480  
35 GCCTGGGAGC TCTCTGGCTA ACTAGGGAAC CCACTGCTTA AGCCTCAATA AAGCTTGCTT 540  
TGAGTGCTCA AAGTAGTGTG TGCCCGTCTG TTGTGTGACT CTGGTAACTA GAGATCCCTC 600  
40 AGACCCTTTT AGTCAGTGTG GAAAATCTCT AGCAGTGGCG CCCGAACAGG GACTTGAAAG 660  
CGAAAGTAAA GCCAGAGGAG ATCTCTCGAC GCAGGACTCG GCTTGCTGAA GCGCGCACGG 720  
CAAGAGGCGA GGGGCGGCGA CTGGTGAGTA CGCCAAAAAT TTTGACTAGC GGAGGCTAGA 780  
45 AGGAGAGAGA TGGGTGCGAG AGCGTCGGTA TTAAGCGGGG GAGAATTAGA TAAATGGGAA 840  
AAAATTCCGT TAAGGCCAGG GGGAAAGAAA CAATATAAAC TAAAACATAT AGTATGGGCA 900  
50 AGCAGGGAGC TAGAACGATT CGCAGTTAAT CCTGGCCTTT TAGAGACATC AGAAGGCTGT 960  
AGACAAATAC TGGGACAGCT ACAACCATCC CTTAGACAG GATCAGAAGA ACTTAGATCA 1020  
TTATATAATA CAATAGCAGT CCTCTATTGT GTGCATCAAA GGATAGATGT AAAAGACACC 1080  
55 AAGGAAGCCT TAGATAAGAT AGAGGAAGAG CAAAACAAAA GTAAGAAAAA GGCACAGCAA 1140  
GCAGCAGCTG ACACAGGAAA CAACAGCCAG GTCAGCCAAA ATTACCCTAT AGTGCAGAAC 1200  
60 CTCCAGGGGC AAATGGTACA TCAGGCCATA TCACCTAGAA CTTTAAATGC ATGGGTAAAA 1260  
GTAGTAGAAG AGAAGGCTTT CAGCCCAGAA GTAATACCCA TGTTTTCAGC ATTATCAGAA 1320  
GGAGCCACCC CACAAGATTT AAATACCATG CTAAACACAG TGGGGGGACA TCAAGCAGCC 1380  
65 ATGCAAATGT TAAAAGAGAC CATCAATGAG GAAGCTGCAG AATGGGATAG ATTGCATCCA 1440  
GTGCATGCAG GGCCTATTGC ACCAGGCCAG ATGAGAGAAC CAAGGGGAAG TGACATAGCA 1500

	GGA	ACTACTA	GTACCCTTCA	GGAACAAATA	GGATGGATGA	CACATAATCC	ACCTATCCCA	1560
	GTAGGAGAAA	TCTATAAAAG	ATGGATAATC	CTGGGATTAA	ATAAAATAGT	AAGAATGTAT		1620
5	AGCCCTACCA	GCATTCTGGA	CATAAGACAA	GGACCAAAGG	AACCCTTTAG	AGACTATGTA		1680
	GACCGATTCT	ATAAACTCT	AAGAGCCGAG	CAAGCTTCAC	AAGAGGTAAA	AAATTGGATG		1740
10	ACAGAAACCT	TGTTGGTCCA	AAATGCGAAC	CCAGATTGTA	AGACTATTTT	AAAAGCATTG		1800
	GGACCAGGAG	CGACACTAGA	AGAAATGATG	ACAGCATGTC	AGGGAGTGGG	GGGACCCGGC		1860
	CATAAAGCAA	GAGTTTTGGC	TGAAGCAATG	AGCCAAGTAA	CAAATCCAGC	TACCATAATG		1920
15	ATACAGAAAG	GCAATTTTAG	GAACCAAAGA	AAGACTGTTA	AGTGTTCCTAA	TTGTGGCAAA		1980
	GAAGGGCACA	TAGCCAAAAA	TTGCAGGGCC	CCTAGGAAAA	AGGGCTGTTG	GAAATGTGGA		2040
20	AAGGAAGGAC	ACCAAATGAA	AGATTGTACT	GAGAGACAGG	CTAATTTTTT	AGGGAAGATC		2100
	TGGCCTTCCC	ACAAGGGAAG	GCCAGGGAAT	TTTCTTCAGA	GCAGACCAGA	GCCAACAGCC		2160
	CCACCAGAAG	AGAGCTTCAG	GTTTGGGGAA	GAGACAACAA	CTCCCTCTCA	GAAGCAGGAG		2220
25	CCGATAGACA	AGGAACTGTA	TCCTTTAGCT	TCCCTCAGAT	CACCTCTTGG	CAGCGACCCC		2280
	TCGTCACAAT	AAAGATAGGG	GGGCAATTAA	AGGAAGCTCT	ATTAGATACA	GGAGCAGATG		2340
30	ATACAGTATT	AGAAGAAATG	AATTTGCCAG	GAAGATGGAA	ACCAAAAATG	ATAGGGGGAA		2400
	TTGGAGGTTT	TATCAAAGTA	GGACAGTATG	ATCAGATACT	CATAGAAATC	TGCGGACATA		2460
	AAGCTATAGG	TACAGTATTA	GTAGGACCTA	CACCTGTCAA	CATAATTGGA	AGAAATCTGT		2520
35	TGACTCAGAT	TGGCTGCACT	TTAAATTTTC	CCATTAGTCC	TATTGAGACT	GTACCAGTAA		2580
	AATTAAAGCC	AGGAATGGAT	GGCCCAAAG	TTAAACAATG	GCCATTGACA	GAAGAAAAAA		2640
40	TAAAGCATT	AGTAGAAATT	TGTACAGAAA	TGGAAAAGGA	AGGAAAAATT	TCAAAAATTG		2700
	GGCCTGAAAA	TCCATACAAT	ACTCCAGTAT	TTGCCATAAA	GAAAAAGAC	AGTACTAAAT		2760
	GGAGAAAATT	AGTAGATTTC	AGAGAACTTA	ATAAGAGAAC	TCAAGATTTC	TGGGAAGTTC		2820
45	AATTAGGAAT	ACCACATCCT	GCAGGGTTAA	AACAGAAAAA	ATCAGTAACA	GTACTGGATG		2880
	TGGGCGATGC	ATATTTTTCA	GTTCCCTTAG	ATAAAGACTT	CAGGAAGTAT	ACTGCATTTA		2940
50	CCATACCTAG	TATAACAAT	GAGACACCAG	GGATTAGATA	TCAGTACAAT	GTGCTCCAC		3000
	AGGGATGGAA	AGGATCACCA	GCAATATTCC	AGTGTAGCAT	GACAAAAATC	TTAGAGCCTT		3060
	TTAGAAAACA	AAATCCAGAC	ATAGTCATCT	ATCAATACAT	GGATGATTG	TATGTAGGAT		3120
55	CTGACTTAGA	AATAGGGCAG	CATAGAACAA	AAATAGAGGA	ACTGAGACAA	CATCTGTTGA		3180
	GGTGGGGATT	TACCACACCA	GACAAAAAAC	ATCAGAAAGA	ACCTCCATTC	CTTTGGATGG		3240
60	GTTATGAAC	CCATCCTGAT	AAATGGACAG	TACAGCCTAT	AGTGCTGCCA	GAAAAGGACA		3300
	GCTGGACTGT	CAATGACATA	CAGAAATTAG	TGGGAAAATT	GAATTGGGCA	AGTCAGATTT		3360
	ATGCAGGGAT	TAAAGTAAGG	CAATTATGTA	AACCTCTTAG	GGGAACCAAA	GCACTAACAG		3420
65	AAGTAGTACC	ACTAACAGAA	GAAGCAGAGC	TAGAACTGGC	AGAAAACAGG	GAGATTCTAA		3480
	AAGAACCGGT	ACATGGAGTG	TATTATGACC	CATCAAAAGA	CTTAATAGCA	GAAATACAGA		3540
	AGCAGGGGCA	AGGCCAATGG	ACATATCAAA	TTTATCAAGA	GCCATTTAAA	AATCTGAAAA		3600

	CAGGAAAATA TGCAAGAATG AAGGGTGCCC AACTAATGA TGTGAAACAA TTAACAGAGG	3660
	CAGTACAAAA AATAGCCACA GAAAGCATAG TAATATGGGG AAAGACTCCT AAATTTAAAT	3720
5	TACCCATACA AAAGGAAACA TGGGAAGCAT GGTGGACAGA GTATTGGCAA GCCACCTGGA	3780
	TTCCTGAGTG GGAGTTTGTC AATACCCCTC CCTTAGTGAA GTTATGGTAC CAGTTAGAGA	3840
10	AAGAACCCAT AATAGGAGCA GAAACTTTCT ATGTAGATGG GGCAGCCAAT AGGGAAACTA	3900
	AATTAGGAAA AGCAGGATAT GTAACGTACA GAGGAAGACA AAAAGTTGTC CCCCTAACGG	3960
	ACACAACAAA TCAGAAGACT GAGTTACAAG CAATTCATCT AGCTTTGCAG GATTCGGGAT	4020
15	TAGAAGTAAA CATAGTGACA GACTCACAAT ATGCATTGGG AATCATTCAA GCACAACCAG	4080
	ATAAGAGTGA ATCAGAGTTA GTCAGTCAAA TAATAGAGCA GTTAATAAAA AAGGAAAAAG	4140
20	TCTACCTGGC ATGGGTACCA GCACACAAAG GAATTGGAGG AAATGAACAA GTAGATGGGT	4200
	TGGTCAGTGC TGGAAATCAGG AAAGTACTAT TTTTAGATGG AATAGATAAG GCCCAAGAAG	4260
	AACATGAGAA ATATCACAGT AATTGGAGAG CAATGGCTAG TGATTTTAAC CTACCACCTG	4320
25	TAGTAGCAAA AGAAATAGTA GCCAGCTGTG ATAAATGTCA GCTAAAAGGG GAAGCCATGC	4380
	ATGGACAAGT AGACTGTAGC CCAGGAATAT GGCAGCTAGA TTGTACACAT TTAGAAGGAA	4440
30	AAGTTATCTT GGTAGCAGTT CATGTAGCCA GTGGATATAT AGAAGCAGAA GTAATTCAG	4500
	CAGAGACAGG GCAAGAAACA GCATACTTCC TCTTAAAT AGCAGGAAGA TGGCCAGTAA	4560
	AAACAGTACA TACAGACAAT GGCAGCAATT TCACCAGTAC TACAGTTAAG GCCGCCTGTT	4620
35	GGTGGGCGGG GATCAAGCAG GAATTTGGCA TTCCCTACAA TCCCCAAAGT CAAGGAGTAA	4680
	TAGAATCTAT GAATAAGAA TTAAAGAAAA TTATAGGACA GGTAAGAGAT CAGGCTGAAC	4740
40	ATCTTAAGAC AGCAGTACAA ATGGCAGTAT TCATCCACAA TTTTAAAGA AAAGGGGGGA	4800
	TTGGGGGGTA CAGTGCAGGG GAAAGAATAG TAGACATAAT AGCAACAGAC ATACAACTA	4860
	AAGAATTACA AAAACAAATT AAAAAATTC AAAATTTTCG GGTATTATTAC AGGGACAGCA	4920
45	GAGATCCAGT TTGGAAGGA CCAGCAAAGC TCCTCTGGAA AGGTGAAGGG GCAGTAGTAA	4980
	TACAAGATAA TAGTGACATA AAAGTAGTGC CAAGAAGAAA AGCAAAGATC ATCAGGGATT	5040
50	ATGGAAAACA GATGGCAGGT GATGATTGTG TGGCAAGTAG ACAGGATGAG GATTAACACA	5100
	TGGAAAAGAT TAGTAAAACA CCATATGTAT ATTTCAAGGA AAGCTAAGGA CTGGTTTTAT	5160
	AGACATCACT ATGAAAGTAC TAATCCAAAA ATAAGTTCAG AAGTACACAT CCCACTAGGG	5220
55	GATGCTAAAT TAGTAATAAC AACATATTGG GGTCTGCATA CAGGAGAAAG AGACTGGCAT	5280
	TTGGGTCAGG GAGTCTCCAT AGAATGGAGG AAAAAGAGAT ATAGCACACA AGTAGACCCT	5340
60	GACCTAGCAG ACCAACTAAT TCATCTGCAC TATTTTGATT GTTTTTCAGA ATCTGCTATA	5400
	AGAAATACCA TATTAGGACG TATAGTTAGT CCTAGGTGTG AATATCAAGC AGGACATAAC	5460
	AAGGTAGGAT CTCTACAGTA CTTGGCACTA GCAGCATTAA TAAACCAAAA ACAGATAAAG	5520
65	CCACCTTTGC CTAGTGTTAG GAAACTGACA GAGGACAGAT GGAACAAGCC CCAGAAGACC	5580
	AAGGGCCACA GAGGGAGCCA TACAATGAAT GGACACTAGA GCTTTTAGAG GAACTTAAGA	5640
	GTGAAGCTGT TAGACATTTT CCTAGGATAT GGCTCCATAA CTTAGGACAA CATATCTATG	5700

	AAACTTACGG	GGATACTTGG	GCAGGAGTGG	AAGCCATAAT	AAGAATTCTG	CAACAACTGC	5760
	TGTTTATCCA	TTTCAGAATT	GGGTGTCGAC	ATAGCAGAAT	AGGCGTTACT	CGACAGAGGA	5820
5	GAGCAAGAAA	TGGAGCCAGT	AGATCCTAGA	CTAGAGCCCT	GGAAGCATCC	AGGAAGTCAG	5880
	CCTAAACTG	CTTGTACCAA	TTGCTATTGT	AAAAAGTGTT	GCTTTCATTG	CCAAGTTTGT	5940
10	TTCATGACAA	AAGCCTTAGG	CATCTCCTAT	GGCAGGAAGA	AGCGGAGACA	GCGACGAAGA	6000
	GCTCATCAGA	ACAGTCAGAC	TCATCAAGCT	TCTCTATCAA	AGCAGTAAGT	AGTACATGTA	6060
	ATGCAACCTA	TAATAGTAGC	AATAGTAGCA	TTAGTAGTAG	CAATAATAAT	AGCAATAGTT	6120
15	GTGTGGTCCA	TAGTAATCAT	AGAATATAGG	AAAATATTAA	GACAAAGAAA	AATAGACAGG	6180
	TTAATTGATA	GACTAATAGA	AAGAGCAGAA	GACAGTGGCA	ATGAGAGTGA	AGGAGAAGTA	6240
20	TCAGCACTTG	TGGAGATGGG	GGTGGAAATG	GGGCACCATG	CTCCTTGGGA	TATTGATGAT	6300
	CTGTAGTGCT	ACAGAAAAAT	TGTGGGTCAC	AGTCTATTAT	GGGGTACCTG	TGTGGAAGGA	6360
	AGCAACCACC	ACTCTATTTT	GTGCATCAGA	TGCTAAAGCA	TATGATACAG	AGGTACATAA	6420
25	TGTTTGGGCC	ACACATGCCT	GTGTACCCAC	AGACCCCAAC	CCACAAGAAG	TAGTATTGGT	6480
	AAATGTGACA	GAAAATTTTA	ACATGTGGAA	AAATGACATG	GTAGAACAGA	TGCATGAGGA	6540
30	TATAATCAGT	TTATGGGATC	AAAGCCTAAA	GCCATGTGTA	AAATTAACCC	CACTCTGTGT	6600
	TAGTTTAAAG	TGCACTGATT	TGAAGAATGA	TACTAATACC	AATAGTAGTA	GCGGGAGAAT	6660
	GATAATGGAG	AAAGGAGAGA	TAAAAAATG	CTCTTTCAAT	ATCAGCACAA	GCATAAGAGA	6720
35	TAAGGTGCAG	AAAGAATATG	CATTCTTTTA	TAACTTGAT	ATAGTACCAA	TAGATAATAC	6780
	CAGCTATAGG	TTGATAAGTT	GTAACACCTC	AGTCATTACA	CAGGCCTGTC	CAAAGGTATC	6840
40	CTTTGAGCCA	ATTCCCATAC	ATTATTGTGC	CCCGGCTGGT	TTTGCGATTG	TAAAATGTAA	6900
	TAATAAGACG	TTCAATGGAA	CAGGACCATG	TACAAATGTC	AGCACAGTAC	AATGTACACA	6960
	TGGAATCAGG	CCAGTAGTAT	CAACTCAACT	GCTGTAAAT	GGCAGTCTAG	CAGAAGAAGA	7020
45	TGTAGTAATT	AGATCTGCCA	ATTTACACAGA	CAATGCTAAA	ACCATAATAG	TACAGCTGAA	7080
	CACATCTGTA	GAAATTAATT	GTACAAGACC	CAACAACAAT	ACAAGAAAAA	GTATCCGTAT	7140
50	CCAGAGGGGA	CCAGGGAGAG	CATTTGTTAC	AATAGGAAAA	ATAGGAAATA	TGAGACAAGC	7200
	ACATTGTAAC	ATTAGTAGAG	CAAAATGGAA	TGCCACTTTA	AAACAGATAG	CTAGCAAATT	7260
	AAGAGAACAA	TTTGAAATA	ATAAAACAAT	AATCTTTAAG	CAATCCTCAG	GAGGGGACCC	7320
55	AGAAATTGTA	ACGCACAGTT	TTAATTGTGG	AGGGGAATTT	TTCTACTGTA	ATTCAACACA	7380
	ACTGTTTAAT	AGTACTTGGT	TTAATAGTAC	TTGGAGTACT	GAAGGGTCAA	ATAACACTGA	7440
60	AGGAAGTGAC	ACAATCACAC	TCCCATGCAG	AATAAAACAA	TTTATAAACA	TGTGGCAGGA	7500
	AGTAGGAAAA	GCAATGTATG	CCCCTCCCAT	CAGTGGACAA	ATTAGATGTT	CATCAAATAT	7560
	TACTGGGCTG	CTATTAACAA	GAGATGGTGG	TAATAACAAC	AATGGGTCCG	AGATCTTCAG	7620
65	ACCTGGAGGA	GGCGATATGA	GGGACAATTG	GAGAAGTGAA	TTATATAAAT	ATAAAGTAGT	7680
	AAAAATTGAA	CCATTAGGAG	TAGCACCCAC	CAAGGCAAAG	AGAAGAGTGG	TGCAGAGAGA	7740
	AAAAAGAGCA	GTGGGAATAG	GAGCTTTGTT	CCTTGGGTTC	TTGGGAGCAG	CAGGAAGCAC	7800

	TATGGGCGCA GCGTCAATGA CGCTGACGGT ACAGGCCAGA CAATTATTGT CTGATATAGT	7860
	GCAGCAGCAG AACAAATTGC TGAGGGCTAT TGAGGCGCAA CAGCATCTGT TGCAACTCAC	7920
5	AGTCTGGGGC ATCAAACAGC TCCAGGCAAG AATCCTGGCT GTGGAAAGAT ACCTAAAGGA	7980
	TCAACAGCTC CTGGGGATTT GGGGTTGCTC TGGAAACTC ATTTGCACCA CTGCTGTGCC	8040
10	TTGGAATGCT AGTTGGAGTA ATAAATCTCT GGAACAGATT TGGAATAACA TGACCTGGAT	8100
	GGAGTGGGAC AGAGAAATTA ACAATTACAC AAGCTTAATA CACTCCTTAA TTGAAGAATC	8160
	GCAAAACCAG CAAGAAAAGA ATGAACAAGA ATTATTGGAA TTAGATAAAT GGGCAAGTTT	8220
15	GTGGAATTGG TTAAACATAA CAAATTGGCT GTGGTATATA AAATTATTCA TAATGATAGT	8280
	AGGAGGCTTG GTAGGTTTAA GAATAGTTTT TGCTGTACTT TCTATAGTGA ATAGAGTTAG	8340
20	GCAGGGATAT TCACCATTAT CGTTTCAGAC CCACCTCCCA ATCCCGAGGG GACCCGACAG	8400
	GCCCCAAGGA ATAGAAGAAG AAGGTGGAGA GAGAGACAGA GACAGATCCA TTCGATTAGT	8460
	GAACGGATCC TTAGCACTTA TCTGGGACGA TCTGCGGAGC CTGTGCCTCT TCAGCTACCA	8520
25	CCGCTTGAGA GACTTACTCT TGATTGTAAC GAGGATTGTG GAACTTCTGG GACGCAGGGG	8580
	GTGGGAAGCC CTCAAATATT GGTGGAATCT CCTACAGTAT TGGAGTCAGG AACTAAAGAA	8640
30	TAGTGCTGTT AACTTGCTCA ATGCCACAGC CATAGCAGTA GCTGAGGGGA CAGATAGGGT	8700
	TATAGAAGTA TTACAAGCAG CTTATAGAGC TATTCGCCAC ATACCTAGAA GAATAAGACA	8760
	GGGCTTGGA AGGATTTTGC TATAAGATGG GTGGCAAGTG GTCAAAAAGT AGTGTGATTG	8820
35	GATGGCCTGC TGTAAGGGAA AGAATGAGAC GAGCTGAGCA AGAAATGGCT AGCAAAGGAG	8880
	AAGAACTCTT CACTGGAGTT GTCCCAATTC TTGTTGAATT AGATGGTGAT GTTAACGGCC	8940
40	ACAAGTTCTC TGTCAGTGGA GAGGGTGAAG GTGATGCAAC ATACGGAAAA CTTACCCTGA	9000
	AGTTCATCTG CACTACTGGC AAACCTGCCTG TTCCATGGCC AACACTTGTC ACTACTCTCT	9060
	CTTATGGTGT TCAATGCTTT TCAAGATACC CGGATCATAT GAAACGGCAT GACTTTTTCA	9120
45	AGAGTGCCAT GCCCGAAGGT TATGTACAGG AAAGGACCAT CTTCTTCAAA GATGACGGCA	9180
	ACTACAAGAC ACGTGCTGAA GTCAAGTTTG AAGGTGATAC CTTGTTAAT AGAATCGAGT	9240
50	TAAAAGGTAT TGACTTCAAG GAAGATGGCA ACATTCTGGG ACACAAATTG GAATACAAC	9300
	ATAACTCACA CAATGTATAC ATCATGGCAG ACAAACAAAA GAATGGAATC AAAGTGAAC	9360
	TCAAGACCCG CCACAACATT GAAGATGGAA GCGTTCAACT AGCAGACCAT TATCAACAAA	9420
55	ATACTCCAAT TGGCGATGGC CCTGTCCTTT TACCAGACAA CCATTACCTG TCCACACAAT	9480
	CTGCCCTTTC GAAAGATCCC AACGAAAAGA GAGACCACAT GGTCTTCTT GAGTTTGTA	9540
60	CAGCTGCTGG GATTACACAT GGCATGGATG AACTGTACAA CGGACTCGAG ACCTAGAAAA	9600
	ACATGGAGCA ATCACAAGTA GCAATACAGC AGCTAACAAT GCTGCTTGTC CCTGGCTAGA	9660
	AGCACAAGAG GAGGAAGAGG TGGGTTTTCC AGTCACACCT CAGGTACCTT TAAGACCAAT	9720
65	GACTTACAAG GCAGCTGTAG ATCTTAGCCA CTTTTTAAAA GAAAAGGGGG GACTGGAAGG	9780
	GCTAATTCAC TCCCAAAGAA GACAAGATAT CCTTGATCTG TGGATCTACC ACACACAAGG	9840
	CTACTTCCCT GATTGGCAGA ACTACACACC AGGGCCAGGG GTCAGATATC CACTGACCTT	9900

	TGGATGGTGC	TACAAGCTAG	TACCAGTTGA	GCCAGATAAG	GTAGAAGAGG	CCAATAAAGG	9960
	AGAGAACACC	AGCTTGTTAC	ACCCTGTGAG	CCTGCATGGA	ATGGATGACC	CTGAGAGAGA	10020
5	AGTGTTAGAG	TGGAGGTTTG	ACAGCCGCCT	AGCATTTTCAT	CACGTGGCCC	GAGAGCTGCA	10080
	TCCGGAGTAC	TTCAAGAACT	GCTGACATCG	AGCTTGCTAC	AAGGGACTTT	CCGCTGGGGA	10140
10	CTTTCCAGGG	AGGCGTGGCC	TGGGCGGGAC	TGGGGAGTGG	CGAGCCCTCA	GATGCTGCAT	10200
	ATAAGCAGCT	GCTTTTTGCC	TGTACTGGGT	CTCTCTGGTT	AGACCAGATC	TGAGCCTGGG	10260
	AGCTCTCTGG	CTAACTAGGG	AACCCACTGC	TTAAGCCTCA	ATAAAGCTTG	CCTTGAGTGC	10320
15	TTCAAGTAGT	GTGTGCCCCG	CTGTTGTGTG	ACTCTGGTAA	CTAGAGATCC	CTCAGACCCT	10380
	TTTAGTCAGT	GTGGAATATC	TCTAGCACCC	CCCAGGAGGT	AGAGGTTGCA	GTGAGCCAAG	10440
20	ATCGCGCCAC	TGCATTCCAG	CCTGGGCAAG	AAAACAAGAC	TGTCTAAAT	AATAATAATA	10500
	AGTTAAGGGT	ATTAAATATA	TTTATACATG	GAGGTCATAA	AAATATATAT	ATTTGGGCTG	10560
	GGCGCAGTGG	CTCACACCTG	CGCCCGGCCC	TTTGGGAGGC	CGAGGCAGGT	GGATCACCTG	10620
25	AGTTTGGGAG	TTCCAGACCA	GCCTGACCAA	CATGGAGAAA	CCCCTTCTCT	GTGTATTTTT	10680
	AGTAGATTTT	ATTTTATGTG	TATTTTATTC	ACAGGTATTT	CTGGAAAAC	GAAACTGTTT	10740
30	TTCTCTACT	CTGATACCAC	AAGAATCATC	AGCACAGAGG	AAGACTTCTG	TGATCAAATG	10800
	TGGTGGGAGA	GGGAGGTTTT	CACCAGCACA	TGAGCAGTCA	GTTCTGCCGC	AGACTCGGCG	10860
	GGTGTCTTTC	GGTTCAGTTC	CAACACCGCC	TGCCTGGAGA	GAGGTCAGAC	CACAGGGTGA	10920
35	GGGCTCAGTC	CCCAAGACAT	AAACACCCAA	GACATAAACA	CCCAACAGGT	CCACCCCGCC	10980
	TGCTGCCCAG	GCAGAGCCGA	TTACCAAGA	CGGGAATTAG	GATAGAGAAA	GAGTAAGTCA	11040
40	CACAGAGCCG	GCTGTGCGGG	AGAACGGAGT	TCTATTATGA	CTCAAATCAG	TCTCCCCAAG	11100
	CATTTCGGGA	TCAGAGTTTT	TAAGGATAAC	TTAGTGTGTA	GGGGGCCAGT	GAGTTGGAGA	11160
	TGAAAGCGTA	GGGAGTCGAA	GGTGTCTTTT	TGCGCCGAGT	CAGTTCCTGG	GTGGGGGCCA	11220
45	CAAGATCGGA	TGAGCCAGTT	TATCAATCCG	GGGGTGCCAG	CTGATCCATG	GAGTGCAGGG	11280
	TCTGCAAAAT	ATCTCAAGCA	CTGATTGATC	TTAGGTTTTA	CAATAGTGAT	GTTACCCAG	11340
50	GAACAATTTG	GGGAAGGTCA	GAATCTTGTA	GCCTGTAGCT	GCATGACTCC	TAAACCATAA	11400
	TTTCTTTTTT	GTTTTTTTTT	TTTTATTTTT	GAGACAGGGT	CTCACTCTGT	CACCTAGGCT	11460
	GGAGTGCAGT	GGTGCAATCA	CAGCTCACTG	CAGCCTCAAC	GTCGTAAGCT	CAAGCGATCC	11520
55	TCCCACCTCA	GCCTGCCTGG	TAGCTGAGAC	TACAAGCGAC	GCCCCAGTTA	ATTTTTGTAT	11580
	TTTTGGTAGA	GGCAGCGTTT	TGCCGTGTGG	CCCTGGCTGG	TCTCGAACTC	CTGGGCTCAA	11640
60	GTGATCCAGC	CTCAGCCTCC	CAAAGTGCTG	GGACAACCGG	GGCCAGTCAC	TGCACCTGGC	11700
	CCTAAACCAT	AATTTCTAAT	CTTTTGGCTA	ATTTGTTAGT	CCTACAAAGG	CAGTCTAGTC	11760
	CCCAGGCAAA	AAGGGGGTTT	GTTTCGGGAA	AGGGCTGTTA	CTGTCTTTGT	TTCAAACATAT	11820
65	AAACTAAGTT	CCTCCTAAAC	TTAGTTCGGC	CTACACCCAG	GAATGAACAA	GGAGAGCTTG	11880
	GAGGTTAGAA	GCACGATGGA	ATTGGTTAGG	TCAGATCTCT	TTCAGTGTCT	GAGTTATAAT	11940
	TTTGCAATGG	TGTTCAAAG	ACTGCCCGCT	TCTGACACCA	GTCGCTGCAT	TAATGAATCG	12000



	GCCAACGCGC	GGGAGAGGC	GGTTTGCCTA	TTGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	12060
	CTCGCTGCGC	TCGGTTCGTT	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	12120
5	ACGGTTATCC	ACAGAATCAG	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	AAGGCCAGCA	12180
	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	TTCCATAGGC	TCCGCCCCC	12240
10	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	12300
	AAGATACCAG	GCGTTTCCCC	CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTC	CGACCCTGCC	12360
	GCTTACCGGA	TACCTGTCCG	CCTTTCTCCC	TTCGGAAGC	GTGGCGCTTT	CTCAATGCTC	12420
15	ACGCTGTAGG	TATCTCAGTT	CGGTGTAGGT	CGTTCGCTCC	AAGCTGGGCT	GTGTGCACGA	12480
	ACCCCCGTT	CAGCCCGACC	GCTGCGCCTT	ATCCGGTAAC	TATCGTCTTG	AGTCCAACCC	12540
20	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	12600
	GTATGTAGGC	GGTGCTACAG	AGTTCTTGAA	GTGGTGGCCT	AACTACGGCT	ACACTAGAAG	12660
	GACAGTATTT	GGTATCTGCG	CTCTGCTGAA	GCCAGTTACC	TTCGGAAAAA	GAGTTGGTAG	12720
25	CTCTTGATCC	GGCAAACAAA	CCACCCTGG	TAGCGGTGGT	TTTTTTGTTT	GCAAGCAGCA	12780
	GATTACGCGC	AGAAAAAAG	GATCTCAAGA	AGATCCTTTG	ATCTTTTCTA	CGGGGTCTGA	12840
30	CGCTCAGTGG	AACGAAACT	CACGTTAAGG	GATTTTGCTC	ATGAGATTAT	CAAAAAGGAT	12900
	CTTCACCTAG	ATCCTTTTAA	ATTAAAAATG	AAGTTTTTAA	TCAATCTAAA	GTATATATGA	12960
	GTAAACTTGG	TCTGACAGTT	ACCAATGCTT	AATCAGTGAG	GCACCTATCT	CAGCGATCTG	13020
35	TCTATTTTCG	TCATCCATAG	TTGCTGACT	CCCCGTCGTG	TAGATAACTA	CGATACGGGA	13080
	GGGCTTACCA	TCTGGCCCCA	GTGCTGCAAT	GATACCGCGA	GACCCACGCT	CACCGGCTCC	13140
40	AGATTTATCA	GCAATAAACC	AGCCAGCCGG	AAGGGCCGAG	CGCAGAAGTG	GTCTGCAAC	13200
	TTTATCCGCC	TCCATCCAGT	CTATTAATTG	TTGCCGGGAA	GCTAGAGTAA	GTAGTTCGCC	13260
	AGTTAATAGT	TTGCGCAACG	TTGTTGCCAT	TGCTACAGGC	ATCGTGGTGT	CACGCTCGTC	13320
45	GTTTGGTATG	GCTTCATTCA	GCTCCGGTTC	CCAACGATCA	AGGCGAGTTA	CATGATCCCC	13380
	CATGTTGTGC	AAAAAAGCGG	TTAGCTCCTT	CGGTCCCTCG	ATCGTTGTCA	GAAGTAAGTT	13440
50	GGCCGCACTG	TTATCACTCA	TGGTTATGGC	AGCACTGCAT	AATTCTCTTA	CTGTCATGCC	13500
	ATCCGTAAGA	TGCTTTTCTG	TGACTGGTGA	GTACTCAACC	AAGTCATTCT	GAGAATAGTG	13560
	TATGCGGCGA	CCGAGTTGCT	CTTGCCCGGC	GTCAATACGG	GATAATACCG	CGCCACATAG	13620
55	CAGAACTTTA	AAAGTGCTCA	TCATTGGAAA	ACGTTCTTCG	GGGCGAAAAAC	TCTCAAGGAT	13680
	CTTACCGCTG	TTGAGATCCA	GTTGATGTA	ACCCACTCGT	GCACCCAACT	GATCTTCAGC	13740
60	ATCTTTTACT	TTCACCAGCG	TTTCTGGGTG	AGCAAAAAACA	GGAAGGCAAA	ATGCCGCAAA	13800
	AAAGGGAATA	AGGCGGACAC	GGAAATGTTG	AATACTCATA	CTCTTCCTTT	TTCAATATTA	13860
	TTGAAGCATT	TATCAGGGTT	ATTGTCTCAT	GAGCGGATAC	ATATTTGAAT	GTATTTAGAA	13920
65	AAATAAACAA	ATAGGGGTTT	CGCGCACATT	TCCCCGAAAA	GTGCCACCTG	ACGTCTAAGA	13980
	AACCATTATT	ATCATGACAT	TAACCTATAA	AAATAGGCGT	ATCACGAGGC	CCTTTCGTCT	14040
	TCAAGAACTG	CCTCGCGCGT	TTCGGTGATG	ACGSTGAAAA	CCTCTGACAC	ATGCAGCTCC	14100

	CGGAGACGGT CACAGCTTGT CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG	14160
	CGTCAGCGGG TGTGGCGGG TGTCGGGGCG CAGCCATGAC CCAGTCACGT AGCGATAGCG	14220
5	GAGTGTACTG GCTTAACTAT GCGGCATCAG AGCAGATTGT ACTGAGAGTG CACCATATGC	14280
	GGTGTGAAAT ACCGCACAGA TCGTAAGGA GAAAATACCG CATCAGGCGC CATTGCCAT	14340
10	TCAGGCTGCG CAACTGTTGG GAAGGGCGAT CGGTGCGGGC CTCTTCGCTA TTACGCCAGC	14400
	GCGGGGAGGC AGAGATTGCA GTAAGCTGAG ATCGCAGCAC TGCACTCCAG CCTGGGCGAC	14460
	AGAGTAAGAC TCTGTCTCAA AAATAAAATA AATAAATCAA TCAGATATTC CAATCTTTTC	14520
15	CTTTATTTAT TTATTTATTT TCTATTTTGG AAACACAGTC CTTCTTTATT CCAGAATTAC	14580
	ACATATATTC TATTTTCTT TATATGCTCC AGTTTTTTTT AGACCTTCAC CTGAAATGTG	14640
20	TGTATACAAA ATCTAGGCCA GTCCAGCAGA GCCTAAAGGT AAAAAATAAA ATAATAAAAA	14700
	ATAAATAAAA TCTAGCTCAC TCCTTCACAT CAAAATGGAG ATACAGCTGT TAGCATTAAA	14760
	TACCAAATAA CCCATCTTGT CCTCAATAAT TTTAAGCGCC TCTCTCCACC ACATCTAACT	14820
25	CCTGTCAAAG GCATGTGCCC CTTCCGGGCG CTCTGTGTG CTGCCAACCA ACTGGCATGT	14880
	GGACTCTGCA GGGTCCCTAA CTGCCAAGCC CCACAGTGTG CCCTGAGGCT GCCCCCTCCT	14940
30	TCTAGCGGCT GCCCCACTC GGCTTTGCTT TCCCTAGTTT CAGTTACTTG CGTTCAGCCA	15000
	AGGTCTGAAA CTAGGTGCGC ACAGAGCGGT AAGACTGCGA GAGAAAGAGA CCAGCTTTAC	15060
	AGGGGGTTTA TCACAGTGCA CCCTGACAGT CGTCAGCCTC ACAGGGGGTT TATCACATTG	15120
35	CACCCTGACA GTCGTCAGCC TCACAGGGGG TTTATCACAG TGCACCCTTA CAATCATTCC	15180
	ATTTGATTCA CAATTTTTTT AGTCTCTACT GTGCCTAACT TGTAAGTTAA ATTTGATCAG	15240
40	AGGTGTGTTT CCAGAGGGGA AAACAGTATA TACAGGGTTC AGTACTATCG CATTTTCAGGC	15300
	CTCCACCTGG GTCTTGGAAT GTGTCCCCCG AGGGGTGATG ACTACCTCAG TTGGATCTCC	15360
	ACAGGTCACA GTGACACAAG ATAACCAAGA CACCTCCCAA GGCTACCACA ATGGGCCGCC	15420
45	CTCCACGTGC ACATGGCCGG AGGAACTGCC ATGTCGGAGG TGCAAGCACA CCTGCGCATC	15480
	AGAGTCCTTG GTGTGGAGGG AGGGACCAGC GCAGCTTCCA GCCATCCACC TGATGAACAG	15540
50	AACCTAGGGA AAGCCCCAGT TCTACTTACA CCAGGAAAGG C	15581

## (2) INFORMATION FOR SEQ ID NO:36:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 74 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..74  
(D) OTHER INFORMATION: /note= "primer #17982"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

GGGGCGTACG GAGCGCTCCG AATTCGGTAC CGTTTAAACG GGCCCTCTCG AGTCCGTTGT 60  
ACAGTTCATC CATG 74

## (2) INFORMATION FOR SEQ ID NO:37:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 66 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA

(ix) FEATURE:

- (A) NAME/KEY: -  
(B) LOCATION: 1..66  
(D) OTHER INFORMATION: /note= "primer #17983"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

GGGGGAATTC GCGCGCGTAC GTAAGCGCTA GCTGAGCAAG AAATGGCTAG CAAAGGAGAA 60  
GAACTC 66

WHAT IS CLAIMED IS:

- 1           1. An isolated nucleic acid that encodes an  
2 engineered *Aequorea victoria* fluorescent protein, wherein the  
3 protein encoded by the isolated nucleic acid is selected from  
4 the group that consists of:
  - 5           a. a protein that has leucine at amino acid position  
6           65, and wherein said protein has a cellular  
7           fluorescence that is at least five times greater  
8           than the cellular fluorescence of wild type *Aequorea*  
9           *victoria* green fluorescent protein;
  - 10          b. a protein that has leucine at amino acid position 65  
11          and threonine at position 168, and wherein said  
12          protein has a cellular fluorescence that is at least  
13          five times greater than wild type *Aequorea victoria*  
14          green fluorescent protein;
  - 15          c. a protein that has leucine at amino acid position 65  
16          threonine at position 168, and cysteine at position  
17          66, wherein said protein has a cellular fluorescence  
18          that is at least five times greater than the  
19          cellular fluorescence of wild type *Aequorea victoria*  
20          green fluorescent protein;
  - 21          d. A blue fluorescent protein that has histidine at  
22          amino acid position 67, leucine at position 65 and  
23          has a cellular fluorescence that is at least five  
24          times greater than that of BFP(Tyr<sub>67</sub>→His);
  - 25          e. a blue fluorescent protein that has histidine at  
26          amino acid position 67, alanine at amino acid  
27          position 164 and has a cellular fluorescence that is  
28          at least five times greater than that of  
29          BFP(Tyr<sub>67</sub>→His);
  - 30          f. a blue fluorescent protein that has histidine at  
31          amino acid position 67, leucine at amino acid  
32          position 65, alanine at amino acid position 164 and  
33          has a cellular fluorescence that is at least five  
34          times greater than that of BFP(Tyr<sub>67</sub>→His).

1                   2.    An isolated nucleic acid of claim 1, which  
2    encodes an engineered *Aequorea victoria* green fluorescent  
3    protein ("GFP") having a cellular fluorescence that is at  
4    least five times greater than that of wild type GFP, wherein  
5    the engineered GFP has a leucine at amino acid position 65.

1                   3.    An isolated nucleic acid according to claim 2,  
2    wherein the nucleic acid further encodes a threonine at amino  
3    acid position 168.

1                   4.    An isolated nucleic acid according to claim 3,  
2    wherein the nucleic acid further encodes a cysteine at amino  
3    acid position 66.

1                   5.    An isolated nucleic acid of claim 1 that  
2    encodes an engineered blue fluorescent protein ("BFP") that  
3    has histidine at amino acid position 67 and leucine at  
4    position 65, and has a cellular fluorescence that is at least  
5    five times greater than that of BFP(Tyr<sub>67</sub>→His).

1                   6.    An isolated nucleic acid of claim 1 that  
2    encodes an engineered blue fluorescent protein ("BFP") that  
3    has histidine at amino acid position 67 and alanine at amino  
4    acid position 164, and has a cellular fluorescence that is at  
5    least five times greater than that of BFP(Tyr<sub>67</sub>→His).

1                   7.    An isolated nucleic acid according to claim 6,  
2    wherein the nucleic acid further encodes leucine at amino acid  
3    position 65.

1                   8.    A transformed cell that expresses a protein  
2    encoded by a nucleic acid of claim 1.

1                   9.    A vector comprising a nucleic acid of claim 1.

1                   10.   A transformed cell comprising a vector of  
2    claim 9.

1           11. A transformed cell that expresses a protein  
2 encoded by the nucleic acid of claim 1 fused to a protein  
3 encoded by a second nucleic acid of interest.

1           12. An isolated engineered *Aequorea victoria* green  
2 fluorescent protein ("GFP") wherein the engineered GFP  
3 comprises leucine at amino acid position 65, said engineered  
4 GFP having a cellular fluorescence that is at least five times  
5 greater than wild type GFP.

1           13. An isolated engineered *Aequorea victoria* green  
2 fluorescent protein ("GFP") according to claim 12, wherein the  
3 engineered GFP has threonine at amino acid position 168.

1           14. An isolated engineered *Aequorea victoria* green  
2 fluorescent protein ("GFP") according to claim 13, wherein the  
3 engineered GFP has cysteine at amino acid position 66.

1           15. An isolated blue fluorescent protein ("BFP")  
2 that comprises histidine at amino acid position 67 and leucine  
3 at amino acid position 65 and has a cellular fluorescence that  
4 is at least five times greater than that of BFP(Tyr<sub>67</sub>→His).

1           16. An isolated blue fluorescent protein ("BFP")  
2 that has a histidine at amino acid position 67 and an alanine  
3 at amino acid position 164, that has a cellular fluorescence  
4 that is at least five times greater than that of  
5 BFP(Tyr<sub>67</sub>→His).

1           17. An isolated blue fluorescent protein ("BFP")  
2 according to claim 16, wherein the BFP further has leucine at  
3 amino acid position 65.

1           18. A method of detecting and optionally isolating  
2 an engineered cell that contains a selected nucleic acid which  
3 encodes a selected protein or nucleic acid, comprising:

4           a) stably introducing into a host cell in a population of  
5 host cells a vector that contains a first nucleic acid which

6 encodes a polypeptide selected from the group consisting of  
7 SG11, SG12, SG25, SB42, SB49, SB50 and a second nucleic acid  
8 which encodes a selected protein or nucleic acid, and  
9 b) detecting cells in the population of host cells that  
10 express SG11, SG12, SG25, SB42, SB49, or SB50, and  
11 c) optionally sorting cells that express SG11, SG12,  
12 SG25, SB42, SB49, or SB50 with a fluorescence-activated cell  
13 sorter to isolate individual cells that express said  
14 fluorescent protein.

1 19. A nucleic acid construct wherein a coding  
2 sequence selected from the group consisting of sequences that  
3 encode SG11, SG12, SG25, SB42, SB49, and SB50 is operably  
4 linked to a regulatory sequence of a selected gene.

1 20. A nucleic acid construct wherein a first coding  
2 sequence that encodes a selected polypeptide is fused using  
3 genetic engineering to a second coding sequence selected from  
4 the group consisting of sequences that encode SG11, SG12,  
5 SG25, SB42, SB49, and SB50, such that expression of the fused  
6 sequence yields a fluorescent hybrid protein in which the  
7 polypeptide encoded by the first coding sequence is fused to  
8 the polypeptide encoded by the second coding sequence.

1 21. A method of detecting and characterizing  
2 regulatory and coding sequence elements that regulate  
3 subcellular expression and targeting of proteins, comprising:  
4 a) expressing in an engineered cell, in the presence and  
5 absence of selected culture conditions and components, a  
6 nucleic acid wherein a first nucleic acid selected from the  
7 group consisting of nucleic acids that encode SG11, SG12,  
8 SG25, SB42, SB49, and SB50 is operably linked to a second  
9 nucleic acid derived from a selected gene;  
10 b) detecting the presence and subcellular localization of  
11 fluorescent signal.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/07625

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/12 C12N15/62 C12N15/85 C12N15/86 C12N5/10 C07K14/435 C12Q1/02 C12Q1/68 G01N33/50 G01N33/52		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K C12Q G01N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 97 11094 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 27 March 1997  see the whole document ---	1,2,5, 8-10,12, 15,18, 19,21
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 91, 1 December 1994, pages 12501-12504, XP000574454 HEIM R ET AL: "WAVELENGTH MUTATIONS AND POSTTRANSLATIONAL AUTOXIDATION OF GREEN FLUORESCENT PROTEIN" cited in the application see page 12504, left-hand column, line 8 - right-hand column, line 8; table 1 --- -/--	1-21
<div style="display: flex; justify-content: space-between;"> <span><input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.</span> <span><input checked="" type="checkbox"/> Patent family members are listed in annex.</span> </div>		
* Special categories of cited documents : <div style="display: flex;"> <div style="flex: 1;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="flex: 1;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search  <div style="text-align: center; font-size: 1.2em;">14 August 1997</div>		Date of mailing of the international search report  <div style="text-align: center; font-size: 1.2em;">26.08.97</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer  <div style="text-align: center; font-size: 1.2em;">Hornig, H</div>



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/07625

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NATURE, vol. 373, 23 February 1995, page 663/664 XP002029558 HEIM R ET AL: "IMPROVED GREEN FLUORESCENCE" cited in the application see the whole document ---	1-21
A	BIO/TECHNOLOGY, vol. 13, no. 2, February 1995, pages 151-154, XP002033686 DELAGRAVE S ET AL: "RED-SHIFTED EXCITATION MUTANTS OF THE GREEN FLUORESCENT PROTEIN" cited in the application see table 1 ---	1-21
A	FEBS LETTERS, vol. 367, 1 January 1995, pages 163-166, XP000579119 EHRIG T ET AL: "GREEN-FLUORESCENT PROTEIN MUTANTS WITH ALTERED FLUORENCE EXCITATION SPECTRA" see page 165, left-hand column, line 1 - right-hand column, line 37 ---	1-21
A	TIBS TRENDS IN BIOCHEMICAL SCIENCES, vol. 20, November 1995, pages 448-455, XP000606919 CUBITT A B ET AL: "UNDERSTANDING, IMPROVING AND USING GREEN FLUORESCENT PROTEINS" see the whole document ---	1-21
A	WO 95 07463 A (UNIV COLUMBIA ;WOODS HOLE OCEANOGRAPHIC INST (US); CHALFIE MARTIN) 16 March 1995 see the whole document ---	18-21
P,X	GENE, vol. 173, no. 1, 1 July 1996, ELSEVIER SCIENCE PUBLISHERS,B.V.,AMSTERDAM,NL;, pages 33-38, XP002037756 B.P. CORMACK ET AL.: "FACS-optimized mutants of the green fluorescent protein (GFP)" see page 37, left-hand column, line 12 - right-hand column, line 4 ---	1,2, 8-10,12, 19
P,A	WO 96 23810 A (UNIV CALIFORNIA ;TSIEN ROGER Y (US); HEIM ROGER (US)) 8 August 1996 see the whole document -----	1-21

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/07625

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9711094 A	27-03-97	AU 4482996 A	09-04-97
WO 9507463 A	16-03-95	US 5491084 A	13-02-96
		AU 7795794 A	27-03-95
		CA 2169298 A	16-03-95
		EP 0759170 A	26-02-97
WO 9623810 A	08-08-96	US 5625048 A	29-04-97
		AU 4155096 A	21-08-96